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Equipped with his five senses, man explores the 
universe around him and calls the adventure Science. 
Edwin Powell Hubble
The Nature of Science, 1954
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 1man population, which in its turn cause differences in the ability of humans to activate their immune system 
upon infection or outgrowth of tumors.
MHC-I molecules are divided in two categories: the 
classical MHC-I molecule (MHC-Ia), and the non-
classical MHC-I molecule (MHC-Ib). Both molecules 
are similar in the responses that they can induce. 
However, they are not familial: MHC-Ia molecules are 
extremely polymorphic whereas MHC-Ib molecules 
have few alleles which are highly homologous between 
individuals (3, 4). The limited diversity of antigens 
which are presented in MHC-Ib molecules places 
distinct constraints on their interactions and their role 
in T-cell biology (4). 
In humans we refer to MHC-I molecules as Human 
Leukocyte Antigens-I (HLA-I). The classical MHC-Ia 
molecules in human are referred to as HLA-A, -B, and 
-C, and MHC-Ib molecules are referred to as HLA-E, 
-F, -G, MIC and CD1. In this thesis we will only focus on 
the classical HLA-I molecules and the non-classical 
molecule HLA-E.
2. Antigen processing
MHC-I molecules present peptides at the cell-surface 
were they can be recognized by CTLs. Peptides 
presented in MHC-I, which are recognized by CTLs, 
are referred to as epitopes. Upon recognition of an 
epitope the CTL becomes activated and efficiently kills 
the cell. The process by which the peptides and 
possible epitopes are generated, and presented in 
MHC-I molecules, is called antigen processing. There 
are numerous pathways and enzymes involved, which 
generates and facilitates the peptides for presentation 
in MHC-I molecules.
2.1 Conventional antigen processing.
Peptides which are presented in the MHC-I molecules 
are mostly acquired in the Endoplasmic Reticulum 
(ER) and are derived from endogenous origin (2). The 
most-defined pathway involves both the proteasome 
and the transporter molecule TAP. Upon entering the 
cytoplasm of the cell, proteins are cleaved by the pro-
teasome, which degrades the protein into short pep-
tide sequences. A majority of the short peptide se-
quences are then able to enter the ER via the Trans-
porter associated with Antigen Processing (TAP) (fig-
ure 1a). Once in the ER, peptides which have a correct 
binding motive are loaded into the MHC-I molecule 
with help of the Peptide Loading Complex (PLC), in-
cluding tapasin, calreticulin, and the thiol oxidoreduc-
tase ERp57 (2, 5, 6). The MHC-Ia molecule containing 
the peptide is then transported through the Golgi ap-
paratus, towards the cell surface where it presents it-
self to CD8+ T cells (figure 1).
1. CD8 T-cell immunity
1.1 CD8+ T cells
In this thesis we study CD8+ T cells. This subset of T 
cells recognizes and kills host cells, which are infected 
or that display changes related to transformation. They 
are also referred to as cytotoxic T-lymphocytes (CTLs). 
The T-cell receptor (TCR) of a CTL recognizes a small 
peptide fragment that is displayed in molecules called 
the class-I major histocompatibility complex (MHC-I), 
which are very specific and present in every nucleated 
cell. To recognize the peptide fragment presented in a 
MHC-I molecule, each TCR has to recognize the 
residues of the peptides presented, and to recognize 
residues of the MHC-molecule, which is displaying the 
peptide.
T cells originate in the thymus where they undergo 
selection before they migrate to the lymph nodes and 
circulate throughout the body. Selection in the thymus 
occurs via two subsequent processes called positive- 
and negative selection. During positive selection T 
cells are considered for their ability to recognize 
MHC-I molecules. If the TCR of the T cell recognizes a 
self-MHC-I molecule it is rescued from death by 
neglect. The negative selection occurs through 
deleting immature T cells, with receptors interacting to 
strong for self MHC-I complexes. This negative 
selection prevents contribution to auto-immunity and 
induces self-tolerance (1).
Once the T cells have survived both positive- and 
negative selection they migrate towards the lymph 
nodes where they resides or circulate throughout the 
body until they become activated. 
1.2 The MHC-I molecule
The MHC-I molecule is expressed by virtually all nu-
cleated somatic cells and consists out of two parts: 
β2-microglobulin (β2m), and the heavy chain. The 
heavy chain is further divided into three regions: α1, 
α2, and α3. The α3 region is conserved and contains 
the binding site for the T-cell co-receptor CD8. The 
amino-terminus of α1 and α2 form the peptide-bind-
ing groove. This groove can bind to peptides which are 
generally 8-10 aminoacids (aa) in length, but bulging in 
the middle is possible and therefore sometimes longer 
peptides are found (2). Peptides bind into the binding 
groove through so called anchor residues, which are 
favorable amino acids at a certain position within the 
presented peptide. Polymorphic residues within the α1 
and α2 region cause differences in MHC-I molecules. 
Some of these residues contribute to variantion in the 
peptide-binding groove, causing differences in the 
preference of the type of amino acid and position for 
the anchor residues. This polymorphism contributes to 
the large variety of MHC-I molecules found in the hu-
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paragraph three possible TAP-independent pathways 
will be described: the pathway involving signal 
peptides, the furin mediated pathway, and the 
liberation of peptides from the C-terminus of ER 
resident proteins.
2.3.1 Signal peptides
Perhaps the most well studied TAP-independent 
pathway is the one that involves the enzymes Signal 
Peptide Peptidase (SPPase) and Signal Peptidase 
(SPase). Their role in the MHC-I antigen processing is 
just one example of how peptides are able to enter the 
ER without the use of TAP. Newly synthesized proteins 
can contain a signal sequence, which plays a key role 
in targeting the protein from the cytosol towards the 
ER-membrane (16). Once the proteins are inserted in 
the membrane the signal sequences can be cleaved 
from the precursor protein by the membrane-bound 
SPase. The signal peptide is then further processed 
by SPPase (16).
The cleavage of SPase is dependent on particular 
amino acids, which are present on position -1 and -3 
N-terminal of the cleavage site. An amino acid with a 
short side chain at the -1 position, and no charged 
amino acids at the -3 position favor SPase cleavage. 
Also the length and properties of other regions in the 
signal sequence can influence the cleavage of SPase. 
Once the signal sequence is cleaved from their 
precursor sequence further cleavage occurs by the 
less well defined SPPase (16).
Peptides that after cleavage of SPase and SPPase are 
inside the lumen of the ER, may contain epitopes 
which after further processing can bind to MHC-I 
molecules, implicating that these epitopes are 
processed in a TAP-independent fashion. Two 
examples are a peptide derived from the interferon-
inducible protein IP30 and an epitope derived from 
calreticulin (16, 17). Recently another epitope derived 
from a signal sequence was described. This epitope, 
derived from the signal sequence of preprocalcitonin, 
was a result of overexpression of the CALCA gene in 
lung carcinoma, indicating a possible role for epitopes 
derived from signal sequences in cancer 
immunotherapy (18).
2.3.2 Proprotein convertases: furin mediated 
pathway
The proprotein convertases are part of a family 
consisting out of six classes of proteases.  There are 
nine proprotein convertases and they play a role in 
protein processing by converting an inactive precursor 
to its mature form, and have a role in peptide precursors 
trafficking through the secretory pathway. Four of the 
convertases are type-I membrane-bound proteases, 
which are: furin, PC7, the isoform PC5/6B, and SKI-1. 
2.2 Enzymes involved in antigen processing
The proteasome is the primary source for generating 
peptides, which can be loaded into the MHC-I mole-
cule. However, there are studies, showing the involve-
ment of other enzymes able to generate peptides in 
the cytosol. One enzyme that was described to be 
generating pathogen-derived peptides in the cytosol 
in a proteasome-independent fashion is Tripeptidyl 
peptidase II (TPPII) (7). This enzyme generates a HIV-
Nef epitope, which is presented in both HLA-A3 and 
HLA-A11 molecules (7). Another enzyme is Thimet 
oligopeptidase (TOP) is a soluble thiol-sensitive me-
tallopeptidase that cleaves internal bonds in peptides 
of 6-17 aa (8). The role of TOP is debated. TOP may 
play a protective role for antigenic peptides (9, 10). 
However, another study described that TOP actually 
degrades class I ligands efficiently (11), suggesting 
that TOP plays a role in limiting peptide availability for 
antigen loading (11). Regardless the function of TOP 
the preference for binding and trimming of peptides 
indicates an important role for TOP in antigen process-
ing (8).
Recently other proteolytic enzymes like caspases 5 
and -10 (12, 13), Nardilysin (14) and insulin degrading 
enzyme (15) are implicated to play a role in protea-
some-independent antigen processing.
2.3 TAP-independent presentation pathways
Although the majority of the peptides/epitopes are 
processed via the conventional pathway there are 
several processing pathways, which are independent 












Figure 1: The classical HLA-I presentation pathway. Pep-
tides derived from endogenous origin are transported through 
the HLA-I presentation pathway. The endogenously derived 
peptides are degraded by the proteasome and enter the en-
doplasmic reticulum through the TAP transporter after which 
they are loaded into HLA-Ia molecules. The HLA-I molecules 
are then transported through the Golgi towards the cell-sur-






 1are mostly designated towards MHC-II molecules, in MHC-I molecules. Currently two pathways for cross-
presentation are proposed which are the cytolic- and 
the vacuolar route. The cytolic route is a TAP-
dependent process in which internalized antigens are 
released into the cytosol, which can then be 
transported to the ER by the TAP transporter and 
loaded into MHC-I molecules.
In the vacuolar route, antigens remain in the endocytic 
compartments, where they can be cleaved by prote-
ases before being transported into MHC-I molecules. 
This process is independent of TAP and its underlying 
mechanisms are still unclear (2, 27). One question that 
remains is how the MHC-I molecule is transported to 
the endocytic compartment. A possible candidate 
might be the invariant chain (Ii), a chaperone molecule 
known for its role in the MHC-II peptide presentation 
pathway.
Several studies show a formation of Ii/MHC-I 
complexes in B-LCLs (28-30). Increasing the Ii 
expression through transfection also influences the 
MHC-I surface expression levels (31). More importantly 
upon Ii/MHC-I complex formation, transport towards 
the endocytic compartment is seen (29). The role for 
the Ii in the cross-presentation pathway is 
unconventional but recent studies show that the Ii is 
also responsible for transporting the TNF-related 
CD70 molecule towards the MHC-II compartments 
(32) anticipating a much broader function of the Ii than 
thus far described. 
The association of Ii with the MHC-II is mediated via 
the CLIP region and it is believed that the same region 
is responsible for association to the MHC-I molecule 
(33). This matter however needs more investigation as 
binding towards only one MHC-I molecule has been 
shown (33) whereas association between Ii and MHC-I 
has been observed between several MHC-I molecules 
(28-30).
Other members are either packaged into dense core 
granules (PC1/3, PC2, PC5/6A) and/or constitutively 
secreted into the extracellular milieu (PC4, PC5/6A, 
PACE4 and PCSK9) (19). 
It is described that furin has an essential role in 
catalysing the maturation of a diverse collection of 
proprotein substrates (20-23). 
Proprotein convertases can also contribute to the gen-
eration of antigenic peptides, and the role of furin in 
this process has been studied. 
Peptides generated in the endosomes are transported 
into the Golgi network. In the Golgi furin can cleave 
these peptides and trim them at their C-terminus, 
making them available for loading into the MHC-I 
molecules. Furin is ubiquitously expressed in all 
vertebrates and many invertebrate. It cleaves –Arg–X–
Lys/Arg–Arg↓– (Arg = Arginine, Lys = Lysine, ↓ = the 
cleavage site, and X = any amino-acid). The Arginines 
at position one and four are essential whereas the 
Lysine or Arginine at position three is not. Therefore 
-Arg-X-X-Arg↓- represents the minimal furin cleavage 
site and in exceptional cases even -Lys/Arg-X-X-X-Lys/
Arg-Arg↓- can be cleaved by furin when favorable 
residues at position 2 and 6 can compensate for less 
favorable ones at position four (24). After peptides are 
generated through furin cleavage, it remains unclear 
how these peptides are loaded into the MHC-I 
molecule. MHC-I molecules normally travel to the cell-
surface in their peptide-filled conformation and 
peptides generated in the Golgi network by furin have 
to be either transported back to the ER, or have to bind 
to empty MHC-I molecules en- route to the cell-surface 
(20).
2.3.3 Liberation of peptides from the C-terminus 
of ER resident proteins
Some proteins are upon translation directed towards 
the ER and fold itself in the ER-membrane. One ex-
ample of such a protein is Jaw-1. Jaw-1 lacks an NH2-
terminal signal sequence and is inserted in the mem-
brane post-translationally by a hydrophobic trans-
membrane region at residues 480-503.  It contains a 
35-residue luminal tail that can be liberated by non-
proteasomal proteases in a TAP-independent manner. 
Further trimming occurred by carboxypeptidases or 
endoproteases, located inside the ER (25, 26).
2.4 Cross-presentation
Dendritic cells (DCs) play an important role in the 
initiation of the immune response and they initiate the 
clonal expansion of antigen specific T-cells. In order to 
have successful CD4+ and CD8+ T-cell priming against 
exogenously acquired antigens, DCs have a unique 
feature called cross-presentation. This leads to the 
presentation of exogenously derived antigens, which 
Table I: Qdm peptide sequences which bind to 
HLA-E (34)
Locus Sequence Examples of HLA-types
HLA-A VMAPRTLLL A01, A03
VMAPRTLVL A02, A24
HLA-B VMAPRTVLL B07, B08
HLA-C VMAPRTLLL Cw02, Cw15
VMAPRTLIL Cw03, Cw04a
HLA-G VMAPRTLFL G01
a Except the Cw0402 subtype
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membrane, the hydrophilic domain containing a Qdm 
peptide is released in the cytosol by enzymes called 
SPase and SPPase, whereas the MHC-I heavy chain 
is released into the ER (see figure 2) (16). This example 
is in contrast with the idea of  §2.3.1 were the enzymes 
SPase and SPPase are involved in TAP-independent 
peptide presentation. Upon cleavage of SPase and 
SPPase an epitope can be either released into the ER, 
and therefore processed TAP-independently, or it can 
be released in the cytsol where it is then processed in 
a TAP-dependent fashion.
The domain containing Qdm, which remained in the 
cytosol, is processed by the proteasome into small 
peptide fragments and Qdm is transported into the ER 
via TAP. In the ER, the Qdm peptide is loaded into HLA-E 
and then transported to the cell-surface were it is 
recognized by CD94/NKG2 receptors (35, 36) (figure 2).
3.2 Natural Killer- (NK) and T-cell recogni-
tion of HLA-E
NK cells and activated CD8+ T-cells express the invari-
ant transmembrane receptors CD94/NKG2 (34, 37). 
The CD94 subunit makes the most contact with the 
HLA-E molecule and the presented peptide, whereas 
the NKG2 subunit is responsible for the transduction of 
signals (38-40). NKG2 receptor genes are clustered in 
the NK-locus and there are different variants: NKG2A, 
-B, -C, -D, -E and -H. Of these six, only the NKG2D 
does not form a heterodimer with the CD94 complex 
and NKG2D is also clearly distinct from NKG2A, -B, 
-C,  -E and -H; which differ by only a few amino acids 
(37). NKG2A and NKG2B are alternative splice prod-
ucts of one gene in which NKG2B appears to be in 
disadvantage.  Also NKG2E and NKG2H are alterna-
tive splice products of one gene (41). NKG2A, -C and 
–E play a role during recognition of HLA-E and small 
differences in the NKG2A, -C, and -E receptors deter-
mines its affinity to the CD94 receptor. These differ-
ences also determine whether the CD94/NKG2 het-
rodimer acts as an activating or inhibitory receptor. 
NKG2C and NKG2E are both activating receptors and 
are in general less frequently expressed than NKG2A, 
which provides inhibitory signals (41, 42).
NK cells are part of the so-called innate immunity, which 
are the first line of defense against infections or transfor-
mation. If due to these alterations the cells fail to present 
MHC-Ia molecules at the cell-surface the NK cells will 
be activated and lyse the cells. NK cells which express 
either CD94/NKG2A or CD94/NKG2C can engage with 
HLA-E and the MHC-Ia Qdm peptide and provide either 
an activating (NKG2C) or inhibitory (NKG2A) signal, 
which contributes together with other signals to deter-
mine whether the NK cell should become active.
3. HLA-E (and its mouse homolog 
Qa-1)
In contrast to the extreme polymorphic nature of MHC-
Ia molecules, MHC-Ib molecules have few alleles and 
are highly homologous between humans and other 
species (4). 
3.1 HLA-E presentation pathway
HLA-E and its mouse homolog Qa1 are, similar to 
MHC-Ia molecules, expressed in most tissues. Al-
though there is only 73% of homology between both 
molecules, their function and non-variable peptides 
that they bind are surprisingly similar (34). Both mole-
cules can bind so called signal peptides in their hydro-
phobic peptide-binding groove, which are mainly de-
rived from the leader sequence of classical MHC-Ia 
molecules (4, 34). This set of epitopes is also referred to 
as Qdm (Qa-1-determinant-modifier) peptides (table I). 
Qdm peptides are signal sequences located at the N-
terminal regions of MHC-I molecules, serving as a hy-
drophilic segment to co-translationally target the newly 

















Figure 2: The non-classical presentation pathway. Pep-
tides which are presented in HLA-E molecules are mostly 
derived from the leader peptide of the HLA-Ia heavy chain 
molecules. Once the heavy chain of the HLA-Ia is transcribed 
it is targeted to the ER where it is handled by SP and SPPase 
molecules. The leader sequence remains in the cytosol 
whereas the heavy chain is entering the ER where they can 
form the HLA-Ia molecule together with β2m. The leader se-
quence is then processed through the proteasome and en-
ters the ER through the TAP transporter. Here they are loaded 
on HLA-E molecules, which is then presented at the cell-







 1breast carcinoma patients (53). They observed that 50% of the breast carcinoma samples have expres-
sion of HLA-E. Remarkably, patients whose tumors 
had a complete loss of the classical HLA-I molecules, 
but coinciding HLA-E expression had a worse relapse 
free period. Also an association is seen between clas-
sical HLA-I processing pathway and HLA-E expres-
sion (53). The increased expression of HLA-E on tu-
mors is not fully understood. 
In vitro cultured melanoma- and colorectal cancer cell-
lines display low but significant amounts of HLA-E on 
the cell surface. However in these cell-lines HLA-E 
expression is clearly detected intra-cellular. Upon 
IFNγ treatment an increase of HLA-E is observed at 
the cell-surface (49, 50, 54) resulting in a decreased 
susceptibility to CTL lysis of CTL expressing the 
inhibitory receptor CD94/NKG2a (49, 55). In one study 
an imbalance of MHC-Ia heavy chain/β2m expression 
can modulate HLA-E surface expression, meaning 
that expression of HLA-E correlates inversely with the 
expression of MHC-Ia molecules in in vitro cultures 
(54). However, for several studies on other tumor cell 
lines don’t observe such an inverse correlation (49, 
56). It must also be noted that the general low HLA-E 
expression in tumor cell-lines observed in vitro 
contrasts with the in general increased HLA-E 
expression in site using immunohistochemistry.
4. Inhibition of the conventional 
MHC-I pathway upon viral 
infection.
Upon viral infection of a cell, the infected cells start to 
produce viral proteins. Like other proteins, the viral 
proteins are also processed via the antigen 
Apart from NK-mediated recognition, TCR-mediated 
recognition of HLA-E or its mouse homolog Qa-1b has 
previously been described (43-47). Upon cellular 
stress the Qdm peptide is replaced by novel much di-
verse repertoire of peptides (34, 43-47). Epitopes de-
rived from Epstein bar virus (EBV) (43), Mycobacterium 
Tuberculosis (44), and mycobacteria (47) have been 
reported to be presented in HLA-E where then can be 
recognized by CD8+ T cells. Romagnani et al reported 
that allogeneic T-cells might also recognize peptides 
in HLA-E, which are not present in the host of origin 
(46). This makes HLA-E a target for possible implica-
tions upon transplantation, or can be involved in anti 
tumor immune responses. Interestingly, Oliveira et al 
reported Qa-1b restricted CTLs that recognized pep-
tides presented solely on a variety of TAP-impaired 
tumor cells, so called TEIPPs (45). As Qa-1b is highly 
homologous to HLA-E, this finding could imply that this 
type of CTLs can also exist in the human population 
thereby opening new possibilities to treat tumors with 
antigen processing defects (4, 45). 
3.3 HLA-E expression by tumors
Almost all nucleated cells express HLA-E and a major-
ity of tissues from healthy donors show weak to mod-
erate staining for HLA-E. Staining of HLA-E is strong in 
subsets of lymphoid cells, epididymis and the adrenal 
gland. HLA-E expression is not detected in the liver, 
pancreas, myocytes and the central nerve system 
(CNS) (http://www.proteinatlas.org (48)).
It has been observed that in sections of melanomas 
variable fractions of HLA-E expression were found 
ranging form 30-70% on primary tumors and 10-20% 
on metastatic lesions (49). In colorectal cancers, and 
astrocytic tumors, strong HLA-E expression was ob-
served, while its healthy counterpart showed weak 
staining of HLA-E (50, 51). In cervical carcinoma, a 
difference in HLA-E expression 
was observed between inva-
sive- and non-invasive cancers; 
the more invasive the cancer the 
greater the HLA-E expression 
(52). A recent study reports 








































Figure 3: Inhibition of the antigen 
presentation pathway by viral 
proteins. The family of Herpesviri-
dae has adapted numerous ways to 
avoid recognition by CTL. Depicted 
are the viral proteins, which are in-
hibiting molecules involved in MHC-I 
antigen processing and the virus 
they are derived from. Figure adapt-
ed from (57)
12 | CHAPTER 1
the TAP transporter molecule: UL49.5, ICP47, US6, 
BNLF2a and V012 (figure 3). For four of these TAP in-
hibitors their mechanism of action is unraveled. UL49.5 
is a protein belonging to the genus Varicellovirus and 
for the bovine herpesvirus-1 (BHV-1) variant it is known 
to efficiently inactivate TAP by arresting it in a translo-
cation-incompetent state; and promoting the degrada-
tion of TAP (58-60). ICP47 is found in HSV type 1 and 2 
where binds to the cytosolic site of the TAP complex, 
thereby acting as a high-affinity competitor for peptide 
binding (61-64). The human HCMV protein US6 is an 
ER-resident protein and it prevents ATP binding to 
TAP, thereby blocking the peptide transport (65, 66). 
The viral TAP-inhibitor BNLF2a is encoded by EBV 
and prevents both peptide and ATP binding to TAP (67, 
68). The latest identified TAP-inhibitor V012, is found in 
cowpox virus (CPX) and is the first TAP inhibitor out-
side the family of Herpesviridae. Its TAP-inhibiting 
mechanisms has not yet been identified (57, 69, 70).
5. Immune escape of tumors
Like viruses, tumors have adopted mechanisms to 
prevent peptide presentation by MHC-Ia. These 
mechanisms can be divided into two categories to 
which Garrido et al refers to as “hard” or “soft” defects 
(71). Both “hard” and “soft” lesions are associated with 
poor prognosis as it leads to failure of recognition and 
elimination by tumor specific CTLs, as the expression 
of MHC-I molecules at the cell-surface is decreased 
(72-74). “Hard” defects are irreversible and structural 
such as loss of gene copies via loss of heterozygosity 
(LOH), mutations and deletions of MHC-Ia heavy 
chain genes or the β2m gene. These mutations and 
presentation pathways and can 
be presented at the cell-surface. 
If a cell presents such viral 
proteins at the cell-surface they 
can be recognized by CTLs, 
becomes activated, and kills the 
infected cells. To avoid this 
recognition, most DNA viruses 
express so-called immune evasion proteins. The 
protein prohibits presentation of viral proteins in MHC-I 
molecules at the cell-surface, thereby avoiding 
recognition by the CTLs and allowing viruses to persist 
in the human body.
The most well studied viruses and their immune eva-
sion proteins are from the family of Herpesviridae and 
most people are infected with one or more of the eight 
known Herpesviruses: herpes simplex viruses types 1 
and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), 
human cytomegalovirus (HCMV), human herpesvi-
ruses 6 and 7 (HHV-6 and HHV-7), Epstein-Barr virus 
(EBV), and Kaposi’s sarcoma-associated herpesvirus 
(KSHV) (57). Due to their numerous strategies to pre-
vent peptide presentation of the MHC-I molecule ca-
pability the family of Herpesviridae causes life-long 
persistent infections in humans.
For example the viral derived proteins US2, US10, 
US11 (HCMV), mouse cytomegalo virus (MCMC) 
glycoprotein (gp) 48, and murine γ-herpesvirus 68 
(MHV68) mK3, target MHC-I molecules in a selective 
fashion thereby accelerated degradation of MHC-I 
molecules (57). Other mechanisms include intracellular 
retention (US3 (HCMV) and gp40 (MCMV)) or 
increased endocytosis (kK3/kK5 (KSHV) and BILF1 
(EBV)) of MHC-I molecules, as well as interference 
with the recognition of peptide loaded MHC-I by CTLs 
(gp34 (MCMV)) (57). All MHC-I interfering proteins and 
their origin are summarized in figure 3.
Among the proteins involved in immune escape there 
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Figure 4: The “hard”- and “soft” 
defects in tumor tissue. Tumors 
can escape immune recognition 
through numerous ways. “Hard” de-
fects are irreversible such as muta-
tions and deletions of MHC-Ia heavy 
chain genes or the β2m gene or LOH. 
Soft” defects are reversible regula-
tory defects such as downregulation 
of MHC-Ia transcription due to, hy-
permethylation of the promoters, 
oncogene activation, and or block-







increased in metastatic lesions (84). 
Two recent case studies show a clear association be-
tween low HLA-I expression and progression of tu-
mors after immunotherapy (85, 86). In both studies 
metastatic lesions where isolated from a melanoma 
patient treated with autologous melanoma cell vaccine 
(M-VAX) and interferon-α2b. After treatment eight of 
the metastatic lesions regressed in the treated patient, 
while two lesions progressed. Studying the HLA-I sur-
face levels it was seen that the progressive lesions had 
low HLA-I surface expression while the regressing le-
sions maintained their HLA-I surface levels (85, 86). A 
decrease in HLA-I surface expression prevents ex-
pression of tumor-specific antigens on the cell-surface 
thereby avoiding CTL recognition.
6. Tumor antigens 
Tumor antigens, which are expressed at the surface of 
a tumor cell, are divided in different categories based 
the proteins they originate from. These categories are: 
viral epitopes, point mutations, differentiation antigens, 
cancer testis, and cryptic epitopes (Table III).
Viral epitopes expressed by all virus-induced tumors 
e.g. Burkitt lymphoma, nasopharyngeal carcinoma, 
and Hodgkin lymphoma, and cervical cancer in which 
15-20% of tumors is virally induced. Cervical cancer is 
in virtually all cases caused by the Human Papilloma 
deletions are mostly found on chromosome 6, -16, and 
in the interferon signal transduction pathway (71, 75) 
(figure 4). “Soft” defects are reversible regulatory de-
fects such as hypermethylation, oncogene activation, 
and blocking of the Jak-STAT pathway, and results in 
down-regulation of MHC-Ia surface expression (71). 
Similarly decreased transcription of MHC-I locus prod-
ucts and defects in components of the antigen-pro-
cessing machinery (APM) comprising peptide trans-
porter TAP, tapasin, and proteasome subunits, causes 
low MHC-Ia surface expression (76) (figure 4).
The occurrence of either LOH or alterations in the ex-
pression of the PLC and TAP has been thoroughly in-
vestigated. LOH is studied in a wide variety of tumor 
types and is mostly located on either the chromosomes 
harbouring the HLA-A/B/C genes or the β2m gene (71). 
Studies that focuses on LOH in tumors are summa-
rized in table II. In short: LOHs are present at different 
chromosomes and differ between 11-90% depending 
on which microsatellite used. Moreover, no significant 
difference is seen between primary and metastatic le-
sions (77-83). 
The loss or downregulation of TAP is studied in a wide 
variety of tumors and its metastasis (72, 84). The al-
teration of TAP levels is found in all sorts of tumors but 
its frequency varies from 10% for Head and neck squa-
mous cell carcinoma (HNSCC) up to 74% in renal cell 
carcinoma (72). Moreover the frequency of TAP loss is 
Table II: Summary of studies on LOH




Colorectal 6p 65 13.8% (78)
Laryngeal 6p 34 17.6%




NSCLCb 1p, 3p, 5q, 7q, 8q, 9p, 10q 17p, 18q 48
c 44-76% (primary)
23-67% (metastasis) (82)
Colorectal 33 on several chromo-somes 38 26-90% (83)
Bladder 9p21, 9q32, 17p13 79c 30-39% (primary)35-48% (metastasis) (79)
Cervical 6p 30 50% (80)
a= n is number of samples tested
b= HNSCC is Head and Neck Sqaumous Cell Carcinoma, NSCLC is Non-Small Cell Lung Carcinoma
c= both primary and metastatic tumors
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development (94). The epitopes representing this 
group are referred to as cancer/testis antigens, de-
fined on the basis of their normal tissue specific ex-
pression in testis or ovary germ-line cells (89, 90, 93, 
94). CTLs directed against these antigens have been 
identified and as they are expressed in a wide variety 
of tumors, they form an attractive group to use in tumor 
vaccination strategies.
The last group of tumor antigens, cryptic epitopes, is 
derived from aberrant gene transcripts or unusual 
translation products (95-97). Most of these translation 
products appear to be tumor-specific, are not detected 
in normal cells, and are caused through alternative 
open reading frames, translated introns or pseudo-
genes.
Even though there has been a large number of tumor 
antigens identified, T cell based immunotherapy suf-
fers from a discrepancy between the induction of tu-
mor-specific immune responses in experimental set-
tings and therapeutic immunity in clinical relevant 
conditions (98).  
A problem might arise when tumors impair their anti-
gen presentation pathway. In this case, the presenta-
tion at the cell surface of the classical tumor antigens 
is decreased or even lost (99). Studies have shown 
that the residual peptides presented on TAP-impaired 
cells are dramatically different than the normal peptide 
repertoire (17, 100, 101). However, this alteration leads 
to presentation of new self-immunogenic peptides, 
which can be recognized by CTLs, thereby eradicating 
the tumor (45, 102, 103). These newly presented im-
munogenic peptides represent a novel category of tu-
mor antigens, called TEIPP.
Virus and known epitopes are derived from the E6 and 
E7 oncoproteins (87, 88). Burkitt lymphoma, Nasopha-
ryngeal carcinoma, and Hodgkin lymphoma are 
caused by EBV, and expression of the EBV specific 
proteins; EBNA-1, LMP-1 and LMP2 have been ob-
served in tumor cells (89).
The majority of cancer antigens are caused by point 
mutations in constitutive cellular proteins. CTL re-
sponses against e.g. Ras protein have been reported 
in breast carcinoma (90). Moreover, in vitro CTL re-
sponses derived from healthy donors against p53 
have been reported (91) and p53 is frequently mutated 
and/or overexpressed in numerous cancers. Several 
phase I/II immunization trials have been conducted 
using p53 as a target (92). However, thus far therapeu-
tic vaccination strategies targeting p53 have not 
shown consistent or convincing clinical efficiency (92), 
and therefore improvement in the efficiency of the im-
munogenic response against p53 is desirable.
Other mutations such as in MUM-1 and CDK4 have 
shown to lead to presentation of epitopes in MHC-I 
molecules (90). Some point mutations may reflect 
changes contributing to neoplastic transformation, 
while other mutations may reflect the genetic instability 
of tumors. These mutations and their effects are pa-
tient specific.
Differentiation antigens are selectively expressed in 
certain normal tissues and, therefore, also in tumors 
derived from these tissues. Most described epitopes 
were detected as targets for CTL in patients with mela-
noma and are usually not mutated (89, 90, 93). Three 
differentiation antigens are expressed in more than 
90% of human melanoma namely MART-1, tyrosinase, 
and gp100 and it is known that melanoma patients 
have CTLs capable of recognizing these antigens (93).
Several tumors, e.g melanoma, bladder carcinoma, 
lung carcinoma and liver carcinoma, express genes 
which are normally only expressed during embryonic 
Table III: Categories of human tumor antigens recognized by CTL
Category Description Examples
Viral antigens Virus-induced tumors (e.g. EBV, HPV) EBNA-1, E6, E7
Point mutations Unique for each tumor MUM-1, CDK-4, p53, Caspase-8
Differentiation antigens Expressed in tissue lineage Tyrosinase, GP100, Mart-1
Cancer testis antigens Largely expressed during development and cancers MAGE, NYO-ESO-1
Cryptic epitopes Associated with aberrant transcription and translation RU2, GnT-V, HPX42B






 1can be applied to treat a wide variety of processing deficient tumors and limits possible side-reactivity as 
healthy TAP+ cells are not recognized (103). Although 
the reactivity of TEIPP CTLs resembles that of natural 
killer cells, TEIPP antigens behave like conventional 
tumor antigens for CTL.
The induction of TEIPP CTLs has been investigated in 
a mouse model in numerous ways: vaccination with 
the Trh4 short peptide, cellular vaccination with TAP-
deficient dendritic cells and adoptive transfer of in vitro 
expanded CTLs (102, 103). In all three cases the 
TEIPP-targeted immunotherapy resulted in clearance 
of tumors with MHC-I defects, in particular TAP defi-
ciencies. Inducing TEIPP-specific CTLs might provide 
the first local immune activation and cytokine release 
upon recognition of antigen-impaired lesions.
8. Scope of thesis
This thesis focuses on alternative antigen presenta-
tion in the context of tumors with defects in antigen 
processing. In chapter 2, we investigate whether the 
human T-cell repertoire harbors a population reactive 
to TAP-impaired targets. The detection of such T-cell 
reactivity would indicate that, similar to mice, the hu-
man system contains a TEIPP-specific T-cell reper-
toire. To identify TEIPP antigens in humans, we set up 
a bioinformatics approach to predict HLA-I binding 
peptides with potential TEIPP characteristics in chap-
ter 3. We made a start with a screening method to de-
termine the immunogenicity of these self-peptides. 
An attractive strategy towards the development of im-
mune-therapy based on TEIPPs is to identify TEIPPs 
in the human HLA-E molecule. This non-classical 
HLA-I molecule has only two variants among the hu-
man population. As these molecules only differ by one 
amino acid, the presented peptides are the same 
among humans. Moreover, HLA-E is frequently pre-
served or over- expressed in tumors. To gain a more 
profound insight in the peptide repertoire presented by 
the non-classical molecule HLA-E under conditions 
were TAP is impaired; we performed peptide elutions 
in chapter 4. Since these peptides derived from the 
elution are based natural selection through antigen 
presentation we also determine a peptide-binding 
motif for HLA-E. The implications of increased HLA-E 
expression in ovarian- and cervical carcinoma patients 
are assessed in chapter 5, in which we also study the 
presence of T-cells containing CD94/NKG2 receptors 
which are able to interact with HLA-E.
It has been described in literature that the invariant 
chain interacts with HLA-I molecules, especially in the 
absence of TAP. This prompted us to test the idea that 
this protein-protein complex is implicated in the HLA-I 
7. T-cell Epitopes associated with 
Impaired Peptide Processing 
(TEIPP)
TEIPPs are like most tumor antigens not presented at 
the cell-surface of healthy tissue. However, unlike the 
other classes of tumor antigens, TEIPPs are presented 
on tumors that have an impaired antigen presentation 
pathway. Moreover, TEIPPs are derived from house-
keeping proteins and are expressed by a wide variety 
of cells (103, 104). CTLs recognizing TEIPP display 
preferential killing towards antigen-impaired tumors 
and it has been demonstrated that TEIPP T-cell recep-
tors engage with epitopes that are displayed in the re-
sidual MHC-I molecules (103). 
So far, studies on identifying TEIPPs and their CTLs 
have been limited to mouse models (45, 102-104) and 
only one TEIPP has been fully identified namely the 
Trh4-epitope (also known as Lass5), which is pre-
sented in H-2Db molecules, a classical MHC-Ia in the 
mouse. There are also TEIPP-CTLs found directed 
against TAP-independent epitopes presented in the 
non-classical Qa-1, which is the mouse homolog of 
HLA-E (45). However, the exact epitopes have not 
been identified.
The Trh4 epitope is derived from the C-terminus of the 
Trh4-protein, which is an ER membrane spanning 
protein. TAP+ RMA cells were not recognized by the 
Trh4-CTL whereas the TAP-negative counterpart 
RMA-S was efficiently lysed, demonstrating that the 
Trh4-epitope is processed in a TAP-independent fash-
ion. As expression of the Thr4 protein was similar in 
both cells, it was hypothesized that the Trh4 epitope is 
not presented in TAP+ RMA due to the large quantities 
of peptide transported into the ER by TAP, thereby 
creating an unfavorable environment for the TAP-inde-
pendent Trh4-epitope to be loaded in H-2Db molecules 
(103). Further study shows that overexpression of Trh4 
epitope in TAP+ cells resulted in recognition and lysis 
by the Trh4-CTL illustrating that indeed the influx of 
TAP-transported peptides create an efficient barrier to 
inhibit loading of peptides from alternative processing 
routes. The impairment of TAP function lowers this re-
sistance allowing the MHC-I presentation of other 
peptide sources (104). 
The Trh4-protein belongs to a family of fatty-acid regu-
lators and these housekeeping proteins are expressed 
by a wide variety of cells (103). Indeed, tissues derived 
from TAP1 knockout mice were recognized by the 
Trh4-CTL apart from the spleen and liver. As expected, 
none of the tissues derived from wild-type mice were 
recognized (104). This shows that the Trh4-epitope 
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Target cell recognition by Cytotoxic T Lymphocytes 
(CTL) depends on the presentation of peptides by Hu-
man Leukocyte Antigens class I (HLA-I) molecules. 
Tumors and herpes viruses have adopted strategies to 
greatly hamper this peptide presentation at the impor-
tant bottleneck, the peptide transporter TAP. Previ-
ously, we have described the existence of a CD8+ CTL 
subpopulation that selectively recognizes such TAP-
deficient cells in mouse models. Here, we show that 
the human counterpart of this CTL subset is readily 
detectable in healthy subjects. Autologous PBMC cul-
tures were initiated with dendritic cells rendered TAP-
impairment by gene transfer of the viral evasion mole-
cule UL49.5. Strikingly, specific reactivity to B-LCLs 
expressing one of the other viral TAP-inhibitors (US6, 
ICP47 or BNLF2a) was already observed after three 
rounds of stimulation. These short term T-cell cultures 
and isolated CD8+ CTL clones derived thereof did not 
recognize the normal B-LCL, indicating that the cog-
nate peptide-epitopes emerge at the cell surface upon 
an inhibition in the MHC class I processing pathway. A 
diverse set of T-cell receptors were used by the clones 
and the cellular reactivity was TCR-dependent and 
HLA-I-restricted, implying the involvement of a broad 
antigenic peptide repertoire. Our data indicate that the 
human CD8+ T-cell pool comprises a diverse reactivity 
to target cells with impairments in the intracellular pro-
cessing pathway and that these might be exploited for 
cancers that are associated with such defects and for 
infections with immune-evading herpesviruses.
Introduction
CD8+ Cytotoxic T-Lymphocytes (CTLs) have an impor-
tant role in the immune response against infections 
and outgrowth of tumors. They recognize antigenic 
peptides presented at the cell surface by class I mole-
cules of the Major Histocompatibility complex (MHC-
I). Inhibition of the intracellular MHC-I antigen presen-
tation pathway is therefore an efficient strategy to 
avoid CTL recognition. Indeed, both tumors and virus-
es are able to escape CTL-mediated immune control 
through MHC-I down modulation (1-6). Several mecha-
nisms have been described that lead to loss of peptide 
presentation and these involve targeting of the MHC 
class I heavy chain, the β2-microglobulin chain, and 
components of the peptide loading complex (PLC). 
One common target in the PLC that results in efficient 
impairment of MHC-I presentation is the Transporter 
associated with Antigen Processing (TAP), which 
transports peptides generated by the proteasome 
from the cytosol into the Endoplasmic Reticulum (ER). 
Deficiency in TAP expression is frequently found in 
human cancers and several viral proteins have been 
indentified that bind to TAP and block its peptide trans-
port function (2,7). As the heterodimeric TAP1/TAP2 
proteins constitute the bottleneck of the MHC-I pro-
cessing pathway, a blockade at this step results in ef-
ficient and total decrease of antigen presentation at 
the cell surface, and as a consequence, resistance to 
antigen-specific CTL.
Within the family of Herpesviridae four variants of viral 
TAP inhibitors have been characterized. Herpesvirus-
es cause life-long latent infections in their hosts, and 
occasionally reactivate. Therefore, immune evasion is 
an important survival strategy. UL49.5 is a protein en-
coded by herpesviruses belonging to the genus Vari-
cellovirus. In this paper the bovine herpesvirus-1 
(BHV-1) variant of UL49.5 is used, which efficiently in-
activates TAP by arresting it into a translocation-in-
competent state, and, moreover, promotes the degra-
dation of TAP (8-10). The TAP inhibitor ICP47 is found in 
herpes simplex virus type I and II and binds in a stable 
fashion to the cytosolic site of the TAP complex, 
thereby acting as a high-affinity competitor for peptide 
binding (11-14). The human cytomegalovirus protein US6 
is an ER resident protein, which prevents ATP binding 
to TAP and thereby blocking peptide transport (15,16). 
Recently a new TAP inhibitor was indentified in Ep-
stein-Bar Virus (EBV), BNLF2a, which prevents both 
peptide- and ATP binding to TAP (17,18). 
TAP impairment is found in a broad range of tumor 
types with a frequency between 10-74%, and is regu-
larly found in metastatic leasons (1,3). It is the most fre-
quent cause of decreased expression of Human Leu-
kocyte Antigens class I (HLA-I), the MHC-I in man, and 
is associated with a poor prognosis (1,19,20). Loss of anti-
gen presentation as a result of TAP down regulation 
leads to failure of recognition and elimination by tumor-
specific CTLs (21-24). Interestingly, the residual peptides 
that are still presented at the surface of TAP-impaired 
cells are dramatically different from the normal peptide 
repertoire. In 1992, two studies described that the 
peptide repertoire complexity of the TAP-negative T2 
cell-line was much more limited compared to that of 
the TAP–positive counterpart cell-line (25,26). Weinzierl 
et al characterized these peptides in more detail using 
a differential tandem mass-spectrometry approach 
and reported a list of peptides which were much more 
pronounced in the repertoire of TAP-negative B-LCL 
(27). These studies demonstrated that blockades in the 
intracellular antigen processing pathway lead to alter-
ations in the peptide repertoire presented by HLA-I at 
the cell surface.
In a mouse model we recently described that some of 
the differentially presented peptides are immunogenic 
and that a subpopulation of T cells is able to target 
these TAP-independent peptides (28-31). This category 
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of T cells eliminated tumors with a defect in MHC-I 
antigen processing, while cells with no processing 
defects were not eliminated. Such peptides were 
found to be presented by classical MHC-I molecules, 
but also by the conserved non-classical MHC-I Qa-1 
(28). The peptide-epitopes, which were recognized by 
the cognate T cells, were ‘self’ peptides which only 
emerge at the cell surface once there is a defect in the 
antigen presentation pathway. We named these new 
peptides TEIPP, for T cell Epitopes associated with 
Impaired Peptide Processing (28-31). Because TEIPP 
peptides are derived from housekeeping proteins, 
their presentation is also induced by TAP-deficiencies 
in normal, non-transformed cells. Indeed, introduction 
of the viral TAP inhibitor UL49.5 in myeloid dendritic 
cells (DC), which are professional antigen presenting 
cells capable of activating naïve T cells, sensitized 
these cells for recognition by TEIPP-specific CTL (30). 
These TAP-inhibited DCs were equally well recognized 
by TEIPP T-cells, as DCs from TAP1-/- mouse. 
Importantly, vaccination with these TAP-impaired DCs 
elicited strong TEIPP T-cell responses in vivo, which 
were able to prevent outgrowth of TAP-loss lymphoma 
and fibrosarcoma tumor variants (30).
Thus far studies on TEIPP antigens have been limited 
to mouse models. Here, we present the first evidence 
for the existence of a human T-cell subset with TEIPP-
specificity. In analogy with our mouse model, we 
rendered monocyte-derived DC TAP-deficient by 
gene transfer of viral evasion molecules that block the 
peptide transporter TAP. These TAP-deficient DC 
were used as stimulator cells in cultures with 
autologous T cells. This approach revealed an efficient 
outgrowth of CD8+ T-cells with selective reactivity 
against TAP-deficient target cells. Polyclonal cultures 
and T-cell clones exhibited TCR-dependent and HLA-I 
restricted lytic activity against TAP-inhibited targets, 
but not against their non-inhibited counterparts. 
Collectively, our data indicate that the CD8+ T-cell 
repertoire in humans contains reactivity against 
peptides presented by cells with a defect or block of 
the MHC-I antigen-processing route.
Material and methods
Cell lines and primary cell cultures
B-LCLs modo, hodo and HD10 (see Table I) were 
transduced with retroviruses based on the pLZRS vec-
tor, which contains an internal ribosome entry site, fol-
lowed by GFP, and one of the viral TAP inhibitors. This 
system is recently reported (32) and the viral TAP inhibi-
tors UL49.5 (from BHV-1), ICP47, US6 and BNLF2a 
were used, which were previously described (8-18). Cells 
were sorted on GFP expression by FACS to ensure 
homogenous and high expression of the various TAP 
inhibitors. All B-LCL and K562 were cultured in com-
plete IMDM medium (Invitrogen, Carlsbad, CA) con-
taining 8% heat-inactivated FCS, 100 units/ml penicil-
lin, 100μg/ml streptomycin (Life technologies, Rocker-
ville, MD) and 2mM glutamine (Invitrogen).
We obtained blood from healthy donors (HDs), which 
were partly HLA-matched with Modo or Hodo B-LCLs 
(Table I). From these donors Peripheral Blood Mono-
nuclear Cells (PBMCs) were isolated, and positive se-
lection was performed on monocytes and B-cells, us-
ing respectively CD14+ and CD19+ MACS beads (Milt-
enyi Biotec, Gladbach, Germany). CD14+ monocytes 
were MoDCs in a concentration of 2x106 cells/well in a 
6 wells plate (Costar, Cambridge, MA) in RPMI 1640 
(Invitrogen) containing 8% heat-inactivated FCS, 100 
units/ml penicillin, 100μg/ml, streptomycin  and 2mM 
glutamine, 800 units/ml GM-GSF (Invitrogen), and 500 
units/ml IL-4 (Invitrogen) at 37ºC, 5%CO2. After elec-
troporation 250 ng/ml LPS (Sigma-Aldrich, St Louis, 
MO, Escherichia coli 055:B5) was added for 24h to 
ensure maturation into mature dendritic cells, which 
were then washed and used as stimulators for T-cells. 
B-cells (2x106 cells/well) were cultured with irradiated 
CD40 ligand (CD40L) L-cells, 0.5x106 cells/well in 
6-wells plates with 500 units/ml IL-4 and ITES supple-
ment (Lonza group) in complete IMDM medium, with 
8% heat-inactivated FCS. B-cells were stimulated 
once a week and after electroporation the B-cells were 
cultured overnight in complete IMDM medium includ-
ing 500 units/ml IL-4 before usage as stimulators.
RNA electroporation of MoDCs and B-cells
RNA was synthesized from the pGem4Z vector con-
taining the UL49.5 gene from BHV-1. Vector DNA was 
linearized for 1h at 37ºC, with SpeI (Roche, Basel, 
Switzerland). RNA of UL49.5 was then synthesized 
with the High Yield Capped RNA transcription Kit (T7; 
Ambion, Austin, TX).
MoDCs cells were cultured for 6 days before electro-
poration with 20μg synthesized RNA. For each elec-
troporation a maximum of 1x107 cells in 100 μl Opti-
mem media (Invitrogen) was used. Cells were collect-
ed, washed and taken up in Opti-Mem media and 
pulsed with a blockpulser (Biorad, Hercules, CA), in a 
2mM cuvette (Biorad), at 300V, 150 μCF (33). Afterward 
cells were taken up in X-vivo medium (Lonza) without 
phenol red for 15 min at 37ºC, 5%CO2, and then incu-
bated overnight in complete RPMI 1640 medium, with 
8% heat inactivated FCS, 250 ng/ml LPS, 800 units/ml 
GM-GSF, and 500 units/ml IL-4. For electroporation of 
B-cells, 5x106 cells were stimulated with CD40L ex-
pressing L-cells, in a concentration of 0.5x106 cells/
well, and 500 units/ml IL-4 the day before. A maximum 
of 5x106 cells were electroporated with 20μg synthe-
sized RNA with the Nucleofector II, program U-008 






(Amaxa, Lonza, Cologne, Germany), using the human 
B-cell nucleofector kit (Amaxa). After electroporation 
cells were kept in X-vivo medium without phenol red for 
15 min at 37ºC, 5%CO2 and then cultured overnight in 
complete IMDM medium, with 8% heat-inactivated 
FCS containing 500 units/ml IL-4.
T-cell induction protocol
Polyclonal T-cell cultures with a concentration of 6x105 
cells/ml were induced, in a U-bottom 96 wells plate 
(Costar), by co-cultures with electroporated MoDCs 
(week 0 and 4) or B-cells (week 2 and 6) in a 
concentration of 2x105 cells/ml, in complete IMDM 
medium containing 8% human AB serum (Greiner, 
Bio-One, Alphen aan den Rijn, the Netherlands), 10 
ng/ml IL-7 (only week 0), and 60 units/ml IL-2. An 
alternating scheme is used as the amount of MoDCs, 
obtained from our healthy donors, is limited. 
T-cell clones were generated by limiting dilution at 
week 4 or 6. Polyclonal cultures were first depleted for 
CD4+ cells and stimulated with 1x105 cells/ml TAP 
inhibited B-LCLs (Modo or Hodo), 1x106 cells/ml pool 
PBMCs and 60 units/ml IL-2 in complete IMDM medium 
with 8% heat-inactivated FCS. After one week, T-cell 
cultures were restimulation with similar conditions. 
Clones were selected and restimulated every other 
week with 1x105 cells/ml a mixture of various TAP 
inhibited B-LCLs (Modo or Hodo), 1x106 cells/ml pool 
PBMCs, 60 units/ml IL-2, and 5 ng/ml IL-15 (Invitrogen 
Coroperation) in U-bottom wells.
Peptide transport assay
To ensure inhibition of TAP, a peptide transport assay 
was done as described previously (9,10). In brief cells 
where permeabilized, and incubated with the fluores-
ceinconjugated synthetic peptide CVNKTERAY in the 
presence or absence of 10mM ATP. Peptide transloca-
tion was terminated by adding ice-cold lysis buffer, 
and after the removal of cell-debris incubation with 
ConA beads was done to isolated glycosylated pep-
tides. The fluorescence intensity was measured and 
peptide transport is expressed a percentage of trans-
location, which is relative to the translocation in control 
cells.
Western blot
Cells were lysed in 0.5% Nonidet P-40 lysisbuffer (50 
mM Tris, 150 mM NaCl (pH 8.0), 0.5% NP40, 25 mg/ml 
Leupeptin, 25 mg/ml 4-(2-amino-ethyl)-benzene-sul-
fonyl fluoride hydrochloride (Sigma-Aldrich, Zwijn-
drecht, the Netherlands. Depending on the protein, 
either 16.5% Tricine-PAGE (for UL49.5) or 10% SDS 
page gels (for β-actin and TAP1) were made (9). The 
gels were loaded, and BenchMark prestained ladder 
(Invitrogen) was used as marker. For Tricine-PAGE 
gels, gels ran for 3-4h at 25mA/gel. The 10% SDS 
page gel ran for 1.5h at 15mA/gel. Afterwards the gel 
was blotted in a semi-dry manner, (Hep-1 OWL Panter; 
Thermo Scientific, Etten-Leur, the Netherlands) in 
semi-dry blot buffer (25mM Tris-Base, 192mM Gly-
cine), for 45 min at 10V onto a Hybond-PVDF transfer 
membrane (GE healthcare, Zoetermeer, the Nether-
lands), which was activated for 1 min in pure methanol. 
After blotting the membrane was incubated overnight 
at 4ºC in either 5% elk (for UL49.5 and β-actin) or 0.6% 
BSA (for TAP-1) in TBST (10mM Tris-base, 150mM 
NaCl, 0.05% tween20, pH 7.4).
The next day the blots were stained with one of the 
following antibodies, H11Az (anti BHV-1 UL49.5) (34), 
148.3 (anti TAP-1) (35,36), or anti-β-actin (Sigma) in either 
0.6 % BSA in TBST (anti TAP1) or 1% elk in TBST (anti 
UL49.5 and anti-β-actin). After the staining, the 
membrane was washed 3 times for 10 min in TBST, 
followed by 3 times 10 min washing in TBS (10mM Tris-
Base, 150mM NaCl, pH 7.4). HRP labeled secondary 
antibodies were used: anti-rabbit Ig (DakoCytomation, 
Carpinteria, CA) for UL49.5, and anti-mouse Ig for 
TAP1 and β-actin (Dako), followed by 3 times washing 
in TBST and 3 times TBS. The western blot was 
developed on film using ECL Plus Western Blotting 
Dectection Reagents (GE Healthcare).
Flow cytometry
For flow cytometry the following antibodies were used 
from BD bioscience: CD3 (SK7, FITC), CD137 (4B4-1, 
APC), CD8 (SK1, PE or APC), CD4 (SK3, PE) from 
Serotech: anti-HLA A/B/C (W6/32, APC), and from 
Beckman Coulter the Vβ Repetoire Analyses kit was 
used. Cells were analysed using a FACS Calibur, and 
Cellquest software (Becton Dickinson, USA), or Flowjo 
software (Tree star, Inc).
CD8+ T-cells clones were stained for the following NK 
and KIR receptors: CD226 (clone DX11), NKG2A 
(clone Z199PE), NKG2C (clone 134591), NKG2D 
(clone 149810), CD56 (clone MY-31), CD94 (clone 
DX22), 3DL1 (clone DX9), 2DL3 (clone GL183), 
2DS1/2DL1 (clone EB6), 2DS4 (clone FES 172), 3DS1 
(clone Z27), IgG1 (clone A687), 2DL4 (clone A687), 
2DL5 (clone A687), all kindly provided by Dr J. van 
Bergen (Leiden).
T-cell reactivity assays
IFNg production by T-cells was analysed after 24h or 
48h incubation via ELISA (PeliKine compact human 
IFN ELISA kit, Sanquin Amsterdam). ELISA plates 
were developed with TMB (3, 3', 5, 5'-Tetramethyl-
benzidine Liquid Substrate Supersensitive, for ELISA, 
Sigma) and measured at 450nm. On each plate a 
standard curve was added to calculate the IFNg 
production (pg/ml). 
26 | CHAPTER 2
To confirm the receptor dependency of the T-cells, 
several antibodies were used: W6/32 (HB-95, anti 
HLA), BB7.2 (anti HLA-A2) and, B123.2.1 (anti HLA-
B/C) (kindly provided by Dr. E. Verdegaal) and FK18 
(anti CD8) (kindly provided by Dr. A. Mulder). Cells 
were pre-incubated at 37ºC, with 50μl of the antibody 
and IFNγ release was measured after overnight 
incubation.
Lytic activity of CD8+ T-cell clones was determined in a 
4h 51Cr release assay as previously described (37). 
1x106 target cells were labeled with 100μl 51Cr for 1h at 
37Cº. After labeling the cells were washed 3 times with 
PBS. The target cells were incubated for 4h at 37ºC, 
5% CO2, with different concentrations of CD8+ T-cells, 
after which the chrome release was measured. The 
percentage of specific lysis was calculated as follows: 
((specific lysis test well – spontaneous lysis)/(maximum 
lysis – spontaneous lysis)) x 100.
A CD8+ T-cell reactive against the TAP-dependent 
peptide HA-1 (clone HA-1, kindly provided by Dr. E. 
Goulmy) was used to ensure TAP inhibition in the 
B-LCL modo TAP inhibited targets (38). 
Results
RNA electroporation of UL49.5 leads to 
effective TAP inhibition
Previously, we demonstrated that inhibition of peptide 
transport through TAP induces the HLA-I-mediated 
presentation of TEIPP antigens by DCs (30). In analogy 
with this approach in our mouse model, we engineered 
TAP-inhibition in human monocyte-derived DC 
(MoDC) and B cells by the introduction of the TAP 
inhibitor UL49.5 of the BHV-1 virus (8). Gene transfer 
was accomplished through electroporation with 
synthetic RNA in order to prevent artificial vector 
sequences in these professional stimulator cells.  The 
UL49.5 gene was chosen from the four characterized 
viral TAP-blocking molecules, since we previously 
found that this protein is the most efficient inhibitor and 
actively breaks down TAP proteins (32). Introduction of 
synthetic RNA encoding for GFP showed that ~90% of 
both B-cells and MoDC were successfully transfected 
with GFP (fig 1a). Electroporation with synthetic RNA 
of UL49.5 resulted in strong expression of UL49.5 in 
MoDC and B-cells from healthy blood donors (fig. 1b). 
The high expression levels of the viral protein resulted 
in a specific TAP degradation, comparable to B-LCL 
that were stably transfected with the gene (fig 1b), and 
this TAP degradation was still present in B-cells 5 days 
after electroporation (data not shown). Importantly, the 
introduction of UL49.5 in the primary MoDC (12-20% 
reduction in intensity two days after electroporation) 
and B-cells (fig. 1c) led to a decrease of HLA-I 
molecules at the cell surface, illustrating that the 
inhibition of TAP function indeed limited the availability 
of peptides in the ER. Therefore, we concluded that 
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Figure 1: RNA electropora-
tion with UL49.5 into pri-
mary B cells leads to MHC-
I downregulation. (A) Pri-
mary cultures of B-cells or 
MoDCs were electroporated 
with RNA encoding GFP. 
Mock electroporations 
served as negative controls. 
After 24h incubation for B-
cells and MoDCs ~90% of 
the cells where successfully 
transfected with GFP. (B) 
Primary cultures of B-cells or 
MoDCs were electroporated 
with RNA encoding the viral 
TAP-inhibitor UL49.5. Mock 
electroporations served as 
negative controls. After elec-
troporation, cells were lysed 
and expression of UL49.5 (after 24 h) and TAP1 (48 h) was analysed by western blot. B-LCL with stable expression of the UL49.5 
protein served as positive control. (C) Electroporated primary B-cells were stained with anti HLA-I antibody at different time 
points. HLA-I surface expression is depicted of B cells electroporated with UL49.5 RNA (filled histograms) and with control RNA 
(open histograms). A decrease of HLA-I at the cell-surface was seen up till day 5 after electroporation. Data are representative 
for three independent experiments. Monocyte-derived dendritic cells showed similar results (data not shown).






electroporation with synthetic RNA encoding the viral 
UL49.5 is an effective method to generate TAP-
inhibited Anitgen Presenting Cells (APCs). These TAP 
impaired professional APCs were used for the 
induction of TEIPP-specific T-cells in vitro. 
Construction of a target cell panel for the 
analysis of TEIPP-specific T cells
In order to determine the specificity of the T-cell cul-
tures resulting from stimulations with TAP-inhibited 
APCs, we constructed target cell panels on the basis 
of stable B-LCL cell-lines. B-LCLs  hodo and modo cell 
panels were used as these two cell-lines cover around 
80% of the Caucasian population, including HLA-A1, 
-A2, -B8 and -B44 (Table I) (39). TAP was inhibited in 
these cell-lines via stable expression of the inhibitors 
UL49.5, ICP47, US6 and BNLF2a and as a control the 
empty pLZRS vector was used. Flow cytometry analy-
sis was performed to determine surface HLA-I expres-
sion using an anti-HLA-A/B/C mAb. The B-LCL dis-
played decreased HLA-I levels after introduction of 
one of the TAP inhibitors, albeit to variable extent (fig 
2a). Subsequently, we determined the impairment of 
TAP function in these B-LCLs, with a peptide transport 
assay. The efficiency of TAP inhibition was found to 
vary between 70 to 90%, with UL49.5 giving the stron-
gest decrease in TAP transport (fig 2b). These results 
confirmed that all viral proteins were capable of effi-
ciently impair TAP function, although the changes in 
total HLA-I surface levels were not compelling. In ac-
cordance, earlier studies indeed point at a discrepancy 
between TAP blockade and the effects in HLA-I ex-
pression levels at the cell surface (32), implying that 
alternative peptides substitute for the TAP-mediated 
peptide repertoire. To examine this notion, the recog-
nition of the minor histocompatibility antigen HA-1 
presented by HLA-A2 in a TAP-dependent way was 
determined with a previously established CD8+ CTL 
clone (32,38). IFNg production and cytotoxicity by this 
CTL clone upon incubation with the HLA-A2 positive 
B-LCL modo and its TAP-inhibited variants clearly in-
dicated that this peptide-epitope is virtually absent 
from the TAP-inhibited B-LCLs (fig 2c and d). We 
Tabel I. HLA-I serotype of cell-lines and donors
HLA typing
Sort Name HLA-A HLA-B HLA-C
Cell-line B-LCL hodo 1 11 8 60 w3 w7
B-LCL modo 2 2 44 60 w5 w10
B-LCL HD10 1 68 44 58 w3 w7
Donor HD1 2 23 44 44 w5 w4
HD2 11 31 7 44 w5 w15
HD3 2 2 44 18 w5 w7
HD4 1 2 8 44 w5 w7
HD5 2 24 44 39 w5 w7
HD6 1 11 8 40 w2 w7
HD7 2 3 44 57 w5 w6
HD8 1 1 8 58 w7 w7
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Figure 2: B-LCL panel with stable expression of each 
of the four known viral TAP inhibitors. (A) The genes 
of UL49.5, ICP47, US6 or BNLF2a were introduced into 
B-LCL modo using retroviral vectors. MHC-I cell-surface 
display was measured with a pan-HLA-I antibody. All cell 
lines were stained in the same experiments, but are sepa-
rated in two histogram plots for clarity. Isotype control 
(thin lines) and modo B-LCL transfected with vector alone 
(‘control’, thick lines) are the same in both panels. Similar 
results were obtained in three other experiments. (B) All 
viral proteins efficiently inhibit TAP function, as tested in a 
peptide transport assay. Percentage of TAP transport 
was calculated against B-LCL modo control which was 
set at 100%. Means and standard deviations shown are 
representative of two assays with similar outcome. Com-
parable results were observed for B-LCL hodo (data not 
shown). (C-D) IFNγ release (C) and lytic activity (D) by an 
established CTL clone, specific for the HA-1 antigen, was 
measured to ensure that the viral TAP-inhibitors were able 
to block surface presentation of TAP-dependent peptide-
epitopes. The HA-1 antigen is endogenously expressed 
by modo B-LCL and is presented by HLA-A2. Means and 
standard deviations are shown from one out of three ex-
periments with similar outcome
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therefore concluded that the control B-LCL presents a 
TAP-positive peptide repertoire and that the variants 
expressing one of the viral TAP-inhibitors predomi-
nantly present a different, TAP-independent peptide 
repertoire in their broad array of HLA alleles. These 
two cell panels constituted ideal target cells to deter-
mine TEIPP-reactivity by the T cell cultures induced 
with the UL49.5 RNA electroporated APCs .
Polyclonal T-cell cultures display TEIPP-
specificity
Polyclonal T-cell cultures were initiated from PBMC of 
healthy donors whom were selected to match HLA-I 
alleles with the modo or hodo B-LCL (Table I). MoDC 
or B-cells, with an impaired TAP function through 
UL49.5 RNA electroporation, were added to 
autologous T-cell cultures in a bi-weekly alternating 
scheme in order to stimulate the outgrowth of T-cells 
with TEIPP-specificity. Specificity of the T-cell cultures 
was examined after three to four in vitro stimulations by 
measuring IFNg release upon incubation with cells 
from the partly HLA-matched modo and hodo B-LCL 
panels. Strikingly, these short term cultures already 
displayed selective reactivity to the TAP-inhibited 
variants of the B-LCL (fig 3). One donor (HD2) which 
shared HLA-I alleles with both B-LCL lines, also 
exhibited reactivity against both TAP-inhibited cell 
lines (fig 3), suggesting that this T-cell culture 
contained multiple TEIPP-specificities presented by at 
least two different HLA-I molecules. Complete 
mismatched targets showed no reactivity, and the 
HLA-I negative target K562 was also not recognized 
(data not shown). IFNg release by the polyclonal 
T-cells was observed against TAP-inhibited B-LCL, 
irrespective of which viral TAP-targeting protein was 
expressed. Since the viral evasion molecules exert 
different mechanisms for TAP impairment (8-18), these 
data suggested that the T-cell recognition was induced 
by general TAP-impairment in the target cells rather 
than by a particular molecular strategy. An overview of 
the results from all nine polyclonal T-cell cultures is 
depicted in Table II. All cultures, from different blood 
donors, displayed selective reactivity against the TAP-
inhibited B-LCL. These surprisingly broad T-cell 
responses from short-term cultures prompted us to 
Tabel II. IFNγ release by polyclonal T-cell cultures from different donors
Target Medium  Controla  UL49.5  ICP47  US6 
Donor cell-line meanb SDc  mean SD  mean SD  mean SD  mean SD
HD1 Modo 39d 10 354 50 1098 176 1308 81 1407 141
HD2 Modo 44 6 68 16 145 24 198 32 164 4
Hodo 44 6 72 3 354 76 368 78 225 16
HD3 Modo NTe NT 2 2 51 49 121 131 61 26
HD4 Modo 10 0 205 34 122 27 240 47 213 59
Hodo 10 0 418 53 629 98 NT NT NT NT
HD5 Modo NT NT 155 32 269 85 811 120 NT NT
HD6 Hodo 30 4 54 1 114 24 62 1 52 19
HD7 Modo 14 0 134 28 507 49 793 215 466 187
HD8 Hodo 181 14 529 83 737 39 623 27 610 86
HD9 Modo 2 1 4 5 744 109 814 69 744 12
a B-LCLs are transduced with either an empty vector (control) or a vector containing one of the viral TAP inhibitors (UL49.5, ICP47 or US6).
b mean is calculated from triplicate samples
c SD is Standard Deviation
d IFNγ release (pg/ml)
e NT is Not Tested























































Figure 3: Polyclonal T-cell cultures exhibit TEIPP-speci-
ficity. (A-B) Short term T cell cultures from PBMC were stimu-
lated with UL49.5 expressing autologous dendritic cells and 
tested four to six weeks after initial stimulation against two 
panels of TAP-inhibited B-LCL. Healthy subjects were select-
ed on basis of sharing some HLA-I alleles with the modo or 
hodo B-LCL target cell lines (see Table I for HLA typing). IFNγ 
release by one T cell cultures from donor HD2 (A-B) is shown. 
HD2 shared HLA-I alleles with both B-LCL modo (A) and hodo 
(B) and was tested against both panels. Effector to target ratio 
was 2:1 for all experiments. (see Table II for results of all do-
nors).






exclude a super-antigen like response, reflected by 
strong T-cell expansions of one particular TCR Vb-
positive subpopulation. Staining with a panel of Vβ-
specific antibodies demonstrated a wide array of TCR 
Vβ usage (data not shown), indicating that the T-cell 
cultures were clearly polyclonal and were not the result 
of super-antigen mediated expansion. Together, these 
data suggested that TEIPP-specific T-cells can readily 
be detected in short-term T-cell cultures from PBMC of 
healthy blood donors.
Isolation of TEIPP-specific CD8+ T-cell 
clones 
The short-term polyclonal T-cell cultures resulting 
from three stimulations with RNA electroporated 
TEIPP-presenting cells contained both CD4+ and 
CD8+ T cells. CD8+ T-cell clones were isolated from 
these cultures by limiting dilution, stimulating CD4-
depleted cultures with TAP-inhibited modo or hodo B-
LCL. Approximately 10-20% of the isolated clones 
showed higher reactivity against TAP-inhibited B-
LCLs than control B-LCL. Further expansion of these 
T-cell clones resulted in the isolation of three stably 
growing T-cell clones from different donors. These 
three clones (clone 7.12, clone 4.16, and clone 2.3) 
expressed CD3, CD8 and TCR molecules from differ-
ent Vb families (fig. 4), confirming their independent 
origin. 
Flow cytometry profiling of natural killer receptors 
demonstrated that the TEIPP-specific CD8+ clones did 
not display an aberrant expression of these receptors. 
Comparable to the vast majority of activated CTL, the 
lectin receptors CD94, NKG2A and NKG2D were ex-
pressed, but the KIR family was absent (supp. fig 1).
All three CD8+ T-cell clones recapitulated the TEIPP-
specificity of the polyclonal T-cell cultures and 
recognized all TAP-inhibited B-LCL, but not control the 
B-LCL (fig. 5a-c). This indicates that all viral TAP-
inhibitors present an overlapping peptide repertoire 
which is different than its non-inhibited counterpart, 
and that the viral proteins themselves were not 
recognized by our T-cell clones. Of note, the reactivity 
pattern is completely opposed to that of the HA-1-
specific CTL (fig. 2c), illustrating the distinct peptide 
repertoires presented by TAP-proficient and TAP-
impaired target cells (32). The TAP-inhibited B-LCLs 
were recognized with different efficiencies by the CD8+ 
T-cell clones (fig 5). Interestingly, the B-LCLs inhibited 
with US6 had the least TAP-blocking effect (see fig 2b 
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Figure 4: Clones 7.12, 4.16 and 2.3 are CD3+, CD8+ and 
each has their own TCR Vβ usage. All three clones were 
stained for CD3, CD8 and 24 different TCR Vβ. Flow cytometry 
analysis revealed that clone 7.12 has TCR Vβ 14, clone 4.16 
Vβ 20 and clone 2.3 Vβ 4, confirming their independent origin. 
All clones are CD3+ and CD8+.

























































































Figure 5: CD8+ T-cell clones exhibit 
TEIPP-specificity. (A-C) CTL clones 
were obtained by limiting dilution and 
selected on reactivity against TAP-in-
hibited B-LCL. Approximately 10-20% 
of all isolated CTL clones showed 
preferred reactivity against TAP-inhib-
ited B-LCL, similar to the three CD8+ 
CTL clones shown here for 7.12 (A), 
4.16 (B) and 2.3 (C). IFNg release by 
CTL clones upon incubation with the 
B-LCL panels is shown. Means and 
standard deviations are shown from 
one out of four similar assays. NT 
means not tested.
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for modo) and were also the least 
recognized by the T cells, 
suggesting that a correlation exist 
between the degree of TAP-
inhibition and the level of HLA-I 
mediated TEIPP antigen presentation in HLA-I at the 
cell surface. 
Target cell recognition is TCR-mediated and 
HLA-restricted
We previously reported in mouse tumor models that 
TEIPP-specific CTL exert their reactivity strictly via 
their T-cell receptors and that the TEIPP antigens can 
be presented on classical as well as non-classical 
MHC-I molecules (28,29). Since the isolated human 
TEIPP-specific CD8+ T-cell clones described here 
displayed comparable specificity against TAP-inhibit-
ed targets, we anticipated that also the human CD8+ 
T-cell clones mediated target cell recognition in a 
TCR- and HLA-I dependent fashion. To examine this, 
all three CD8+ T-cell clones were incubated with a 
blocking antibody against CD8 during the incubation 
with the B-LCL panel. The anti-CD8 antibody caused a 
complete block of CTL-reactivity, strongly indicating 
that TAP-impaired targets were recognized via the 
TCR (fig 6). Secondly, to determine the HLA-I restric-
tion of the human T-cell clones, we generated an ad-
ditional TAP-inhibited B-LCL, which expresses a 
complementary set of HLA alleles (B-LCL HD10). All 
three CTL clones were tested for IFNγ production 
against B-LCL hodo, modo and HD10 (Table III). Im-
portantly, the CTL clones did not show reactivity 
against completely HLA-I mismatched target cells 
(Table III), even when the UL49.5 TAP-inhibitor was 
properly expressed, clearly indicating a dependency 
on specific HLA class I molecules. With the use of 
these target cell panels we were capable to determine 
the shared HLA-restriction element that determined 
the restriction of the three CTL clones: HLA-A2, HLA-
B8 and HLA-B44 (Tabel III). Some ambiguity was left 
for the CTL clone 7.12 concerning HLA-I restriction, 
since both A2 and Cw5 were still candidates (Tabel III). 
The HLA-A2 allele could, however, be appointed as 
restriction element for this CTL clone, because CTL 
reactivity was blocked using a HLA-A2-specific anti-
body, whereas an antibody against HLA-B and -C 
molecules did not block the recognition (supl fig 2). 
The fact that each T-cell clone used a different HLA-
restriction element for recognition of target cells indi-
Tabel III: HLA-I restriction of CD8+ T-cell clones
CD8+ T-cell
B-LCL target   clone 7.12  clone 4.16  clone 2.3  
Modo shared HLA-Ia A2, B44, Cw5 b  A2, B44, Cw5  B44, Cw5
 T-cell recognition c  654 d  17  474  
Hodo shared HLA-I none  A1, B8, Cw7  A11
 T-cell recognition  4  244   23  
HD10 shared HLA-I B44  A1, B44, Cw7  B44
 T-cell recognition  11  3  121  
a  HLA-I expressed by both the CTL of the donor and the B-LCL
b In bold are possible restriction molecules for CD8+ T-cell clones
c Specific IFNγ release (pg/ml) by the T cell clones calculated by the IFNγ release against B-LCL UL49.5 minus the IFNγ release against the B-LCL control.
d mean value of IFNγ of triplicate samples, SD < 50 pg/ml in all cases








































































































2.3CFigure 6: Recognition of TAP-inhibit-
ed target cells is TCR-mediated. (A-
C) CTL clones were pre-incubated with a 
blocking anti-CD8 antibody before incu-
bation with B-LCL target cells. IFNg re-
lease for all three CTL clones is shown: 
7.12 (A), 4.16 (B) and 2.3 (C). Isotype 
control antibodies did not alter the rec-
ognition of TAP-inhibited B-LCL (not 
shown).






cated that multiple different peptide-epitopes are in-
volved in the TEIPP-specific response of healthy sub-
jects. The broadness of TEIPP-specific T-cells was 
further supported by the finding that the polyclonal T-
cell culture of donor HD2 displayed reactivity against 
both hodo (A11 matched) and modo (B44 matched) 
B-LCLs (fig. 3c), whereas the modo stimulated CTL 
clone derived thereof was solely restricted by the B44-
allele (Tabel III). All together, these data demonstrated 
that the TEIPP-directed T-cell response in humans is 
broad and involves multiple HLA-I presented peptide-
epitopes.
CD8+ T-cell clones lyse TAP-impaired B-LCL
To examine if the CD8+ T-cell clones were also capable 
to lyse TAP-deficient targets, a chromium release 
assays was preformed. The two tested T-cell clones 
7.12 and 4.16 efficiently lysed all four TAP-inhibited 
target cells, whereas their TAP-proficient counterparts 
were not killed (fig 7a,b). The specificity pattern of the 
T-cell clones matched that of the IFNγ release assays 
(fig 5a,b). To determine the contribution of NK-like 
reactivity to this lysis, the K562 cell line, which is 
completely HLA-I negative, was included as a target. 
K562 cells were not killed by the T-cell clones, 
indicating that our cytotoxic T-cell clones did not 
exhibit HLA-I-independent killing activity (fig 7a,b). We 
speculate that our T-cell clones constitute the first 
examples of TEIPP-reactive CTL in humans, and that 
this CD8+ T-cell subset is well represented in PBMC of 
healthy subjects.
Discussion
Here we present the first evidence for the existence 
of TEIPP-specific CTL in humans. These CD8+ T 
cells selectively recognize TAP-inhibited target 
cells, which are generally resistant to detection and 
lysis by conventional CTL. TEIPP-specific CTL were 
already detectable in short term T-cell cultures that 
received only three rounds of stimulation, indicating 
that TEIPP-CTL are well represented in the PBMC of 
healthy subjects. All PBMC cultures exhibited reac-
tivity against B-LCL expressing a viral TAP-inhibitor, 
but not against the normal B-LCL, suggesting that 
TEIPP-CTL are generally present in the human 
population and target a broad repertoire of peptides 
which are presented upon TAP-inhibition. Analyses 
of TEIPP-specific CTL clones revealed that target 
cell recognition depends on the T-cell receptor and 
that several different classical HLA-I molecules 
present these cognate peptides. These data are in 
complete analogy with our previous findings in 
mouse models (28-31).
TEIPP-specific T cells were isolated by stimulations 
of PBMC from healthy donors with autologous 
dendritic cells that were electroporated with RNA 
encoding the BHV-1 gene UL49.5. The protein from 
this bovine herpesvirus efficiently inhibits the 
peptide transporter TAP (see fig 1) through induction 
of a conformational arrest and proteasomal 
degradation (8-10). Using this autologous culture 
system, we minimized the risk of inducing artificial 
T-cell specificities, e.g. allogenic-HLA antigens, 
minor histocompatibility antigens and vector-
derived antigens. The generated T-cell cultures 
were tested against panels of B-LCL stably 
expressing one of four different well characterized 
viral TAP inhibitors (UL49.5, ICP47, US6 and 
BNLF2a). The polyclonal T- cell cultures, and also 
the isolated T-cell clones responded to all four TAP-
inhibited cell lines, excluding the UL49.5 protein, 
which was present during the culture period, as the 
source of target peptides. Although RNA 
electroporation is only transient and not completely 
inhibiting TAP function (fig 1b), it is sufficient enough 
to alter the repertoire of peptides as such that CTLs 
which are specific for TAP-inhibited cells are 
induced. This is in line with our previous studies in 
which both TAP-knockout and TAP-inhibited cells 
where recognized (28-30).
The CTL clones isolated display different HLA-I re-
strictions for their TEIPP epitope. CTL 7.12 is HLA-
A2 restricted, CTL 4.16 is most likely HLA-B8 re-
stricted and CTL 2.3 is HLA-B44 restricted. HLA-I 
molecules associate in the peptide loading complex 
with TAP in order to directly load peptides which are 
Lampen et al figure 7
4.16B7.12A





















































Figure 7: CD8+ T-cell clones lyse TAP-inhibited B-LCL. 
(A-B) The B-LCL cell panels were loaded with chromium and 
used as targets for CTL clones 7.12 (A) and 4.16 (B). K562 cells 
are HLA-negative target cells and were not lysed by the CTL 
clones, indicating the absence of natural killer-like reactivity. 
Different effector to target (E:T) ratios were tested and data 
points represent means and standard deviations from tripli-
cate wells. Similar results were observed in two independent 
experiments.
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there pumped into the ER. The binding of HLA-I to TAP 
is not well understood, but it is shown that position 116 
(p116) in the HLA-I molecule has a great effect on as-
sociation with TAP and/or tapasin (40-42). This is well il-
lustrated by the two closely related alleles HLA-B4402 
and B4405 (40-42). Where B4402, with aspartic acid at 
p116, is highly dependent on TAP, B4405 with tyrosine 
at this position is completely independent of TAP (40-42). 
Detailed analyses showed that peptide loading of 
HLA-A2, -A23, -B7, -B8, and -B4405 molecules is 
largely independent of TAP (25,26,43-47), while the TAP-
dependent pathway is the main processing route for 
HLA-A1, -A3, -A11, -A24, -B15, -B27 and -B4402 (40-46). 
It could be hypothesized that TEIPP peptides are pre-
dominantly presented by HLA-I molecules that are 
normally dependent on TAP for their peptide loading, 
since the transition to TAP-deficiency would then se-
lect for a completely distinct peptide repertoire. How-
ever, we isolated CTL with HLA-I restrictions from both 
categories (HLA-A2, HLA-B8, and HLA-B4402), sug-
gesting that TAP associations are not predictive for 
presentation of TEIPP peptide-epitope, and that all al-
leles could display TEIPP upon inhibition of TAP.
Apart from presenting TEIPP at the cell-surface of 
TAP-deficient cells another explanation for reactivity 
against TAP-deficient targets could the involvement of 
the CD94/NKG2a complex which is expressed on 
some of the CD8+ T-cells. Indeed our CTL 7.12 also 
expresses this complex, while it is absent on CTL 4.16 
(supl fig 1). CD94/NKG2a can bind to surface HLA-E 
molecules loaded with peptide, which then acts as an 
inhibitory molecule (48). Since TAP-deficient cells 
express these HLA-E molecules and TAP-deficients 
cells in lower amounts it could be possible that the 
TAP-independent peptide, which is recognized by the 
TCR of CTL 7.12, is already presented at TAP+ but non-
reactive due to the presence of HLA-E and NKG2a/
CD94. However, in our previous studies in mice 
blocking the NKG2a had no effect on the reactivity of 
the CTLs (28), and we therefore have no reason to 
believe that this would be the case for our CTL 7.12 
which is expressing NKG2a/CD94.
Molecular identification of human TEIPP antigens 
would enable immunotherapeutic approaches for the 
treatment of tumors harboring antigen processing 
defects. Since processing-deficient tumors are 
resistant to conventional anti-tumor CTL and represent 
a major percentage of all tumors, alternative T-cell 
based strategies, like TEIPP antigens, are more than 
welcome. In an attempt to indentify the nature of the 
involved peptide-epitopes, we tested HLA-A2 binding, 
TAP-independently processed peptides that were 
described by the group of Dr. Stevanovic (Tuebingen, 
Germany) (27) for recognition by our TEIPP T-cell 
clones. However, none of the peptides from this list 
stimulated our T-cells, and also the T2 cell-line from 
which these peptides were eluted was not recognized 
by our HLA-A2 specific CTL. Despite the fact that the 
exact identity of our human TEIPP peptides remains 
unknown, TAP-impaired DC could constitute an 
alternative in vaccination studies. RNA electroporation 
of MoDCs or B-cells with a viral TAP inhibitor is feasible 
in clinical settings. RNA electroporation has the 
advantage that the nucleotides are not integrated in 
the host genome, like viral vectors (33,49-53). In our mouse 
model, TAP-deficient dendritic cells were capable to 
prevent the outgrow of TAP-deficient tumors (30). 
Several improvements still need to be made to fully 
optimize dendritic cell vaccination in cancer patients, 
but the process will remain tailored and laborious as 
each patient needs their own manufactured vaccine. 
Therefore, we argue for the molecular identification of 
human TEIPP in order to enable peptide vaccination, 
which holds great promise for the future as a cancer 
treatment.
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Supplementary figure 1: 
Clones 7.12 and 4.16 
have a normal T-cell phe-
notype. CTL clone 7.12 (A) 
and clone 4.16 (B) were 
stained for well known T-
cell, NK and KIR receptors. 
Clone 7.12 was positive for 
CD56, CD94, DNAM, NK-
G2A and NKG2D all mark-
ers which are expressed on 
a subet of T-cells. None of 
the KIR receptors was 
found at its cell surface. 
Clone 4.16 was positive for 
CD56, DNAM and NKG2D 
and again no KIR receptor 
expression was observed.












































































































Lampen et al supl figure 2
7.12 7.12Supplementary figure 2: TEIPP-CTL 
clone 7.12 is HLA-A2 restricted. Target 
cells modo B-LCL and UL49.5 expressing 
modo B-LCL were pre-incubated with anti 
HLA-I, anti HLA-A2, and anti HLA-B/C anti-
bodies, before clone 7.12 was added. IFNγ 
release by CTL was measured. Two panels 
represent independent experiments, which 
show that total HLA-I blocking and specific 
HLA-A2 blocking prevented CTL activation. 
These results corroborate those from figure 
7 on the HLA-A2 restriction of TEIPP-CTL 
clone 7.12.
Development of a target 
discovery approach for the 
identification of human TEIPP 
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in a broad range of tumors varying from 10% in Head 
and Neck squamous cell carcinoma (HNSCC) up to 
74% in renal cell carcinoma (4, 5). Moreover the fre-
quency of TAP loss is increased in metastatic lesions. 
Both “hard” and “soft” lesions are associated with poor 
prognosis as it leads to failure of recognition and 
elimination by tumor specific CTLs (4-9).
Recently, our group identified a new category of tumor 
antigens that recognizes self-peptides emerging at the 
cell-surface upon impairment of the MHC-I antigen 
presentation pathway (10-17). We named this new 
category TEIPP: T-cell Epitopes Associated with Im-
paired Peptide Processing. TEIPP-specific T cells 
recognize neo-antigens and display preferential killing 
to cells with impairment in their antigen presentation 
pathway (10-16). 
Two TEIPP epitopes have been identified so far at the 
molecular level: the Trh4-epitope in mice and the 
CALCA-epitope in human (14-16). The Trh4-epitope is 
presented in H-2Db and derives from the C’-terminus 
of the Trh4-protein, which is an ER membrane span-
ning protein (12, 14). The CALCA-epitope is derived 
from the signal peptide sequence of preprocalcitonin, 
is processed through the enzymes Signal Peptidase 
(SPase) and Signal Peptide Peptidase (SPPase), and 
presented in HLA-A2 (15, 16). Possible therapeutic 
applications in order to induce TEIPP CTLs have been 
studied in mice. Mice were vaccinated with either the 
short peptide Trh4, or TAP-deficient Dendritic Cells 
(DCs). Alternatively, in vitro expanded CTLs were 
transferred back in mice (10, 14). In all three cases the 
TEIPP-targeted immunotherapy mediated clearance 
of tumors with MHC-I defects, in particular TAP defi-
ciencies (10, 14). Inducing TEIPP-specific CTLs might 
provide the first local immune activation and cytokine 
release upon recognition of these antigen-impaired 
lesions, and therefore addition of TEIPP-comprising 
antigens in vaccination could be an attractive strategy 
for immunotherapy. 
In our search for human TEIPP epitopes, we identified 
a group of CD8+ T-cells, specific for TAP-impaired 
target cells (11). The diverse sets of T-cell Receptors 
(TCR) that were used by the isolated CTL clones and 
the confirmed TCR-dependent and different HLA-I re-
strictions implied the involvement of a broad TEIPP-
specific repertoire (11). However the exact epitopes 
recognized remained unidentified. In contrast to this 
forward approach, we here hoped to identify TEIPP 
epitopes using a reverse immunology approach in 
which we selected predicted candidates from the hu-
man proteome, using the Trh4- and CALCA-epitopes 
as examples. Vaccination of HLA-A2 restricted TEIPP-
candidates in HLA-A2 transgenic mice revealed five 
candidates out of twenty-three tested. Immunogenicity 
Abstract
Recently, our group identified a new category of anti-
gens (TEIPP) that emerges at the cell surface upon 
impairment of the antigen presentation pathway via 
the TAP molecule. Two of these antigens have been 
identified at the molecular level, the H-2Db presented 
Trh4-epitope in mice and the HLA-A2 presented CAL-
CA-epitope in humans. Moreover, in humans a large 
subset of T-cells was identified that recognizes target 
cells with a TAP-impaired antigen processing. To char-
acterize new epitopes belonging to the category of 
TEIPP-peptides in humans, we developed an ap-
proach in which we predict and examine possible 
candidates from the human proteome. In silico predic-
tion based on the Trh4- and CALCA-epitope resulted 
in 2308 candidates. Immunization of HLA transgenic 
mice followed by testing naïve and experienced T-cell 
libraries from healthy donors revealed T-cell reactivity 
against three out of twenty-three tested peptides bind-
ing to HLA-A*0201 molecules. It remains to be investi-
gated whether these epitopes are indeed TEIPP-pep-
tides and whether antigen processing results in pre-
sentation at the cell-surface.
The developed method constitutes a tool to select new 
TEIPP-antigens, which might be exploited in the future 
to elicit T-cell immunity to tumor escape variants.
Introduction
CD8+ cytolytic T-lymphocytes (CTLs) have an impor-
tant role in the immune response against viruses and 
tumors. They recognize antigenic peptides that are 
presented in the molecules of the MHC class I region 
(MHC-I). Inhibition of the MHC-I antigen presentation 
pathway is therefore an attractive strategy to avoid 
CTL recognition, and both tumors and viruses adopted 
strategies to impair MHC-I antigen presentation.
Several mechanisms have been described that lead to 
loss of MHC-I presentation. In tumors, MHC-I antigen 
presentation defects are categorized by Garrido et al 
into “hard” and “soft” lesions (1). “Hard” lesions are ir-
reversible and structural, such as loss of gene copies 
via loss of heterozygosity (LOH), mutations or dele-
tions of MHC-I heavy chain genes or the β2m gene. 
“Soft” lesions are reversible regulatory defects such 
as decreased transcription via hypermethylation or 
oncogene activation, and blocking of the Jak-STAT 
pathway. All these defects result in down-regulation of 
MHC-I surface expression (1-3). Similarly, decreased 
transcription of components of the antigen-processing 
machinery (APM), including peptide transporter TAP, 
which transports molecules from the cytosol into the 
Endoplasmic Reticulum (ER), results in low MHC-I 
surface expression (1-5). Alterations of TAP are found 
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22) according to the selection criteria as mentioned in 
method I.
Immunization of mice
HLA-A2 transgenic mice (B6 background HLA-A2/H2-
D) (26) or control C57BL/6 mice were immunized sub-
cutaneously with 50 μg of pools or single HLA-A2 re-
stricted peptides and 150 μg HBV T-helper peptide 
(TPPAYRPPNAPIL) in PBS. As a positive control we 
included the HLA-A2 presented influenza epitope 
(GILGFVFTL). The injection site was covered with 60 
mg of Aldara cream containing 5% imiquimod (3M 
Pharma Nederland BV). Immunization was repeated 
on day 7 and then combined with two intraperitoneal 
injections of 600.000 IU human recombinant IL-2 (No-
vartis) on day 7 and day 8 (27). At day 13, blood sam-
ples were taken and tested for reactivity by overnight 
incubation with the corresponding peptide and intra-
cellular staining with anti-CD8-PE (clone 53-6.7, Biole-
gend) and anti-IFN-APC (clone XMG1.2, BD pharmin-
gen) antibodies, as previously described (27). Sam-
ples were analyzed by flow cytometry using Cell-quest 
(BD bioscience) and Flowjo software (Treestar Inc). 
Samples were considered positive if value was higher 
than four times background.
Competition-based cellular peptide binding 
assay
To test binding affinity of predicted peptides to HLA-I, 
competition-based cellular peptide binding assays 
were performed as described earlier (28). In short, B-
LCLs were treated with a mild acid (1:1 mixture of 
0.263 M citric-acid and 0.126M Na2HPO4*2H2O) to 
remove the naturally bound peptides. After treatment, 
cells were incubated with 150 nM of fluorescently la-
beled HLA-A*0201 (FLPSDC(Fl)FPSV) reference 
peptide, and a serial dilution of one of the peptides of 
interest starting at 100 μg/ml. As a positive control, a 
peptide derived from influenza (GILGFVFTL) was tak-
en, and as negative control we used a HLA-B7 binding 
peptide (SPSVDKARAEL) (28). Reference peptide 
alone was included in each experiment to determine 
the maximum intensity of fluorescence. Cells were 
measured with FACS using CellQuestPro (Calibur, BD 
Dickinson) and analyzed with FlowJo software (Tree 
Star, Ashland, OR, USA).  The concentration of pep-
tide needed to reach half-maximal binding, were de-
fined with GraphPad Prism 4.02 (GraphPad Software 
Inc., La Jolla, USA).
T-cell libraries
T-cell libraries were created as previously described 
(29). CD14+ cells were isolated from Peripheral Blood 
Mononuclear Cells (PBMCs) of healthy HLA-A*0201+ 
for four of these peptide candidates was examined in 
human PBMCs by generating naïve and experienced 
T-cell libraries of healthy donors. This method re-
vealed that T-cell reactivity against these peptides 
could be observed. This developed method consti-
tutes a tool to select new TEIPP-antigens, which might 




Selection of possible TEIPP-comprising antigens was 
based the notion that the epitopes are either present in 
the signal sequence of the protein, like the CALCA-
epitope, or at the C’-terminus of ER-resident proteins, 
like the Trh4 epitope. On the 1st of November in 2007, 
all human protein sequences from UniProtKB were 
downloaded (http://beta.uniprot.org/) resulting in 
71.088 entries. TEIPP candidates were selected using 
two approaches: 1. selection of peptides within the 
TAP-independent part of signal sequences (method I), 
2. selection of peptides from ER resident proteins 
(method II).
For method I we started with the SignalP-3.0 service 
that predicts the presence and location of signal se-
quences, using an algorithm model that predicts the 
cleavages site of SPase (http://www.cbc.dtu.dk/ser-
vices/SignalP) (18-20). The SPase is determining the 
C-terminal amino acid of the TEIPP candidate. To take 
into account further trimming on the C’-terminus site of 
the peptide within the ER, a finding frequently ob-
served for TAP-independent peptides, we predicted 
MHC-I peptide binding ligands up to four amino acids 
upstream of the predicted SPase cleavage site. For 
prediction of MHC-I peptide binding, we used NetM-
HC3.0 (http://www.cbc.dtu.dk/services/NetMHC) (21, 
22). This sever has the best performance among 30 
prediction servers for human MHC-I molecules (23). 
Ligands should fulfill the following criteria: 1. The li-
gand binds to HLA-A0101, A0201, A0301, A2402, 
B0702, or B4001 with a predicted binding affinity below 
250 nM; 2. It has a length between 9-11 amino acids.
Method II C’-terminus: Proteins that have a subcellular 
location, within the UniProtKB database, in either the 
endoplasmic reticulum (ER) or the ER-membrane 
were selected. For the ER-membrane proteins the 
protein topology was predicted with the TMHMM 
server (http://www.cbs.dtu.dk/services/TMHMM/) 
(24, 25). This program gives an indication of the orga-
nization of the protein by predicting the trans-mem-
brane helices. Only those proteins with the C’-terminal 
end located inside the ER were selected. Next, MHC-I 
ligands were predicted by using the NetMHC 3.0 
server (http://www.cbc.dtu.dk/services/NetMHC) (21, 





 3sured in duplicate and as positive control the peptide derived from influenza (GILGFVFTL), and a peptide 
derived from MART-1 (AAGIGILTV) were included. As 
a medium control, T-cells were cultured with autolo-
gous monocytes alone. ELISPOT analysis was per-
formed using manufacturer’s instructions (Mabtech 
Ab). Spots were visualised by SigmafastTM/BCIP®/
NBT (Sigma) and the number of spots was measured 
with a fully automated computer-assisted video-imag-
ing analysis system (BioSys 4000). T-cell libraries 
were considered positive if the number of spots ex-
ceeded the baseline, which was calculated by the 
mean of the medium controls plus 4 times the standard 
deviation (31).
Results
In silico prediction of TEIPP-candidates re-
sults in 2308 candidates
An overview of the complete methodological approach 
to select and test TEIPP-candidates is shown in figure 
1. The two known TEIPP-epitopes are encoded at the 
donors, through positive selection using CD14+ MACS 
beads (Miltenyi Biotec, Gladbach Germany). Subse-
quently, we isolated populations of naïve and experi-
enced CD8+ cells through FACS sorting with CD45 RA 
FITC (ALB11, Immunotech), CD19 PE (J3-119, Beck-
ham Coulter), CD56 PE (MY31, BD Biosciences) , CD4 
PE (HIB19, BD pharmingen), CD62L PeCy7 (DREG56, 
Biolegend) and CD8 APC (DK25, Dako). Naïve and 
experienced CD8+ cells were sorted with a FACSAria 
flow (BD bioscience) by selection of CD8+/CD62L+/
CD45RA+ (naïve) and the remaining CD8+ (experi-
enced) cells. After sorting, 1000 cells/well of naïve or 
experienced CD8+ cells were expanded with 0.5 μg/ml 
PHA ((HA-16) Remel Europe) in 384 wells tissue cul-
ture plates (Corning) with 50.000 irradiated pool 
PBMCs, and 500 units/ml IL-2 (Invitrogen Coropera-
tion) in a volume of 50μl. Cells were cultured in IMDM 
medium containing 5% heat-inactivated Human Ab 
serum (HAb) (Greiner), 100 units/ml penicillin, 100μg/
ml streptomycin (Gibco) and 2mM glutamine (Lonza), 
100x Sodium Pyruvate (SP) (Gibco), and 100X Non 
Essential Amino Acids (NEAA) (Gibco), and incubated 
at 37ºC, 5% CO2.
Four days after initial stimulation, two 384 wells were 
pooled in one 96 well (Corning) generating mini-cul-
tures of 2000 different specificities with a total com-
plexity of 192,000 specificities (96 wells) of naïve T-
cells, and 96,000 specificities (48 wells) of experi-
enced T-cells. If necessary, expanding cultures were 
transferred to a 48 wells (Corning), or 24 wells plate 
(Corning) by adding medium containing 100 units/ml 
IL-2. Cells were tested for immunogenicity in an IFNγ 
ELISPOT assay at day 14 after initial stimulation.
IFNγ ELISPOT assay
ELISPOT assays were done as described before (30). 
Naïve or experienced CD8+ T-cell mini-cultures were 
co-incubated with peptide loaded (1μg/ml) autologous 
CD14+. Per well 100.000 T-cells were co-incubated 
with 10.000 peptide loaded autologous CD14+ cells 
overnight at 37ºC and 5% CO2. Samples were mea-





confirmation of HLA-I specific
binding by binding-assays
study the T-cell repetoire 
against candidates using
T-cell libraries
Step 1: Step 2: Step 3: Step 4:
Figure 1 Lampen et al
Figure 1: Selection methodology for human TEIPP T-cell epitopes. Based on the protein-location of the two TEIPP epit-
opes Trh4 and CALCA, a peptide candidate list was created from the human proteome using bio-informatics (step 1). The im-
munogenicity of these peptides was determined in corresponding HLA class I transgenic mice (step 2). Immunogenic peptides 
were then tested for their HLA binding affinity (step 3). Naïve and experienced T-cell libraries were created from healthy donor 
PBMC in order to determine if a T-cell repertoire against these peptides exist. (step 4).






A0101 A01 3c 0
A0201 A02 1929 24d
A0301 A03 152 18
A2401 A24 52 12
B0702 B07 77 21
B4001 B44 0 20
a These alleles represent most abundant supertypes covering 99.5% of the 
Caucasian population
b For an overview of the selection methods see figure 2
c Number of predicted peptides. Peptides have a length of 9-11 amino ac-
ids and have a predicted HLA-binding Kd of <250nM
d These 24 peptides were tested in this study
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(14-16). We therefore designed two in silico prediction 
methods that represent these two locations of TEIPP 
peptides. First, we selected the TAP-independent seg-
ments of all leader peptides within the human protein 
database, and predict their binding affinity to six su-
pertypes, which cover 99.5% of the Caucasian popu-
lation (32) (HLA-A0101, A0201, A0301, A2402, B0702, 
or B4001) (Figure 2; method I). The C-terminus of 
these peptides are predicted to be generated by the 
ER-resident proteolytic enzyme signal peptidase 
(SPase) and some imprecise determination of this C-
terminus was reported for leader peptides due to 
cleavage variation or further trimming in the ER. 
Therefore, we included peptides from leader sequenc-
es up to four amino acids upstream of the predicted 
SPase cleavage site. Our search resulted in 2213 
peptide candidates of which most were predicted to 
bind in HLA-A*0201 (Table I). This is not surprising as 
the signal peptide sequence is a hydrophobic region 
(20), and HLA-A*0201 prefers hydrophobic amino ac-
ids at its dominant pockets. 
Second, we selected TEIPP candidates derived from 
the C’-terminus of ER resident or ER membrane span-
ning proteins. The mouse TEIPP-epitope from the Trh4 
protein represents the prototype of this group. For this, 
we screened the human protein database for proteins 
with a designation of ER or ER membrane. For ER-
membrane proteins we subsequently predicted their 
trans-membrane topology using the TMHMM-algo-
rithm and selected those proteins that have their C’-
terminal end located within the ER. These selected 
peptides were then subjected to prediction programs 
for HLA-I binding affinity to the previously described 
alleles (Figure 2; method II). This resulted in 95 TEIPP 
peptide candidates, which is considerably less than 
the peptides predicted in the signal sequences of pro-
teins (Table I). However, the exact cellular localization 
of most peptides is not described in the SwissProt da-
tabase and therefore this collection is an underrepre-
sentation of potential TEIPP-candidates by this meth-
od. 
To validate our methodology, we decided to test the 
immunogenicity of 24 HLA-A*0201 peptide candidates 
derived from ER-resident proteins, as HLA-A*0201 is 
the most abundant allele within the Caucasian popula-
tion. 
Immunization of HLA-A2 transgenic mice 
reveals peptide immunogenicity
To assess the immunogenicity of the selected 24 pep-
tides, HLA-A2 transgenic mice were immunized with 
pools of the peptide candidates. One peptide was not 
analyzed because it was hard to produce due to its 
very hydrophobic nature. A total of 5 pools were made, 
extreme ends of proteins. The human CALCA peptide 
is comprised at the TAP-independent segment of the 
leader sequence and the mouse Trh4 peptide resides 
at the complete C-terminus of this ER located protein 
N’ C’
Selection for SPase cutting
Binding to MHC-I
Method-I: N-terminus
Selection of location to ER
Selection of transmembrane
position



























Figure 2: Overview of in silico prediction methods for the 
selection of peptide candidates. Two methods were used 
to select TEIPP candidates. Method I is based on the CALCA-
epitope derived from the leader sequenced of preprocalcito-
nin, which is processed through the signal sequence pathway. 
Signal sequences from the complete human proteome were 
predicted with SignalP3.0 algorithm. Further trimming at the 
C’-terminal site of the peptide might occur within the ER and 
we therefore selected peptides up to four amino acids up-
stream of the predicted cleavage site. Binding affinity to one of 
the representatives of six HLA class I supertypes was then 
determined with netMHC 3.0.
Method II is based on the mouse Trh4-epitope, located at the 
C’-terminus of a ER-membrane spanning protein. All ER lo-
cated proteins from the complete human proteome were se-
lected and the transmembrane position of ER-membrane 
proteins was determined with the prediction program TM-
HMM2.0. Peptides with their C’-terminual end inside the cyto-
sol of the ER were included. Selection of TEIPP candidates 
was then based on HLA class I binding predictions using net-
MHC 3.0






lyzed in blood samples five days after the last vaccina-
tion. High IFNg production was directly observed ex 
vivo for two peptide pools, pool 1 and 3 (Figure 3A). 
Comparable frequencies of peptide-specific CD8 T 
cells were observed for the HLA-A2 –restricted posi-
tive control peptide from influenza (GILGFVFTL) (not 
shown). CD8 T cells from mice immunized with pool 4 
and 5 were weakly positive, and in each group one 
mouse exceeded the cut-off of 4 times above back-
ground (0.09% positive cells). To determine which 
each containing five (pools 1, 2 and 3) or four peptides 
(pools 4 and 5), to prevent possible competition be-
tween high affinity and low affinity peptides. Pool 1 
contained five peptides with the highest predicted 
HLA-binding affinity, and pool 5 contained four pep-
tides with the lowest predicted binding affinity.
Mice were subcutaneously immunized and boosted 
with the peptide pools and stimulated with the toll-like 
receptor-7 ligand imiquimod and low dose IL-2. The 
induction of peptide-specific CD8 T cells was ana-
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Figure 3: Immunization of HLA-A2 transgenic mice. Mice were immunized with 23 synthetic peptides from the subset of 
ER-resident C’-terminal ends (Method 2) that were predicted to bind to HLA-A2. These peptides were divided into 5 pools ac-
cording to their predicted binding affinity (A). For each peptide pool, two mice were immunized. Intracellular flowcytometry 
staining of blood cells ex vivo with anti-IFNg  and anti-CD8 antibodies revealed peptide-specific CD8 T cells in pool 1, 3 and 4 
(percentages are shown in upper right corner). For each pool the peptide specific response per pool is shown (e.g. pool 1 mice 
1a and 1b) Average medium control of all mice was 0.18%.
(B) Spleens were isolated from IFNg+/CD8+ mice and each peptide was tested separately for immunogenicity by means of in-
tracellular flowcytometry. Percentage of IFNg+/CD8+ cells after peptide stimulation is shown. In total 5 peptides showed im-
munogenicity in HLA-A2 transgenic mice ((indicated with a *: peptide 1.1, 1.2, 1.3, 3.2 and 4.1), exceeding the cut-off of 4 times 
higher than the % of the corresponding medium control. As positive control, the peptide pool was included (mix). Medium 
controls were non-stimulated spleen cells stained for IFNg and CD8. 
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with 1.35% and 1.92% of CD8+ cells producing IFNg 
(Figure 4). Peptide 1.2 (0.08%) and 4.1 (0.11%) dis-
played a low capacity to induce a CD8 T-cell response 
and no reactivity cells was seen against peptide 1.1 
(0.04%) (Figure 4). Unfortunately, we observed similar 
results in C57BL/6 mice (data not shown) and, there-
fore, could not conclude that the observed T-cell reac-
tivity was a result of HLA-A2-mediated presentation of 
the peptides.
Binding affinity of the selected peptides for 
HLA-A2
A competitive-based cellular peptide-binding assay 
was performed to measure the actual HLA-A2 binding 
affinity of the selected peptides 1.1, 1.2, 1.3, 3.2 and 
4.1. Flow cytometry analysis showed that peptides 1.1, 
1.2, 3.2, and 4.1 were able to bind to HLA-A2 (Figure 
5). Peptide 1.1 and 1.2 showed high affinity for HLA-A2 
molecules (Table II), peptide 3.2 showed intermediate 
affinity, and peptide 4.1 low affinity, corresponding to 
the predicted binding affinities by the netMHC program 
(Table II). No data could be generated for peptide 1.3 as 
high concentrations of the peptide in the cellular binding 
assays showed toxicity (data not shown). This prompted 
us to exclude this peptide in further experiments.
peptides within each pool were responsible for the T 
cell response, spleens of the positive mice were iso-
lated and tested for T-cell reactivity against single 
peptides from the peptide pools. In pool one we ob-
served 1.4% of IFNγ+/CD8+ cells against peptide 3 
(peptide 1.3, Figure 3B), whereas peptides 1 (0.15%) 
and 2 (0.11%) showed responses that were slightly 
higher than medium background (peptide 1.1 and 1.2, 
Figure 3B). In pool three, peptide 2 showed 8.6% of 
IFNγ+/CD8+ response and in pool 4 peptide number 1 
(0.22%) exhibited some immunogenicity (peptide 3.2 
and 4.1, Figure 3B). Reactivity against each peptide 
pool was confirmed from these splenocytes without 
further in vitro expansions (Figure 3B). 
Single peptide vaccinations were then performed to 
test whether these peptides indeed were capable of 
inducing CD8+ T-cell responses. HLA-A2 transgenic- 
mice were immunized with peptide 1.1, 1.2, 1.3, 3.2 or 
4.1. We included control wild type C57BL/6 mice to 
assess HLA-A2-restricted immunogenicity. We again 
observed high immunogenicity for peptide 1.3 and 3.2 




































Figure 4: Single peptide immunization in HLA-A2 trans-
genic mice. Peptides displaying immunogenicity were se-
lected for single peptide vaccinations in HLA-A2 transgenic 
mice. Mice were immunized twice with 50 μg of peptide and 
150 μg HBV T-helper peptide in PBS.  At the 13 after the initial 
stimulated blood was taken and tested for reactivity by over-
night incubation with the corresponding peptide. The next day 
intracellular flow cytometry stainings with anti-IFNγ (APC) 
and anti-CD8 (PE) were performed. Peptides 1.1, 1.2 and 4.1 
showed a low percentage of IFNγ+/CD8+ cells, whereas 
higher percentages of IFNγ+/CD8+ were observed for pep-
tides 1.3 and 3.2. As controls, blood samples were tested in 

















Figure 5 Lampen et al



















Figure 5: Peptide binding analysis for HLA-A2. Immuno-
genic peptides were tested for HLA-A2 binding affinity by 
means of a competitive-based cellular binding assay. One 
representative experiment is shown. Peptide binding was 
calculated as percentage of inhibition of the reference pep-
tide. Peptide 1.3 showed toxicity to the cells and was therefore 
not included. The average IC50 values were determined 
based on the outcome of two independent experiments and 
are show in Table II.






Table II: Peptide binding affinity to HLA-A2 of C-terminal TEIPP peptide candidates
HLA-A*0201
Measured Predicted
Peptide IC50 (mM)a Affinityb Kd (nM)c Affinityd
Peptide 1.1 2.37 High 2.1 Strong
Peptide 1.2 4.08 High 6.0 Strong
Peptide 1.3 NDe ND 14.6 Strong
Peptide 3.2 10.39 Intermediate 90.1 Weak
Peptide 4.1 36.31 Low 111.9 Weak
Positive controlf 1.2 High 18 Strong
Negative controlg >100 24413
a IC50 is half maximal peptide concentration in a peptide binding competition assay and represents the mean value of two independent experiments.
b Binding affinity is classified according to the following cutoff. High affinity IC50 ≤ 5 μM; intermediate affinity 5 μM < IC50 ≤ 15 μM; low affinity 15 μM < IC50 
≤ 100 μM; no binding IC50 > 100 μM.
c Kd is affinity of peptide binding according to NetMHC3.0 prediction software.
d Affinity is classified as follows: peptides with an affinity <50nM are strong binders, peptide with an affinity <500nM are classified as weak binders, no 
binding >500 nM
e ND= Not Determined due to cell toxicity
f Positive control is short peptide derived from influence (GILGFVFTL) 
g Negative control is a HLA-B7 binding peptide (SPSVDKARAEL)
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Figure 6: Naïve and experienced 
T-cell libraries of healthy do-
nors. Naïve and experienced T-cell 
were selected by means of flowcy-
tometry sorting (A). CD8+/CD62L+/
CD45RA+ cells were considered 
naïve T-cells and all other CD8+ 
were considered experienced T-
cells. Mini-cultures of 2000 cells 
were expanded through mitogen-
driven stimulation with PHA. Two 
weeks after initial stimulation 96 
naïve T-cell mini-cultures and 48 
experienced T-cell mini-cultures 
were tested in ELISPOT analysis 
using peptide loaded autologous 
CD14+ cells as targets and around 
105 of T-cells (B). As controls the 
HLA-A*0201-restricted influenza 
peptide and a HLA-A*0201 restrict-
ed peptide derived from the tumor 
antigen Melan-A/MART-1 were in-
cluded. Non-peptide pulsed autolo-
gous CD14+ cells functioned as 
negative targets Samples were 
considered positive once they ex-
ceed the line. The cut-off was deter-
mined as the mean of medium plus 
four times its standard deviation. 
Tables in right corner of graphs 
show summarizing data for three 
healthy donors.
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spots per positive culture, a phenomenon indeed ob-
served in the data (Figure 6B). Interestingly, we could 
also detect influenza M1 specific T cells in the naïve 
repertoire, implying an even greater potential of im-
mune cells that have not been recruited in the anti-in-
fluenza response yet. An HLA-A2 binding peptide de-
rived from the melanoma antigen Melan-A/MART-1 
was also included, since it is known that the naïve 
CD8+ T-cell precursor frequency is exceptionally high 
against this peptide due to thymic positive selection 
(29, 34, 35). Indeed, MART-1 specific T cells were only 
detected in the population of naïve T cells (10 out of 96 
cultures for donor 1; Figure 6B). 
In two out of three donors tested, we observed low re-
activity against peptide 4.1 in the naïve T cell reper-
toire, indicating the presence of T-cells against this 
self-peptide. One donor also showed somewhat higher 
reactivity against peptides 1.1, and 1.2 (Figure 6B). 
Further research needs to confirm the TEIPP identity 
of the peptides. We conclude that the approach de-
scribed in this paper is suitable for identifying new T-
cell epitopes.
Discussion
In this paper, we describe an in silico selection method 
for potential human TEIPP-epitopes. Immunogenicity 
and binding capacity to HLA-A*0201 of 24 peptide can-
didates were tested for peptides that derive from C’-ter-
mini of ER-membrane- or ER-resident proteins in vitro. 
Immunization of HLA transgenic mice selected five im-
munogenic peptides that were shown to bind to HLA-A2 
molecules. Using naïve and experienced CD8+ T-cell 
libraries of healthy HLA-A*0201+ donors we observed 
T-cell reactivity in the naïve repertoire against peptide 
4.1 in two out of three donors and in one donor against 
peptides 1.1 and 1.2. This indicates that our method is 
suitable for identifying new TEIPP-epitopes.
Naïve T-cells mini-cultures reveal human T-
cells reactive to TEIPP-candidates
To determine whether peptides 1.1, 1.2, 3.2 and 4.1 
have existing cognate T-cell repertoires in humans, 
naïve and experienced CD8+ T-cell libraries were cre-
ated. For these T-cell libraries, CD8 T were separated 
into naïve and experience T-cells by flow cytometry 
sorting and subsequently expanded in order to get 
mini-cultures with a maximum of 2000 different speci-
ficities. This results in a vastly increased frequency of 
potential peptide-specific T cells compared to their 
natural prevalence in the total T cell pool (29). This ap-
proach was chosen because we expected too low fre-
quencies in the human T-cell repertoire for staining 
and isolation with peptide/MHC-I tetramers (29) of 
both naïve and experienced CD8+ T-cells. Naïve T 
cells from HLA-A*0201 positive healthy donor PBMCs 
were sorted on basis of the cell surface profile CD8+/
CD45RA+/CD62L+ and the remaining CD8+ cells 
comprised all antigen-experienced CD8+ T-cells, in-
cluding effector, effector-memory and central memory 
cells (Figure 6A). 
Mini-cultures originating from 2000 different T-cell 
specificities were generated by mitogen-driven expan-
sion, and tested for reactivity against peptides 1.1, 1.2, 
3.2, and 4.1 in an ELISPOT assay. The HLA-A2-pre-
sented influenza peptide (GILGFVFTL) was included 
as positive control and reactivity against this peptide 
was indeed found in several mini-cultures of both na-
ïve and experienced T-cells of all three tested donors 
(33) (Figure 6B). 
For donor 1 (Figure 6B) nearly all mini-cultures from 
antigen-experienced T cells (45 out of 48) an influen-
za-specific response was detected, indicating a fre-
quency of at least 1 in 2000 (0.05%) of the experienced 
T cell pool. Multiple M1-specific T cells in one mini-
culture will result in multiplication of the number of 
Table III: Summary of HLA-A2 restricted peptide
Experiment Immunization HLA-A2 mice Binding assay T-cell library
pool single
Peptide IFNγ+/CD8+a IFNγ+/CD8+ Affinityb +/(no. tested)
1.1 + - High 1/3
1.2 + + High 1/3
1.3 +++ +++ ND ND
3.2 +++ +++ Intermediate 0/3
4.1 ++ + Low 2/3
a classified as follow: - = <0.05 , + = 0.05<x<0.20, ++ <1.0, +++ >1.0
b Binding affinity is classified according to the following cutoff. High affinity IC50 ≤ 5 μM; intermediate affinity 5 μM < IC50 ≤ 15 μM; low 
affinity 15 μM < IC50 ≤ 100 μM; no binding IC50 > 100 μM.






overview of the results is shown in Table III. 
In the competitive cellular binding assay one peptide 
was excluded because it showed toxicity with high 
concentration. This is most likely due to its very high 
hydrophobic region at the C’-terminus of the protein 
(two tryptophan’s at position 9 and 10 of this 11mer 
peptide). In two out of three donors we observed pep-
tide reactivity against peptide 4.1, and one donor 
showed reactivity against peptides 1.1 and 1.2 (Figure 
6). We concluded that T-cell reactivity against these 
self-antigens is present within the human population.
Additional experiments have to be done before we can 
conclude whether these three peptides are TEIPP-an-
tigens and whether antigen processing results in pre-
sentation of these epitopes at the cell-surface. There-
fore, T-cell clones specific for these peptides have to 
be isolated. However, the frequencies of these T-cells 
are low. As example only one library of the 96 tested 
shows a positive reaction of 30 spots. The occurrence 
of this T-cell specificity in this particular mini-culture is 
then estimated as 0.03% (=(30/100.000)*100), as each 
ELISPOT test well contained roughly 100.000 cells/
well. This nicely corresponds to the number of one 
specific T cell in the original pool of 2000 other speci-
ficities. In total 96 mini-cultures were tested resulting in 
a final frequency of this T cell in the total naïve T-cell 
library of approximately 0.0003% (=0.03/96). 
To successfully isolate a specific T-cell clone our ap-
proach should therefore first focus on increasing the 
frequency of these T-cells. Unfortunately not enough 
material remains after testing the mini-cultures in 
ELISPOT and therefore a different approach should be 
used after determining possible candidates by the 
above-described method.
One method we could use is enrichment of peptide 
specific T cells with a method described by Hombrink 
et al (39). Here they stain PBMC of healthy donors with 
peptide specific tetramers and then isolate these tetra-
mer positive cells through MACS sorting (39). To fur-
ther increase enrichment of the T-cell frequency we 
could combine this method with pre-selection of naïve 
T cells. Once a T-cell clone is established its reactivity 
should be tested against a broad panel of cell lines to 
determine possible cell-specific reactivity. Since the 
approach we used is reverse immunology it is not de-
termined yet whether the peptides are processed and 
presented at the cell surface of cells. If the T cells are 
selectively reactive against some processing impaired 
cell lines, a broader panel of tumor cells should be an-
alyzed to exclude possible autoimmune reactions. 
Restoration of the antigen presentation machinery 
could furthermore determine TEIPP specificity. If the 
identified epitope is indeed a TEIPP, and is expressed 
on a broad range of tissues, this epitope could be used 
TEIPP antigens are presented by HLA class I mole-
cules at the cell-surface of cells with impairment in the 
antigen presentation pathway. The transporter mole-
cule TAP is the major target in both tumors and viruses. 
Since only two TEIPPs have been identified so far, the 
Trh4-epitope in mouse models (14) and the CALCA-
epitope in human (15, 16), we conducted our predic-
tions according to the nature of these epitopes.
In our first in silico prediction method that was based 
on the CALCA-epitope, we found 2213 peptide candi-
dates for six different HLA alleles, covering 99.5% of 
the Caucasian population (32). Most of these peptides 
were predicted to bind in HLA-A*0201 molecules (Ta-
ble I), which is not surprising as signal sequences and 
this allele both have a preference for hydrophobic resi-
dues (20). This is also substantiated by the fact that 
hydrophobic signal peptides were observed in HLA-
A2 molecules in TAP-negative T2 cells (36, 37). HLA-
A2 molecules are indeed relatively unaffected by de-
fects in the peptide transporter and TAP-independent 
leader sequences emerge in HLA class I molecules on 
T2 cells (38). 
The CALCA-epitope was not among these 2213 pep-
tide candidates as the predicted binding affinity was 
weaker than the cut-off value 250nM. So far, T-cells 
directed against the CALCA-epitope have been identi-
fied in one lung-carcinoma patient (15, 16), and CAL-
CA-reactive T cells were not observed in our T-cell li-
braries (data not shown). Furthermore, stimulation of 
T-cells with CALCA-loaded autologous dendritic cells 
did not result in peptide specific expansion (data not 
shown). We were also unable to detect CALCA-specif-
ic responses in PBMCs derived from the original lung-
carcinoma patient ten years after treatment (data not 
shown). We concluded that CALCA is a weakly immu-
nogenic epitope and this prompted us to first focus on 
strong HLA-binding epitopes.
Identification of TEIPP-candidates derived from the 
C’-terminus of ER-resident proteins, resembling the 
mouse TEIPP Trh4, resulted in 95 candidates (Table I). 
This is considerably less then the candidates derived 
from the N’-terminus of the whole protein, mainly due 
to much lower numbers of C’-terminus peptides pre-
dicted to bind in HLA-A*0201. The 24 TEIPP candi-
dates from this category with a predicted binding to 
HLA-A*0201 were tested in the current study. The 23 
synthesized peptides (one candidate could not be 
produced) were divided into 5 pools according to their 
predicted binding affinity and HLA-A2 transgenic mice 
were immunized. Five peptides showed immunoge-
nicity in HLA-A2 transgenic mice (Figure 2 and 3), but 
these peptides were also shown to be reactive in 
C5BL7/6 mice (data not shown). We continued our ap-
proach with these five immunogenic peptides and an 
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The non-classical HLA-E is a conserved class I mole-
cule that mainly presents monomorphic leader pep-
tides derived from other HLA class I molecules. These 
leader peptides comprise an optimized sequence for 
tight and deep binding into the HLA-E groove. Viruses 
and tumors have, however, adopted strategies to in-
hibit the peptide transporter TAP and thereby prevent 
the loading of classical leader peptides in HLA-E. This 
alternative peptide repertoire has not been revealed so 
far. We identified more than 500 unique peptide se-
quences carried by HLA-E and found that their binding 
motif is different from the dominant leader peptides. 
Hydrophobic amino acids were only found at positions 
2 and 9, closely mimicking the peptide binding motif of 
HLA-A*0201. HLA-E-eluted peptides were indeed ca-
pable to bind this classical HLA class I molecule. Our 
findings suggest that the dominant leader peptides 
uniquely conform to HLA-E, but that in its absence a 
peptide pool is presented like that of HLA-A*0201.
Introduction
HLA-E molecules are encoded by the MHC class I re-
gion and belong to the non-classical antigens. They 
display a similar conformation as the classical HLA 
class I (HLA-I) molecules and also carry peptide frag-
ments in their binding grooves. The unique feature of 
HLA-E is its extreme conserved nature in the human 
population: only two alleles exist (E*0101 and E*0103), 
which vary in one amino acid at a position outside the 
peptide-binding groove [1]. The presented peptides 
are also monomorphic and predominantly derive from 
the leader sequences of other HLA-I molecules and 
harbour optimal residues for deep binding in the hy-
drophobic pockets of HLA-E [2]. Interestingly, signal 
sequences from HLA-I are strikingly homologous 
throughout mammal species, pointing at a conserved 
function of this HLA-E/peptide complex [3]. Indeed, 
the germline encoded receptors CD94/NKG2 that en-
gage HLA-E are found in multiple species and play an 
important role in natural killer cell function [4]. These 
heterodimer receptors interact with residues from the 
monomorphic leader peptides and can therefore be 
designated as peptide specific [4, 5]. 
HLA-E protein expression can be detected on almost 
all nucleated cells of the body and the levels on im-
mune cells, endothelial cells and keratinocytes are 
particularly high [6, 7]. Increased expression has been 
demonstrated upon cellular stress caused by viral in-
fection or heat shock and in cancer cells [2, 8, 9]. In 
these cases, HLA-E can present peptides from other 
sources than the signal sequences of classical HLA-I 
molecules. An efficient way to replace the dominant 
leader peptides is through inhibition of the peptide 
transporter TAP, which is frequently targeted by virus-
es and tumors. Some of the alternative peptides were 
able to induce CD8 T cell responses [2, 9], showing 
that HLA-E has a more versatile role than only serving 
natural killer cells by an indirect display of ‘self’ MHC. 
So far, the peptide-binding motif of HLA-E has been 
based on the HLA-I leader peptide or random peptide 
libraries that poorly associated with HLA-E [5, 10, 11]. 
Here we characterized more than 550 natural peptides 
from TAP-deficient cells. Due to this large number of 
sequences, we were able to determine a clearly de-
fined peptide-binding motif for HLA-E and surprisingly 
found that this motif mirrors that of HLA-A*0201. These 
peptides might adopt another conformation than the 




HLA-I negative K562 cells were transfected with HLA-
E*0103. K562.HLA-E.B8 cells were obtained from Dr. 
E. Weiss (Munchen, Germany) and contained a hu-
man b2m construct with the leader sequence of HLA-
B8. The UL49.5 gene of Bovine Herpes Virus-1 was 
introduced via retroviral transduction [12]. The endog-
enous HLA-I typing of K562 is HLA-A11, -B18 and 
-Cw05. All cell lines were cultured in IMDM medium 
(Lonza group Ltd, Switzerland) containing 8% heat-in-
activated FCS (Gibco), 100 units/ml penicillin, 100 μg/
ml streptomycin (Gibco) and 2mM glutamine (Lonza).
Flow cytometry
The following antibodies were used: anti-HLA-A/B/C 
(clone W6/32) from Serotech and anti-HLA-E (clone 
3D12) and anti-HLA-A2 (clone BB7.2) from BD biosci-
ence. Cells were measured using a FACS Calibur with 
Cellquest software (BD bioscience), and analysed 
with Flowjo software (Tree star, Inc).
Peptide transport assay
Peptide transport was performed on permeabilized 
K562 cells and fluorescein-conjugated synthetic pep-
tide CVNKTERAY as described previously [12]. The 
fluorescence intensity was measured and peptide 
transport calculated as a percentage of translocation 
relative to control cells.
Purification and sequencing of HLA-E pep-
tides
HLA-I/peptide complexes were purified from 1011 
cells by affinity chromatography using antibody W6/32. 
After 10 kD filtration of acetic acid eluates, the complex 
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firmed the impediment of TAP activity by 70% (Suppl 
figure 2), while the surface expression of HLA-E did 
not change (Suppl Fig 1). Therefore, we used the 
K562.HLA-E cells with the viral TAP-inhibitor to ex-
plore the alternative peptide-binding repertoire of 
HLA-E.
Description of the peptide binding motif of 
HLA-E
Biochemical purification and mass spectrometry se-
quencing of HLA-E bound peptides revealed 552 
unique sequences (Suppl Table I). Interestingly, only 
eight of these peptides were also found in TAP-suffi-
peptide pool was fractionated using capillary C18-
chromatography and peptide fractions were analyzed 
by on-line nanoHPLC mass spectrometry as described 
earlier [13]. Tandem mass spectra were matched 
against the IPIhuman v 3.72 using Mascot 2.2.04 
(http://www.matrixscience.com) and sorted using 
Scaffold 2.2 (http://www.proteomesoftware.com). 
8-13-mer peptides with a mascot ion score higher than 
35 were selected.
Peptide binding assays
Peptide binding affinity to HLA-A*0201 was performed 
as described earlier [14]. Influenza derived peptide 
(GILGFVFTL) functioned as positive control and a 
HLA-B7 binding peptide (SPSVDKARAEL) as nega-
tive control. Binding affinity of peptides to HLA-E*0103 
was determined in a competition-based refolding as-
say as described earlier [15]. As a positive control we 
used the leader peptide (VMAPRTLVL) from HLA-A2. 
Peptide binding of Qa-1b eluted peptides [13] to H-2Kb 
and H-2Db was assessed by cell-surface stabilization 
on RMA-S cells as described earlier [16]. As control 
peptides E1A234-243 (SGPSNTPPEI) (for Db) and MuLV 
env189-196 (SSWFITV) (for Kb) were used.
Results and Discussion
Absence of HLA-I derived leader peptides 
by inhibition of TAP in K562 cells
For the characterization of the natural peptide reper-
toire of HLA-E that emerges at the cell surface in the 
absence of the dominant HLA-I leader peptides, we 
made use of the myeloid leukemia cells K562. This cell 
line is devoid of surface HLA-I molecules and transfec-
tion of HLA-E*0103 resulted in low expression levels of 
this non-classical HLA (Suppl Fig 1). Increased sur-
face display was observed after introduction of a good 
binding leader peptide from HLA-B8 (‘K562.HLA-E.
B8’), confirming previous data that these leader pep-
tides optimally stabilize HLA-E by making full use of all 
binding pockets [17]. Surprisingly, affinity purification 
of HLA-E/peptide complexes from K562.HLA-E cells 
without the HLA-B8 leader construct revealed the 
presence of leader sequences from HLA-A11 and 
-Cw05, the endogenous HLA genes of K562 (Suppl 
Table I). This indicated that transcription of HLA genes 
was not completely silent in our K562 cells and that the 
HLA-E peptide repertoire of these cells still comprised 
some dominant HLA-I leader peptides. To prevent 
these endogenous leader peptides from loading unto 
HLA-E, we impaired the activity of the peptide trans-
porter TAP in K562.HLA-E cells using the small viral 
evasion molecule UL49.5 from a herpes virus (‘K562.
HLA-E.UL49.5’) [12]. A peptide transport assay con-
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Figure 1: Peptide binding motif of HLA-E is similar to that 
of HLA-A*0201. (A) 9-mer peptides eluted from HLA-E and 
sequenced by mass spectrometry (407 hits) were subjected 
to a motif search algorithm [18]. The Swiss-Prot database of 
human proteins was set as a reference to correct for the gen-
eral occurrence of amino acids. Letter sizes reflect the domi-
nance of that amino-acid at that position. Positions 2 and 9 
were assigned as major anchor positions and position 4 might 
represent a minor anchor. Amino acid color code: black for 
aliphatic or small, red for acidic, blue for basic, green for aro-
matic and purple all others. (B) Heat-maps of HLA-E (all 
9-mers from K562.HLA-E.UL49.5 cells) and HLA-A*0201 
(www.SYFPEITHI.de) are strikingly similar. Frequently occur-
ring amino acids are indicated in green and underrepresented 
residues are indicated in red. Heat-maps show great similari-
ty, indicating a shared peptide-binding motif. Statistical sig-
nificance was stringently set on p=0.001. N is number of pep-
tides of that set.






chor for the HLA-I leader peptide is position 7 and the 
crystal structure of HLA-E showed that the large hy-
drophobic group of leucin (L) at this site completely 
occupies the deep E-pocket and pulls the leader pep-
tides down into the groove much lower than in any 
other class I molecule [17]. Strikingly, the TAP-inde-
pendent peptide repertoire did not exhibit a preferred 
amino acid at position 7 nor for two shallower sockets 
at position 3 and 6. These additional discrepancies 
confirm the notion that the broad array of peptides 
found in HLA-E in the absence of the dominant HLA-I 
leader peptide displays a more central position in the 
groove, which is more comparable with other HLA-I 
molecules. The deep and firm position of HLA-I leader 
peptides is unique for this particular MHC/peptide 
complex that is engaged by CD94/NKG2 receptors on 
natural killer and CD8 T cells. We concluded that the 
main anchors of HLA-E binding peptides are positions 
2 and 9 for aliphatic residues, and that position 4 might 
serve as a secondary minor anchor site.
Peptides eluted from HLA-E display a high 
binding capacity to HLA-A*0201, revealing a 
shared binding motif.
Surprisingly, evaluation of the peptide sequences ob-
tained through mass spectrometry revealed six pep-
tides that were described in literature to be presented 
cient K562 cells, indicating that the peptide transporter 
greatly impacts on the peptide repertoire of HLA-E. 
We recently showed the same diversity of peptides on 
TAP-deficient cells for the mouse homologue of HLA-E 
[13]. A vast majority of the natural HLA-E ligands were 
9 amino acids long (73%) and less than 2% were lon-
ger than 11-mer (Suppl Table I). Of note, we did not 
observe an overrepresentation of signal sequences. 
So far, the peptide-binding motif of HLA-E has been 
determined with synthetic peptides based on the clas-
sical HLA-I leader peptides or using random nona-
meric peptide libraries that poorly associated with 
HLA-E [5, 10, 11]. So the described motif was not 
based on the naturally presented peptide repertoire 
and we are the first to report sequencing of the actual 
natural ligands. Due to the large number of peptide 
sequences we identified from HLA-E, we were able to 
analyze preferred amino acid occurrence at each posi-
tion of the total pool of 9-mers (407 peptides) using 
IceLogo software [18]. At amino acid position 2 and 9, 
the aliphatic amino acids L, M, V, I, and A were clearly 
preferred (Fig 1a). These positions correspond to the 
deep pockets B and F, respectively, of HLA-E [17]. This 
finding corroborates previous studies on HLA-E bind-
ing peptides that assign position 2 and 9 as major an-
chor positions [10]. The presence of glutamine (Q), 
which followed the aliphatic amino acids at position 2, 
was also reported before [5]. The third dominant an-
Table I: Binding affinity of some HLA-E eluted peptides
HLA-E*0103 HLA-A*0201
Peptide sequence IC50a (µM) IC50 (µM) Comment
ALLDKLYAL 30.75 1.18
FLMFIHQV 38.60 0.24
LLLDVPTAAVQA >200 1.89 Previously eluted from HLA-A*0201b
LLLDVPTAAV >200 0.53 Previously eluted from HLA-A*0201b
KMDASLGNLFA 150 1.11 Previously eluted from HLA-A*0201b
ALVVQVAEA 11.15 2.58 Previously eluted from HLA-A*0201b
LLDRFLATV >200 0.56 Previously eluted from HLA-A*0201b
ALWGPDPAAA >200 1.62 Previously eluted from HLA-A*0201c
VMAPRTLVL 0.0065 10.47 Control peptide HLA-E binding
GILGFVFTL 8.58 1.2 Control peptide HLA-A2 binding
SPSVFKARAEL >200 >100 Negative control peptide
a IC50 is peptide concentration needed for half maximal competition of reference peptide and represents the
  mean value of two independent experiments. Of note: HLA-E binding was determined in a cell-free protein 
  refolding assay and HLA-A2 assays were performed with  acid stripped cells.
b see reference 20.
c see reference 19.
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and compared them with a heat-map of all 9-mer HLA-
A*0201 binding peptides reported in the SYFPEITHI 
database (492 hits) (http://www.syfpeithi.de). These 
heat-maps allow the visualization of preferred (in 
green) as well as underrepresented (in red) amino ac-
ids at all positions of the peptide repertoires. The pat-
terns of HLA-E and HLA-A*0201 were strikingly similar 
(Fig 1b). Great similarities in presence and absence of 
amino acids were detected. Heat-maps of 8-mer or 
10-mer peptides confirmed the presence of aliphatic 
amino acids at position 2 and 9, but numbers were too 
low to yield statistical significance for most positions. 
Main anchor positions 2 and 9 of HLA-E are indeed 
strikingly comparable with those of the most frequent 
Caucasian HLA allele HLA-A*0201, but are clearly 
distinct from those of all other HLA supertypes [23]. 
Indeed, submission of the 407 9-mer peptides to HLA 
prediction algorithms (www.cbc.dtu.dk/services/Net-
MHC) revealed that 77% yielded a high score for HLA-
A*0201, but less than 2% had a high score for A*0101, 
A*0301, A*2402, B*0701, B*4002 and the endogenous 
alleles of K562 A*1101, and B*1801, illustrating the 
unique match between HLA-A2 and HLA-E. We con-
cluded that the peptide binding motif of HLA-E and 
HLA-A*0201 are strikingly similar, suggesting that both 
molecules present a comparable peptide repertoire 
when the dominant HLA-I derived leader peptide is 
absent.
Finally, we obtained very similar findings for the re-
cently identified peptides isolated from the mouse 
equivalent of HLA-E, the Qa-1 molecule [13] and eval-
uating this list with algorithms revealed that nearly 
40% fulfilled the binding motif of the classical MHC-I 
molecules H2-Db or H2-Kb. We investigated the dual 
binding capacity of some of these Qa-1b-eluted mouse 
sequences to the classical class I molecules and 
found they indeed bound with high affinity (Suppl Table 
II). Thus, the alternative peptide repertoire of HLA-E 
and its equivalent Qa-1 largely display cross-binding 
to classical MHC-I molecules. 
MHC-I derived leader peptide efficiently 
binds to classical class I molecules
Finally, we wondered if the dominant MHC-I derived 
peptides that represent the optimized ligands for HLA-
E were also capable of binding to classical MHC mol-
ecules. Strikingly, the human leader peptide 
VMAPRTLVL also showed clear binding to HLA-
A*0201 (Fig 2, Table I) and the mouse leader peptide 
AMAPRTLLL demonstrated affinity for H-2Kb (Fig 2, 
Suppl Table II). These leader peptides were indeed 
found in elution studies using allele-specific antibod-
ies of these classical HLA molecules. Together, these 
data indicated that even the typical HLA-E/Qa-1-pre-
by HLA-A*0201 (Table I) [19, 20]. Our previous peptide 
elution experiments confirmed that these peptides 
could be found in HLA-A2. To examine the actual ca-
pacity, of these six peptides, to stabilize HLA-A*0201, 
we preformed peptide binding affinity assays for this 
HLA molecule and confirmed their high affinity asso-
ciation (Table I). Two additional selected peptides from 
our HLA-E collection also bound with high affinity to 
this classical HLA. Importantly, K562 cells do not carry 
any HLA-A2 alleles in their genome, excluding the 
possibility that our 552 identified peptides were puri-
fied from contaminating endogenous HLA-A2 mole-
cules. Four of the tested peptides displayed binding to 
HLA-E in a cell-free refolding assay (Table I). 
Two other examples of peptides with dual binding ca-
pacity to both HLA-E and HLA-A*0201 were found in 
literature [21, 22], suggesting that this might be a more 
common feature. To further explore this idea of a 
shared binding motif, we created so-called heat-maps 














































Figure 2 Lampen et al
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Figure 2: HLA-I derived leader peptides bind to classical 
class I molecules. (A) The human leader peptide 
VMAPRTLVL displays intermediate affinity to HLA-A2 mole-
cules as tested in a cellular competition-based assay and (B) 
the mouse leader peptide AMAPRTLLL displays high affinity 
to H-2Kb molecules as tested in an RMA-S binding assay. 
Binding affinity is expressed as percentage inhibition of the 
reference peptide (in A) or as an index of surface stability (in 
B). These assays were performed three times with similar 
outcome.







1 Strong, R. K., Holmes, M. A., Li, P., Braun, L., Lee, N. and 
Geraghty, D. E., HLA-E allelic variants. Correlating differential 
expression, peptide affinities, crystal structures, and thermal 
stabilities. J. Biol. Chem. 2003. 278: 5082-5090.
2 van Hall, T., Oliveira, C. C., Joosten, S. A. and Ottenhoff, T. H., The 
other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in 
times of stress. Microbes Infect 2010. 12: 910-918.
3 Kurepa, Z., Hasemann, C. A. and Forman, J., Qa-1b binds 
conserved class I leader peptides derived from several mammalian 
species. J Exp Med 1998. 188: 973-978.
4 Braud, V. M., Allan, D. S., O'Callaghan, C. A., Soderstrom, K., 
D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., 
Phillips, J. H., Lanier, L. L. and McMichael, A. J., HLA-E binds to 
natural killer cell receptors CD94/NKG2A, B and C. Nature 1998. 
391: 795-799.
5 Miller, J. D., Weber, D. A., Ibegbu, C., Pohl, J., Altman, J. D. and 
Jensen, P. E., Analysis of HLA-E peptide-binding specificity and 
contact residues in bound peptide required for recognition by 
CD94/NKG2. J Immunol 2003. 171: 1369-1375.
6 Coupel, S., Moreau, A., Hamidou, M., Horejsi, V., Soulillou, J. P. 
and Charreau, B., Expression and release of soluble HLA-E is an 
immunoregulatory feature of endothelial cell activation. Blood 
2007. 109: 2806-2814.
7 Derre, L., Corvaisier, M., Charreau, B., Moreau, A., Godefroy, E., 
Moreau-Aubry, A., Jotereau, F. and Gervois, N., Expression and 
release of HLA-E by melanoma cells and melanocytes: potential 
impact on the response of cytotoxic effector cells. Journal of 
immunology 2006. 177: 3100-3107.
8 Gooden, M., Lampen, M., Jordanova, E. S., Leffers, N., Trimbos, J. 
B., van der Burg, S. H., Nijman, H. and van Hall, T., HLA-E 
expression by gynecological cancers restrains tumor-infiltrating 
CD8 T lymphocytes. Proc Natl Acad Sci U S A 2011. 108: 10656-
10661.
9 Rodgers, J. R. and Cook, R. G., MHC class Ib molecules bridge 
innate and acquired immunity. Nat Rev Immunol 2005. 5: 459-471.
10 Braud, V., Jones, E. Y. and McMichael, A., The human major 
histocompatibility complex class Ib molecule HLA-E binds signal 
sequence-derived peptides with primary anchor residues at 
positions 2 and 9. Eur J Immunol 1997. 27: 1164-1169.
11 Stevens, J., Joly, E., Trowsdale, J. and Butcher, G. W., Peptide 
binding characteristics of the non-classical class Ib MHC molecule 
HLA-E assessed by a recombinant random peptide approach. 
BMC Immunol 2001. 2: 5.
12 Lampen, M. H., Verweij, M. C., Querido, B., van der Burg, S. H., 
Wiertz, E. J. and van Hall, T., CD8+ T cell responses against TAP-
inhibited cells are readily detected in the human population. J 
Immunol 2010. 185: 6508-6517.
13 Oliveira, C. C., van Veelen, P. A., Querido, B., de Ru, A., Sluijter, 
M., Laban, S., Drijfhout, J. W., van der Burg, S. H., Offringa, R. and 
van Hall, T., The nonpolymorphic MHC Qa-1b mediates CD8+ T 
cell surveillance of antigen-processing defects. The Journal of 
experimental medicine 2010. 207: 207-221.
14 Kessler, J. H., Mommaas, B., Mutis, T., Huijbers, I., Vissers, D., 
Benckhuijsen, W. E., Schreuder, G. M., Offringa, R., Goulmy, E., 
sented peptides, which contain full pocket occupancy 
in the non-classical molecules can be presented by 
classical MHC class I counterparts.  
Concluding remarks
HLA-E is predominantly filled with conserved peptides 
derived from leader sequences of HLA-I molecules. 
However, this repertoire is greatly altered upon TAP-
impairment, giving a broad diversity of alternative 
peptides that harbor a binding motif strikingly similar to 
that of HLA-A*0201. Most of these alternative peptides 
do not emerge in HLA-E at the cell surface under nor-
mal conditions, because the HLA-I leader peptide 
contains a sequence that optimally fits into the binding 
pockets of HLA-E, including the deep pockets at posi-
tion 2, 7 and 9 and the shallower pockets at position 3 
and 6 [17]. Our data suggest that the alternative reper-
toire presented by HLA-E adopts another conforma-
tion and docks much less deep into the groove, now 
primarily interacting with amino acids at positions 2 
and 9 for pockets B and F. So, the absence of the 
dominant leaders allows peptides with an HLA-
A*0201-binding motif to be presented by HLA-E. Since 
this alternative repertoire is normally not presented, 
they might constitute neo-antigens for the immune 
system and elicits T cell responses, like we recently 
showed for Qa-1 [13]. 
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Supplementary figure 1: HLA-I negative K562 cells ex-
press HLA-E after gene transfer.  The genes for HLA-
E*0103 and the viral TAP inhibitor UL49.5 were introduced into 
HLA-I negative K562 cells. To enhance HLA-E expression, a 
β2m construct was transferred with the leader sequence of 
HLA-B8. Surface display of HLA-E was determined on K562.
HLA-E cells (black-line), K562.HLA-E.UL49.5 cells (dotted 
line), and K562.HLA-E.B8 cells (grey line) using antibodies 
against HLA-E (3D12, left plot) and pan-HLA-I (W6/32, right 





























Supplementary figure 2: Lampen et al
Supplementary figure 2: Inhibition of peptide transport 
via TAP by viral TAP inhibitor UL49.5. HLA-I negative K562 
cells were stably transfected with HLA-E and in addition with 
the viral TAP-inhibitor UL49.5. A peptide-transport assay was 
performed using fluorescently labelled reporter peptide in the 
presence of ATP. As control, TAP activity is blocked by deple-
tion of ATP. The percentage of TAP transport was calculated 
and compared to that of K562.HLA-E without the TAP inhibi-
tor.






Supplementary Table I: Characteristics of the HLA-E binding peptide pool
K562 HLA-E K562 HLA-E UL49.5
Number of peptidesa 104 552
Presence of leader peptides Yesb No


























a peptides are included if the Mascot score ≥35 with a length between 8 and 13 amino acids
b peptides found: VMAPRTLIL – HLA-Cw05
  VMAPRTLLL – HLA-A11
c amino-acids
Supplementary Table II: Peptide binding affinity 
of Qa-1 eluted peptides in H-2Kb and H-2Db
H-2Kb H-2Db








a Peptides derived from reference 13.
b Binding affinity is classified according to the
following cutoff: ++ = 0.001 μM <IC50<1 μM;
 + = 1 μM <IC50<100 μM, - = IC50>100 μM.
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HLA-E is a non-classical HLA class I molecule, which 
differs from classical HLA molecules by its non-poly-
morphic, conserved nature. Expression and function 
of HLA-E in normal tissues and solid tumors is not fully 
understood. We investigated HLA-E protein expres-
sion on tissue sections of 420 ovarian and cervical 
cancers and found equal or higher levels than normal 
counterpart epithelia in 80% of the tumors. Expression 
was strongly associated with components of the anti-
gen presentation pathway, e.g. TAP, ERAP, b2m, HLA 
class I and II, and for ovarian cancer with tumor infil-
trating CTL. This argues against the idea that HLA-E 
would compensate for the loss of classical HLA in tu-
mors. In situ detection of HLA-E interacting receptors 
revealed a very low infiltrate of NK cells, but up to 50% 
of intra-epithelial CTL expressed the inhibiting CD94/
NKG2A receptor. In cervical cancer, HLA-E expres-
sion did not alter the prognostic effect of CTL, most 
likely due to very high infiltrating CTL numbers in this 
virus-induced tumor. Overall survival of ovarian can-
cer patients, however, was strongly influenced by 
HLA-E, because the beneficial effect of high CTL infil-
tration was completely neutralized in the subpopula-
tion with strong HLA-E expression. Interestingly, these 
results indicate that CTL infiltration in ovarian cancer is 
only associated with better survival when HLA-E ex-
pression is low, and that intratumoral CTL are inhibited 
by CD94/NKG2A receptors on CTL in the tumor micro-
environment.
Introduction
HLA-E is a non-classical Major Histocompatibility 
Complex (MHC) class I molecule that is almost non-
polymorphic, in contrast to its classical class I counter-
parts HLA-A, -B, and -C (1, 2). There are two HLA-E 
subtypes, which differ by only one amino acid (3-5). 
This coding variation is located outside the peptide 
binding groove, and both HLA-E variants are indeed 
indistinguishable in their structure and peptide binding 
features (3-5). HLA-E normally presents a very limited 
variety of peptides, derived from signal peptide se-
quences of classical MHC class I. However, infections 
and transformation can mediate the presentation of 
alternative peptides (1, 2). Surface expression of HLA-
E is largely dependent on β2 microglobulin (β2m) as 
well as transporter associated with antigen processing 
(TAP) and tapasin (6, 7). 
HLA-E/peptide complexes are ligands of the CD94 
receptor in conjunction with the inhibitory NKG2A or 
the stimulatory NKG2C molecule, which are expressed 
on the majority of natural killer (NK) cells and some 
activated CD8+ T lymphocytes (CTL) (8, 9). The pre-
sentation of ‘self’ signal peptides by HLA-E enables 
these lymphocytes to gauge the overall MHC class I 
expression on the surface of target cells. Engagement 
of CD94/NKG2A receptors on lymphocytes reduces 
the reactivity of NK cells or CTL, which protects 
against excessive immune-mediated tissue damage, 
for instance during infections (10, 11). On the other 
hand, CD94/NKG2A expression can be induced in re-
sponse to cytokines such as IL-15 (12) and transform-
ing growth factor β (TGF-β) (13). These cytokines are 
frequently present in the tumor microenvironment, 
suggesting that CD94/NKG2A inhibitory receptors 
play a role in immune escape by tumor cells. 
With the availability of specific antibodies to detect 
HLA-E in native conformation (clone 3D12; ref. (6)) or 
as denatured protein (clone MEM-E/02; ref. (14)), we 
recently investigated the normal expression of HLA-E 
on human tissues in collaboration with the Human 
Proteome Resource program (HPR at www.proteinat-
las.org). Expression on blood cells, endothelium, me-
lanocytes and intestinal epithelial cells was confirmed 
(6, 15-17). Furthermore, we observed a pattern of tis-
sue staining that was very similar to that of classical 
MHC class I. 
Here, we determined the expression of HLA-E in 150 
cervical and 270 ovarian cancer samples and ana-
lyzed its association with clinical and immunological 
parameters. Our results indicate that HLA-E is fre-
quently overexpressed in these tumor types and posi-
tively associated with expression patterns of antigen 
processing components, classical HLA molecules 
and immune cell infiltrate. In situ analysis of the inter-
acting receptors of HLA-E, i.e. the inhibitory CD94/
NKG2A and the activating CD94/NKG2C, revealed a 
frequent expression of the inhibitory receptor on intra-
epithelial CD8+ T cells. NK cells, the predominant cell 
type expressing CD94/NKG2A and CD94/NKG2C, 
were hardly found in both tumor types. Importantly, the 
beneficial prognostic effect of infiltrating CTL in ovarian 
cancer was neutralized by high expression of HLA-E, 
indicating that HLA-E hampers activity of anti-tumor 
CTL in the tumor microenvironment. 
Materials and methods
Patient selection
Since 1985, the Department of Gynecological Oncol-
ogy at the University Medical Center Groningen 
(UMCG) keeps a computerized database of patients 
with malignant epithelial ovarian cancer treated at this 
hospital at any time point during the course of their 
disease, prospectively collecting information on clini-
copathologic characteristics and follow-up. For the 
current study, ovarian cancer patients were selected if 
primary surgery was performed by a gynecological 
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oncologist from the UMCG between May 1985 and 
June 2006, and if paraffin-embedded ovarian tumor 
tissue was available (N = 270). Follow-up was updated 
in July 2009. Patients were staged according to FIGO 
classification (61). Tumors were graded and classified 
according to WHO criteria by a gynecological patholo-
gist. Adjuvant chemotherapy consisted of different 
platinum-based treatment regimens. Response to 
chemotherapy was evaluated according to WHO crite-
ria. Specimens from seven patients (three premeno-
pausal, four postmenopausal) who underwent prophy-
lactic bilateral salpingo-oophorectomy were sepa-
rately included as controls for the HLA-E staining of 
normal ovarian epithelium.
We included all patients with cervical cancer who un-
derwent radical hysterectomy with complete pelvic 
lymphadenectomy in the Leiden University Medical 
Center (LUMC) from 1985 to 1999, for whom formalin-
fixed, paraffin-embedded tissue available, and had not 
received radiotherapy or chemotherapy before sur-
gery (N = 150). All patients had FIGO stages I and II 
disease, since higher stages are treated by primary 
chemoradiation. Tumors were HPV typed by PCR and 
sequencing. For all patients, a minimum of five years of 
follow up was available. Histologic specimens of nor-
mal cervices from women who underwent hysterecto-
mies for benign uterine diseases with no cervical ab-
normalities (n = 9) were used as a control group in all 
section stainings. 
Immunohistochemistry
Previously described ovarian (20) and cervical cancer 
(21) tissue microarrays (TMA) were used, which were 
constructed as described previously (62, 63). TMA 
sections were stained with mouse monoclonal anti-
bodies recognizing HLA-E (clone MEM-E/02, Abcam 
ab2216). In brief, TMA sections were dewaxed in xy-
lene and rehydrated using graded concentrations of 
ethanol to distilled water. After antigen retrieval using 
citrate buffer, endogenous peroxidase activity was 
blocked by submersion of sections in a 0.3% H2O2 so-
lution for 30 minutes. Sections were incubated with the 
primary antibody for 60 minutes at room temperature 
and subsequently with DAKO Envision+ for 30 min-
utes. The antigen-antibody reactions were visualized 
with 3,3’-diaminobenzidine. Sections were counter-
stained with hematoxylin. Paraffin embedded sections 
were also stained with anti-CD56 (clone 1B6, Mono-
san, Uden, The Netherlands) and anti-NKp46 (poly-
clonal AF1850, R&D systems) and subsequently, rat-
anti-mousepo and goat-anti-ratpo as secondary and 
tertiary antibodies, respectively. 
Simultaneous detection of CD3, CD94 and NKG2A 
was performed by three color fluorescence staining on 
ten cryosections of cervical carcinomas using anti-
CD3 (mouse IgG1, DAKO, clone F7.2.38), anti-CD94 
(mouse IgG2a, Abcam, clone ab61974) and anti-NK-
G2A (mouse IgG2b, Immunotech, clone Z199). Second 
step antibodies were all goat-anti-mouse isotype spe-
cific antibodies with Alexa fluorochromes Alexa Fluor 
546, Alexa Fluor 647 and Alexa Fluor 488 (Molecular 
Probes). Images were captured with a confocal laser 
scanning microscope (LSM510, Zeiss) in a multitrack 
setting and analyzed as previously described (64).
Scoring
All stainings were scored independently by two ob-
servers. Observers had no prior knowledge of clinico-
pathological information. To obtain a high concor-
dance rate with whole tissue slides, it was decided that 
minimally two cores with a minimum of 20% tumor tis-
sue had to be present on the TMA for a sample to be 
entered into analysis (63). The scoring system pro-
posed by Ruiter et al. (18) was used. The intensity of 
staining was scored as 0, 1, 2, or 3, indicating absent, 
weak, positive, or strong positive expression, respec-
tively. The percentage of positive tumor cells was 
scored as 0 for 0%; 1 for 1–5%; 2 for 5–25%; 3 for 25–
50%; 4 for 50–75% and 5 for 75–100%. The two scores 
were added up, averaged over the number of evalu-
able cores per tumor, and dichotomized based on the 
lowest quartile. This resulted in a cutoff score of 5.25 in 
ovarian cancer, and 5.00 in cervical cancer. We also 
performed analyses with previously published data on 
antigen processing and presentation molecules, as 
well as tumor infiltrating lymphocytes, using the same 
cutoff points as described earlier (19-22).
Flow cytometry analyses
Fresh ovarian and cervical cancer specimens were 
dissected in small fragments with surgical blades and 
passed through a cell strainer to obtain single cell 
suspensions. Patients had similar characteristics as 
those from the TMA cohort. After isolating living cells 
using centrifugation with ficoll, cells were washed 
twice in PBS/0.5% BSA buffer and incubated for 30 
minutes with CD14-PeCy7 (clone M5E2, BD Biosci-
ence), CD3-PB (clone UCHT1, Dako), CD56-Alexa700 
(clone B159, BD Biosciences), CD4-PeTxRed (clone 
S3.5, CALTAG), CD8-PerCP (clone SK1, BD Biosci-
ences), CD94-FITC (clone 131412, R&D systems), 
NKG2A-PE (clone z199, Beckman Coulter), and NK-
G2C-APC (clone 134591, R&D systems). After fixation 
in paraformaldehyde, cells were measured using an 
LSR II flow cytometer (BD Biosciences) and analyzed 
by FlowJo software.
Statistics
Associations between clinicopathological characteris-
tics, antigen processing and presentation pathway 






components, and intratumoral T-lymphocytes were 
tested using Pearson Chi square tests using our previ-
ously published cutoff points (19-22). Al continuous 
variables were tested for normality by plotting histo-
grams and performing Kolmogorov-Smirnov tests. 
Since none of these variables was normally distribut-
ed, nonparametric tests were used to compare con-
tinuous variables. Mann-Whitney U tests were used to 
determine differences between CD8 scores in ovarian 
and cervical cancer. Survival was defined as date of 
surgery until death of cancer, or date of last follow-up. 
Survival was estimated using the Kaplan Meier meth-
od. The Log Rank test and Cox regression analyses 
were used to assess survival differences between 
groups. To compare CD94, NKG2A, and NKG2C ex-
pression among different T lymphocyte subsets, we 
used the Mann Whitney U test. For all tests, p-values 
<0.05 were considered significant. All p-values were 
two-sided. All statistical analyses were performed us-
ing SPSS 16.0 software package for Windows (SPSS 
Inc., Chicago, IL, USA). 
Results
HLA-E expression in gynecological cancers
Two cohorts of gynecological tumor tissue were evalu-
ated: 270 ovarian and 150 cervical cancers. Supple-
mentary Table I summarizes clinicopathological char-
acteristics and survival data of the two cohorts. Nota-
bly, ovarian cancer is generally diagnosed at a much 
later stage than cervical cancer. Hence, this cohort 
consists mainly of high stage tumors with an average 
disease-specific survival of only 3.5 years, whereas 
cervical cancer patients live on average 14 years after 
diagnosis. 
We first determined the expression of HLA-E on non-
malignant ovarian and cervical tissue. For ovarian tis-
sue, we selected seven pre- and postmenopausal 
samples with intact, nonmalignant ovarian epithelium. 
Also, we stained nine cervical sections containing 
normal ectocervical squamous epithelium and endo-
cervical glands (Fig. 1). These are the structures that 
give rise to ovarian- and cervical cancer, respectively. 
The ovarian epithelium showed a weak positive stain-
ing in both pre- and postmenopausal samples, where-
as ovarian stroma was negative (Fig. 1a, b). Both cervi-
cal epithelia stained negative to weak positive for 
HLA-E, stroma was negative (Fig. 1e, f). The endothe-
lium of blood vessels was highly positive for HLA-E as 
well as resident leukocytes, in line with previous re-
ports (15). 
Next, we assessed HLA-E expression on ovarian can-
cer (n=270) and cervical cancer (n=150) confined in 
tissue micro arrays using a validated specific antibody. 
Examples of negative and positive staining tumors are 
depicted for ovarian cancer (respectively Fig. 1c, d) 
and cervical cancer (respectively Fig. 1g, h). Staining 
of HLA-E on tumor cells was scored for intensity and 
percentage surface area, as previously described 
(18), giving a range from 0 to 8.0. For both tumor types 
the median score was 6.0, with a range between 0 and 
7.75. Based on the mean intensity score of normal epi-
thelium (score 1 on a scale of 0 to 3), ovarian tumors 
and cervical tumors expressed equal or higher levels 
of HLA-E in 89% and 83% of the tumors, indicating that 
expression of HLA-E is mostly conserved in these tu-
mors.
Gooden et al, figure 1
Figure 1. HLA-E expression in ovarian and cervical can-
cer. Paraffin embedded tissue sections were stained with the 
monoclonal HLA-E specific antibody MEM-E/02. (A-B) Two 
examples of the one layer epithelial cells of normal ovaries. 
No difference was observed between pre- and postmeno-
pausal ovaries. Endothelial cells of the blood vessels in the 
connective tissue and resident leukocytes are known for posi-
tive HLA-E staining. (C-D) Two examples of tissue micro array 
spots containing ovarian cancer, one negative (C) and one 
positive (D) for HLA-E expression. (E-F) Examples of HLA-E 
staining on normal ectocervical squamous epithelium (E) and 
normal endocervical glands of the cervix (F). (G-H) A negative 
(G) and a positive (H) example of HLA-E expression from the 
cohort of cervical cancer.
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Associations between HLA-E, clinicopatho-
logic and immunologic factors
To assess whether HLA-E expression was preferen-
tially associated with certain patient groups, we deter-
mined the relationship between HLA-E expression 
and well-known clinicopathologic factors. To this end, 
the gradual scores of HLA-E expression were dichoto-
mized based on the lowest quartile. For ovarian can-
cer, there was no relationship between HLA-E expres-
sion and histology, stage, grade, or presence of resid-
ual tumor after debulking surgery (Supplementary Ta-
ble II). Similarly, HLA-E expression in cervical cancer 
was not related to histology, stage, infiltration depth, 
tumor size, Human Papillomavirus (HPV) infection, 
lymph node positivity, and vascular invasion (Supple-
mentary Table II). 
We previously collected data from these cohorts of 
tumor samples describing immune cell infiltration and 
HLA-related molecules (19-22). We determined asso-
ciations between HLA-E and components of the anti-
gen processing machinery, using the same cutoff val-
ues as previously described for these molecules (19-
22). The proteasome subunit LMP7, peptide trans-
porter heterodimer TAP1, and the aminopeptidase 
ERAP (23) were associated with increased HLA-E ex-
pression in ovarian cancer (Table I). In cervical cancer, 
the TAP1 and TAP2 transporters were the only compo-
Table I Relationship of HLA-E expression in ovarian and cervical cancer with immunological characteristics
HLA-E ovarian cancer HLA-E cervical cancer
low high p-valuea low high p-valuea
LMP7
low 17 (65.4%) 9 (34.6%) <0.001 5 (23.8%) 16 (76.2%) 0.645
high 28 (19.6%) 115 (80.4%) 17 (19.3%) 71 (80.7%)
TAP1
low 11 (52.4%) 10 (47.6%) 0.004 9 (42.9%) 12 (57.1%) 0.017
high 33 (22.6%) 113 (77.4%) 16 (18.4%) 71 (81.6%)
TAP2
low 7 (31.8%) 15 (68.2%) 0.439 14 (31.8%) 30 (68.2%) 0.007
high 34 (24.1%) 107 (75.9%) 7 (10.9%) 57 (89.1%)
ERAP
low 13 (40.6%) 19 (59.4%) 0.041 4 (25.0%) 12 (75.0%) 0.524
high 32 (23.0%) 107 (77.0%) 16 (18.2%) 72 (81.8%)
ERp57
low 17 (27.4%) 45 (72.6%) 0.805 13 (21.7%) 47 (78.3%) 0.514
high 28 (25.7%) 81 (74.3%) 8 (16.7%) 40 (83.3%)
HLA-A
low 25 (46.3%) 29 (53.7%) <0.001 22 (26.2%) 62 (73.8%) 0.083
high 20 (17.2%) 96 (82.8%) 8 (14.0%) 49 (86.0%)
HLA-B/C
low 27 (56.2%) 21 (43.8%) <0.001 22 (26.2%) 62 (73.8%) 0.083
high 32 (17.7%) 149 (82.3%) 8 (14.0%) 49 (86.0%)
HLA-DP/DQ/DR
low 31 (39.2%) 48 (60.8%) <0.001 13 (29.5%) 31 (70.5%) 0.028
high 14 (15.2%) 78 (84.8%) 8 (12.5%) 56 (87.5%)
B2M
low 26 (45.6%) 31 (54.4%) <0.001 25 (26.9%) 68 (73.1%) 0.012
high 19 (16.7%) 95 (83.3%) 7 (10.6%) 59 (89.4%)
CTL
low 30 (39.5%) 46 (60.5%) 0.001 8 (23.5%) 26 (76.5%) 0.656
high 28 (18.8%) 121 (81.2%) 13 (19.7%) 53 (80.3%)
Treg
low 30 (32.6%) 62 (67.4%) 0.126 12 (31.6%) 26 (68.4%) 0.085
high 24 (22.9%) 81 (77.1%) 9 (16.4%) 46 (83.6%)
CTL/Treg ratio
low 26 (36.1%) 46 (63.9%) 0.018 9 (18.0%) 41 (82.0%) 0.343
high 32 (21.2%) 119 (78.8%) 11 (26.2%) 31 (73.8%)
a p-values were calculated using Pearson Chi square-test. Bold signifies p<0.05.






nents that associated with HLA-E expression. These 
results suggest that antigen processing components 
contribute to the protein expression of HLA-E. 
Next, the association with classical HLA class I mole-
cules (HLA-A, HLA-B/C and β2m) and HLA class II 
molecules (HLA-DP/DQ/DR) was analyzed (Table I). 
Induction of HLA class II molecules is observed in a 
majority of these cancers and can be mediated by cy-
tokines such as interferon-γ, similar to HLA-E (24-26). 
This revealed a clear association with HLA-E expres-
sion, especially in ovarian cancer. This indicates that 
HLA-E is present in tumors with strong classical HLA 
expression and contrasts with the idea that HLA-E ex-
pression would compensate for loss of classical HLA 
molecules in cancer. In contrast, high expression of 
classical HLA class I promotes the stabilization of 
HLA-E through the delivery of leader sequences which 
bind to the groove of HLA-E (2, 6, 27). 
Furthermore, expression of HLA-E was correlated with 
the presence of T cells. The degree of infiltration of 
CTL and regulatory T lymphocytes (Treg) was recently 
reported by our groups for these two cohorts (20, 21). 
The number of tumor-infiltrating CTL was positively 
correlated to HLA-E expression in ovarian cancer, but 
not in cervical cancer (Table I). We previously found 
that the ratio between CTL and Treg is predictive of 
clinical outcome in cervical cancer instead of the CTL 
counts as such (21). For the current study, we exam-
ined the relation between the CTL/Treg ratio and HLA-
E expression, but these two parameters were not as-
sociated (p=0.343, Table I). 
Concluding, HLA-E expression in ovarian and cervical 
cancers is positively associated with other compo-
nents of HLA-mediated antigen presentation – indica-
tive of a well functioning processing and presentation 
pathway – and the influx of T cells. These associations 
are especially prominent in ovarian cancer.
Intra-tumoral CTLs express HLA-E engag-
ing receptors
The receptors for HLA-E, i.e. CD94/NKG2A and CD94/
NKG2C, are predominantly expressed on natural killer 
(NK) cells. We therefore assessed the presence of 
these innate immune cells in our cohort of ovarian and 
cervical cancers using antibodies against the NK-as-
sociated markers CD56 and CD57, and the NK-specif-
ic marker NKp46 (28). In ovarian cancer, only 14% of 
the samples contained detectable NK cells, and the 





































































































































Figure 2. Flow cytometry analysis of CD94, NKG2A and NKG2C expression on T cells. Dissociated tissues from fresh 
tumor samples from surgery were stained with fluorescently labeled antibodies against CD14, CD56, CD3, CD4, CD8, CD94, 
NKG2A and NKG2C. (A) Eight color staining of dispersed cervical tumor. Leukocytes were first gated on forward and sideward 
scatter plot and all CD14-negative cells to exclude non-specific staining to immunoglobulin receptors on monocytes. Natural 
killer cells were also excluded from the analysis by removing CD3-CD56+ cells from the selecting gate. (B) Nine tumor samples 
and nine age-matched PBMC samples were analyzed for percentage CD4 T cells and CD8 T cells that express CD94, NKG2A 
or NKG2C. Ovarian cancer contained very low numbers of CD4 T cells. Percentage CD94- and NKG2A-positive CD8 T cells in 
tumor tissues was significantly higher than the percentage in blood (p=0.0012 for CD94, p<0.0001 for NKG2A, Mann-Whitney 
U test). Other comparisons were not significantly different.
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than 7/mm2). Cervical cancers also largely lacked 
infiltrating NK cells, and stainings with an anti-
NKp46 antibody corroborated our previous results 
where we scored CD3-CD57+ cells (21). Clinico-
pathologic factors or HLA-E expression did not dif-
fer between tumors with or without NK cells. 
Besides on NK cells, the inhibiting heterodimer 
CD94/NKG2A and the activating CD94/NKG2C are 
also expressed on a small subset of CTL (2). We 
hypothesized that HLA-E in cancers might serve as 
ligand for these receptors on intratumoral CTL. We 
applied 8-color flow cytometry analysis on fresh surgi-
cal samples, which were mechanically dissected to 
single cell suspensions (Fig. 2). Gating on CD3+CD4+ 
T cells and CD3+CD8+ cytotoxic T cells visualized the 
expression of CD94, NKG2A and NKG2C receptors on 
these T cell subsets (Fig. 2a). Importantly, a high fre-
quency of the tumor-infiltrating CTL displayed the in-
hibiting NKG2A chain, but not the activating NKG2C 
chain (Fig. 2a). Nearly all NKG2A-positive CTL also 
co-expressed the partner CD94 (overall 98%). In con-
trast, CD4+ T cells were largely devoid of these HLA-E 
interacting receptors. The ovarian cancers contained 
very low numbers of CD4+ T cells, leading to seem-
ingly high frequencies of receptor-positive subsets. 
Interestingly, large populations of CD4-CD8- T cells 
were observed in the samples of ovarian cancer and a 
high percentage of these cells were positive for CD94/
NKG2A and these cells are currently subject of further 
investigation. When five cervical cancer and four ovar-
ian cancer samples were analyzed, up to 50% of CTL 
were CD94/NKG2A+ with a median of 12% (Fig. 2b). 
The frequency of CD94/NKG2A+ CTL in age-matched 
normal blood was found to be around 3%, indicating 
that this inhibiting HLA-E binding receptor is enriched 
at the site of the tumor. To substantiate this finding and 
to analyze the localization of these CD94/NKG2A-
positive CTL, we performed triple stainings on cryo-
sections of cervical cancer using fluorescently labeled 
antibodies to CD3, CD94, and NKG2A (Fig. 3). Most 
T-cells resided in stoma areas and not within tumor 
nests, in line with our previous findings (20, 21). Strik-
ingly, CD94/NKG2A expression was found on only 6% 
of the stoma T cells, whereas 48% of intra-epithelial T 
cells displayed this inhibiting receptor (SD 9% and 
32%, respectively). Together, these data implied that 
the frequency of tumor-interacting T cells expressing 







Figure 3. Triple fluorescence staining of cervical can-
cer detecting intra-epithelial CD94+NKG2A+ T cells.
Immunofluorescent staining of T cells (CD3+ in blue) ex-
pressing NKG2A (in green) and CD94 (in red). These two 
pictures of different cervical tumor samples are represen-
tative of ten tumors analyzed. Arrow heads in the merged 
picture (lower right quadrants) designate triple positive 
cells within tumor nests, whereas the surrounding single 
blue cells (T cells without CD94/NKG2A) are located in 
stroma. CD94/NKG2A expression was found on 6% (±9%) 
of stromal T cells, but 48% (±32%) of intra-epithelial T cells.
Table II Cox regression survival analysis
HR (95% C.I) p-value
Ovarian cancer univariate analysis
   HLA-E high vs. HLA-E low 1.10 (0.74-1.64) 0.653
   CD8 high vs. CD8 low 0.71 (0.50-0.99) 0.047
   HLA-E low: CD8 high vs. CD8 low 0.53 (0.36-0.78) 0.001
   HLA-E high: CD8 high vs. CD8 low 0.97 (0.77-1.22) 0.816
Cervical cancer univariate analysis
   HLA-E high vs. HLA-E low 0.43 (0.21-0.87) 0.020
   CD8 high vs. CD8 low 0.94 (0.40-2.19) 0.879
   HLA-E low: CD8 high vs. CD8 low 1.68 (0.34-8.36) 0.524
   HLA-E high: CD8 high vs. CD8 low 0.75 (0.27-2.05) 0.569
Cervical cancer multivariate analysis
   HLA-E high vs. HLA-E low 0.58 (0.28-1.23) 0.582
   Tumor size >4 cm 4.88 (2.17-11.00) <0.001
   Lymph node metastasis 2.73 (1.33-5.59) 0.006






CD94/NKG2A (Fig. 3) is much higher than anticipated 
on basis of the total pool of T cells in the resected tu-
mor sample (see Fig. 2b). 
Expression of HLA-E neutralizes survival 
benefit of infiltrating CTL in ovarian cancer 
We wondered whether the observed expression of 
HLA-E and CD94/NKG2A in the tumor site would 
translate into survival differences in the context of CTL 
infiltration. In ovarian cancer, HLA-E expression on its 
own did not affect survival (Table II). We previously 
demonstrated (20) that high CTL counts do predict im-
proved survival in ovarian cancer (HR 0.71, Table II and 
Fig. 4a). We hypothesized that, due to the presence of 
CD94/NKG2A on infiltrating CTL, HLA-E high tumors 
might resist CTL mediated lysis. To this end, we per-
formed survival analysis for CTL infiltration stratified by 
HLA-E expression. Indeed, the prognostic benefit of 
CD8+ T cells was strongly present in the stratum with 
low HLA-E expression (HR 0.53, p=0.001, Table II, Fig. 
4b). This hazard ratio was much lower than that of the 
whole population, without HLA-E stratification. Strik-
ingly, patients with high HLA-E expression, represent-
ing 75% of our cohort, completely lost the benefit of 
infiltrating CTL (HR 0.97, p=0.816, Table II, Fig. 4c). 
These data indicate that the minor subpopulation of 
patients with low HLA-E expression on their tumors 
benefits from infiltrating CTL and, moreover, that ex-
pression of HLA-E neutralizes the survival benefit of 
ovarian cancers with high numbers of CTL.
In cervical cancer, we observed a decreased risk of 
death associated with high HLA-E expression in uni-
variate analysis. However, HLA-E expression was not 
an independent predictor of death in multivariate 
analysis (Table II). We previously reported that infiltrat-
ing CTL frequency is not an independent predictive 
survival factor (p=0.879, Table II) (21). Stratified analy-
sis of CTL infiltration based on HLA-E expression did 
not affect these results. When repeating these analy-
ses for disease free survival, similar results were ob-
tained. 
A notable difference between ovarian and cervical 
cancer is the number of intratumoral CTL, as cervical 
cancers are infiltrated with at least three times more 
CTL (median 95.3 ± 221.6/mm2; ovarian cancer: 28.3 ± 
120/mm2; p<0.001), suggesting that the virus-positive 
cervical cancers are relatively overloaded with infiltrat-
ing CTL. When we repeated the stratified analysis in 
the subpopulation of cervical cancer with CTL counts 
comparable to ovarian cancer, HLA-E expression 
seemed to have the same impact as in ovarian cancer. 
However, the numbers of cervical cancer with such 
low numbers of CTL were insufficient for proper statis-
tical analysis. We are currently further evaluating the 
differences between CTL numbers in several tumor 
types.
In conclusion, HLA-E is regularly expressed in ovarian 
and cervical cancer, often concurrently with classical 
MHC molecules. Instead of inhibiting NK cells, which 
are hardly present in these tumor types, the main role 
of HLA-E seems to be the inhibition of infiltrating CD8+ 
CTL. This effect translates into survival differences in 
ovarian cancer, which contains fewer CTL and might 
therefore be more affected by a decrease of CTL be-
low a certain threshold. 
Figure 4. Kaplan-Meier survival curves of ovarian cancer. Overall survival of 249 patients with ovarian cancer for whom ≥2 
cores were available in months is plotted. (A) Infiltrating CD8+ T cells were counted and stratified in two groups with a cut off on 
the lowest tertile. Patients with a high CTL count showed a better survival than those with low CTL counts (p=0.044, log rank 
test). (B-C) Subsequently, HLA-E expression was added as parameter, dividing the population into HLA-E low expression (low-
est quartile) (B) and high HLA-E expression (C). The beneficial effect of high CTL counts on survival was not attributable for 
those cancers with high HLA-E (p=0.815, log rank). Consequently, the beneficial role of high CTL infiltration of the whole cohort 
was the result of a small subpopulation of patients with low expression of HLA-E.
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Discussion
In the current study, we determined the clinical and 
immunological relevance of HLA-E expression in ovar-
ian and cervical cancer. Knowledge on the expression 
of HLA-E in these two cancer types was limited to 
small cohorts, and here we show that 89.4% of ovarian 
cancers and 83.7% of cervical cancers display higher 
levels compared to their normal epithelial counter-
parts. Total lack of HLA-E is rare in these tumors. Im-
portantly, HLA-E protein expression was strongly as-
sociated with expression of classical HLA molecules 
(class I and class II) and components of the antigen 
processing machinery (immunoproteasome, peptide 
transporter TAP, trimming enzyme ERAP and chaper-
one Erp57) (Table I). This implies that tumor expres-
sion of HLA-E is regulated in a comparable fashion to 
classical HLA and that its presence on tumors is not a 
defense mechanism against NK cell mediated lysis in 
classical class I-negative tumors, as sometimes sug-
gested in literature (26, 29-31). Instead, our data argue 
that HLA-E expression arises in the setting of an intact 
antigen processing apparatus and, in ovarian cancer, 
abundant CTL infiltration. A positive association be-
tween classical and non-classical HLA expression 
has recently also been reported for a large cohort of 
breast cancers (32), and is moreover anticipated on 
basis of the stabilization of HLA-E by leader peptides 
derived from classical HLA molecules (2, 33). 
Traditionally, interaction with NK cells via receptors 
CD94/NKG2A and CD94/NKG2C was considered the 
main purpose of HLA-E. The presence of infiltrating 
NK cells in ovarian and cervical cancers was previ-
ously reported by several groups (34-39). Detection of 
NK cells in tumor samples has predominantly been 
performed with antibodies against CD56 and CD57, 
whereas these molecules can also be found on T lym-
phocytes. We carefully analyzed NK infiltration by in-
clusion of the CD3-specific T lymphocyte marker, or 
using the really specific molecule NKp46, which is not 
expressed on T lymphocytes (28). Our data reveal that 
NK cells hardly infiltrate ovarian and cervical cancers, 
in line with the general impression in solid tumors (40), 
in contrast to leukemias, where NK cell responses 
have been connected to better survival (41). 
In addition to NK cells, the inhibiting receptor CD94/
NKG2A and activating receptor CD94/NKG2C are ex-
pressed by minor populations of CD8+ T cells. Al-
though this subset is generally very scarce in PBMC of 
healthy subjects (approximately 4%) (Fig. 2) (32, 42), 
the frequency of CD94/NKG2A expressing CD8+ T 
cells is much higher in tumor infiltrating lymphocytes, 
as shown in our study and by others (43, 44). 
Interestingly, the immunosuppressive cytokine TGF-b, 
which is regularly detected in ovarian and cervical 
cancer (45-47), seems to induce this inhibiting recep-
tor on T cells (44). Several studies have shown that the 
inhibiting receptor CD94/NKG2A dampens the incom-
ing activation signals of T cells by recruitment of phos-
phatases like SHP-1 to the signal transducing synaps, 
resulting in decreased effector functions (1, 44, 48). 
Strikingly, the activating receptor CD94/NKG2C was 
absent on tumor infiltrating T cells (Fig. 2), whereas it is 
expressed in other inflammatory situations (49-51). 
This implies that expression of the NKG2 chains is dif-
ferentially and independently regulated and that NK-
G2A is selectively upregulated in tumors.   
Protein expression of HLA-E was previously analyzed 
on cultured cancer cell lines and small cohorts of sur-
gical specimen of some cancer types (16, 26, 52-54). 
HLA-E expression was correlated with increased infil-
tration of CD8+ CTL in glioblastoma (53), and de-
creased infiltration of NK cells as well as a worse pro-
gression free survival in colorectal cancer (26). In cer-
vical cancer, HLA-E expression seemed to gradually 
increase from cervical intraepithelial neoplasia (CIN) I 
to invasive cervical cancer (54). Intriguingly, we and 
others (55) found no associations with tumor stage or 
grade. We have to note, however, that our cervical 
cancer cohort represented early stage patients with 
relatively highly differentiated tumors, whereas the 
ovarian cancer cohort consisted of mostly late stage, 
high grade tumors. The expression pattern and fre-
quency of HLA-E was quite similar in our two studied 
cancer types as well as its positive association with 
antigen presenting molecules. The effect on survival 
was however clearly different. High HLA-E expression 
in ovarian cancer appeared to neutralize the beneficial 
effect of CTL infiltration. These results are in line with 
the in vitro data by Malmberg et al. (56), who demon-
strated that HLA-E on freshly isolated ovarian cancer 
cells was upregulated by IFN-γ treatment, resulting in 
a CD94/NKG2A-mediated resistance to CTL lysis. 
However, in cervical cancer HLA-E did not influence 
the prognostic effects of CTL nor the CTL/Treg ratio. 
This difference might be explained by the significantly 
higher numbers of infiltrating CTL in cervical cancer. 
At least three times more intratumoral CTL can be 
found in this tumor type (20, 21, 57), which is most 
likely the result of the presence of viral antigens from 
HPV and an active inflammatory response. 
In conclusion, our results suggest that HLA-E expres-
sion in ovarian and cervical cancer is the result of a 
smoldering inflammatory response. This emerging 
concept (58) entails the presence of an inflammatory 
milieu which can either promote tumor progression or 
antitumor activity. The inhibiting impact of HLA-E in 
cervical cancer is limited due to beneficial signs of in-






flammation such as high CTL infiltrate, strong viral an-
tigens and stimulating HLA ligands (MICA and classi-
cal HLA). In ovarian cancer, the presence of HLA-E is 
able to neutralize the protective role of the relatively 
scarce intratumoral CTL (19-21, 59, 60).
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Supplementary Table I  Clinicopathological characteristics and survival data
Ovarian cancer (n=270) Cervical cancer (n=153)
Age (years) Age (years)
Mean (SD) 57.2 (13.8) Mean (SD) 47.8 (14.3)
DSS (months) DSS (months)
Median (95% C.I.) 42.0 (31.3-52.7) Median (95% C.I.) 176 (160.5-192.1)
FIGO Stage FIGO Stage
Early stage 93 (34.6%) Stage Ib1 64 (45.4%)
Late stage 176 (65.4%) Stage Ib2/II 77 (54.6%)
Missing 1 Missing 12
Tumor type Tumor type
Serous 147 (52.1%) Squamous 123 (82.6%)
Other 123 (43.6%) Adeno(squamous) 26 (17.4%)
Missing 4
Tumor Grade Lymph nodes
Grade I/II 133 (47.2%) Negative 106 (70.2%)
Grade III/ undiff 149 (52.8%) Positive 45 (29.8%)
Missing 18 Missing 2
Residual disease Tumor size
< 2 cm 155 (62.2%) <40 mm 82 (57.7%)
>= 2 cm 94 (37.8%) >=40 mm 60 (42.3%)
Missing 21 Missing 11
DSS = disease specific survival; FIGO = International Federation of Gynaecology and Obstetrics.
Supplementary Table II HLA-E expression and clinicopathological factors
HLA-E ovarian cancer HLA-E cervical cancer
low high p-valuea low high p-valuea
Histology Histology
Serous 27 98 0.203 Squamous 29 94 0.361
Non-serous 26 63 Adeno(squamous) 4 22
Tumor stage Tumor stage
FIGO I/II 19 64 0.580 FIGO Ib1 16 48 0.325
FIGO III/IV 39 110 FIGO Ib2 / II 14 63
Tumor grade Infiltration depth
Grade I/II 30 78 0.435 <15 mm 14 64 0.125
Grade III/IV 25 83 >= 15 mm 20 50
Residual tumor Tumor size
<2 cm 17 42 0.219 <40 mm 21 61 0.587
>=2 cm 15 61 >= 40 mm 13 47
HPV infection
HPV 16 or 18 27 86 0.787
HPV negative 4 15
Lymph nodes
Negative 23 83 0.508
Positive 12 33
Vascular invasion
No 12 51 0.588
Yes 18 61
a p-values were calculated using Pearson Chi square-test. Bold signifies p<0.05.
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ated antigens (TAAs) is pivotal for T cell priming of 
and/or recognition by specific effector T cells. We and 
others previously showed that such endogenous anti-
gen presentation can also involve HLA-II complexes 
[5,6]. Ii silencing in certain tumor cells downmodulates 
CLIP, but not HLA-II expression levels [7] and results in 
increased presentation of endogenous antigens and 
tumor-specific CD4+ T cell activation [5,8]. These stud-
ies contradict with the proposed requirement of Ii for 
HLA-II stabilization and transport [9], but agree with its 
function in preventing binding of endogenous peptides 
to HLA-II complexes in the ER [10].
For HLA-I antigen presentation, endogenous proteins, 
e.g. tumor- and virus-associated proteins, are normally 
degraded by the cytoplasmic proteasome followed by 
translocation of peptides into the ER via the transporter 
associated with antigen processing (TAP) molecule. 
Here, peptides with the appropriate binding motif asso-
ciate with newly formed HLA class I (HLA-I) heavy 
chain/β2m heterodimers and are transported to the 
plasma membrane for presentation to CTLs (reviewed 
in ref. 11). Professional APCs, including macrophages, 
dendritic cells (DCs) and B cells, have well-equipped 
machinery to detect, internalize and process exoge-
nous antigens. These antigens are processed for HLA-
II-mediated presentation, but can also be routed for 
presentation by HLA-I, resulting in cross-priming of 
CTLs (reviewed in ref. 12). Two general routes for this 
so-called cross-presentation have been described: ex-
ogenous antigens are degraded and directly loaded 
onto HLA-I molecules in the endo-lysosomal pathway 
[13] or, alternatively, gain access to the cytoplasm for 
proteasome-dependent processing and are directed 
either back into endosomes or the ER via TAP [14,15]. 
The precise mechanism by which HLA-I molecules may 
enter the endo-lysosomal pathway is poorly defined. 
Ii is a type II transmembrane protein that exists in dif-
ferent isoforms and contains one or more internal tar-
geting signals for specific transport of newly synthe-
sized HLA-II complexes to the MIICs [16,17]. In addition 
to its role in HLA-II transport, the role of Ii as chaperone 
seems to be more versatile. Ii binds to the actin-based 
motor protein myosin-II to negatively affect DC migra-
tion [18], to adhesion molecule CD44 to activate T cells 
[19] as well as to costimulatory molecule CD70 for tar-
geting to the MIICs [20]. In the present study, we show 
an accessory role for Ii and CLIP in HLA-I processing 
and antigen presentation by leukemic cells.
Methods
Patient material
Bone marrow samples from nine newly diagnosed 
acute myeloid leukemia (AML) patients were collected 
after obtaining written informed consent and accord-
Abstract
Antigen presentation by HLA class I (HLA-I) and HLA 
class II (HLA-II) complexes is achieved by proteins that 
are specific for their respective processing pathway. 
The invariant chain (Ii)-derived peptide CLIP is re-
quired for HLA-II-mediated antigen presentation by 
stabilizing HLA-II molecules before antigen loading 
through transient and promiscuous binding to different 
HLA-II peptide grooves. Here, we demonstrate alter-
native binding of CLIP to surface HLA-I molecules on 
leukemic cells. In HLA-II-negative AML cells, we found 
plasma membrane display of the CLIP peptide. Silenc-
ing Ii in AML cells resulted in reduced HLA-I cell sur-
face display, which indicated a direct role of CLIP in 
the HLA-I antigen presentation pathway. In HLA-I-
specific peptide eluates from B-LCLs, five Ii-derived 
peptides were identified, of which two were from the 
CLIP region. In vitro peptide binding assays strikingly 
revealed that the eluted CLIP peptide RMATPLLMQA-
LPM efficiently bound to four distinct HLA-I supertypes 
(-A2, -B7, -A3, -B40). Furthermore, shorter length vari-
ants of this CLIP peptide also bound to these four su-
pertypes, although in silico algorithms only predicted 
binding to HLA-A2 or -B7. Immunization of HLA-A2 
transgenic mice with these peptides did not induce 
CTL responses. Together these data show a remark-
able promiscuity of CLIP for binding to a wide variety of 
HLA-I molecules. The found participation of CLIP in 
the HLA-I antigen presentation pathway could reflect 
an aberrant mechanism in leukemic cells, but might 
also lead to elucidation of novel processing pathways 
or immune escape mechanisms.
Introduction
In immune surveillance against invading pathogens 
and tumor cells, antigen processing and presentation 
by HLA molecules is essential for induction of potent T 
cell-mediated immunity.
Classically, exogenously derived antigens, such as 
bacterial components, are processed in the endo-
somal/lysosomal system for loading onto HLA class II 
(HLA-II) complexes. After synthesis in the endoplas-
mic reticulum (ER), the HLA-II heterodimer binds to the 
invariant chain (Ii) for transport to late endosomes [1]. 
Here, Ii is cleaved until only a small fragment, the class 
II-associated invariant chain peptide (CLIP) remains 
bound to the class II peptide-binding groove [2]. In 
MHC class II loading compartments (MIICs), CLIP is 
exchanged for an antigenic peptide with aid of HLA-
DM [3,4], and HLA-II/peptide complexes are exported 
to the plasma membrane and presented to CD4+ T 
cells. In tumor cells that have APC function, efficient 
processing of endogenous, potentially tumor-associ-
74 | CHAPTER 6
was added. Moabs were added during 15 min at room 
temperature (RT). Intracellular staining for Ii was per-
formed on cells fixed with PBS 1% paraformaldehyde 
and permeabilized with PBS 0.1% saponin (Sigma-Al-
drich). After incubation with PIN1.1 for 30 min at RT, 
cells were stained for 20 min with a secondary, PE-la-
beled rabbit anti-mouse (RAM) IgG (Dako). Each incu-
bation step was followed by two washing steps in PBS 
with 0.1% HSA and 0.05% sodium azide. We used a 
FACSCalibur flow cytometer and CellQuestPro soft-
ware (BD Biosciences) or Flowjo software (Treestar 
Inc, Ashland, OR, USA) to analyze the percentage of 
positive cells. Leukemic cells of AML patients were 
defined by CD45dim/SSClow expression. 
Retrovirus production and transduction
Ii expression was silenced using the retroviral pSIREN-
RetroQ vector (Clontech, Palo Alto, CA, USA) consist-
ing of a puromycin resistance gene together with a 
cloned Ii siRNA insert (sequence no. 53; ref. 22) Retro-
virus, a kind gift from Dr. S. Ostrand-Rosenberg (Uni-
versity of Maryland, Baltimore, USA), was produced as 
reported [23]. For retroviral transduction, 1 x 106 cells/
ml were cultured until 40% confluency. Following wash-
ing with PBS, cells were resuspended in DMEM (Gibco) 
containing 10% FBS, 10 mM Hepes and polybrene, 
followed by the drop-wise addition of retroviral superna-
tant to attain a polybrene concentration of 4 μg/ml. Cells 
were incubated at 37°C for 6 h, washed three times with 
excess PBS and kept in culture medium for three days. 
Subsequently, 0.5 μg/ml puromycin was added and in-
creased gradually during a period of two weeks to a fi-
nal concentration of 1.0 μg/ml in order to select Ii siRNA-
transduced cells. Ii expression in transduced cells was 
checked by flow cytometric analysis. The process of 
siRNA formation and retroviral transduction itself was 
validated not to affect Ii expression [6,22].
HLA class I peptide isolation, HPLC and 
mass spectrometry
HLA-I/peptide complexes were purified from >1010 EBV-
transformed B-LCLs by affinity chromatography using 
protein A beads (GE Healthcare) covalently bound to 
MoAbs against HLA-I (clone W6/32; used for B-LCL JY) 
or HLA-A2 (clone BB7.2, ref. 24; used for B-LCL PHEB 
and 5544). Peptides were eluted from isolated HLA-I 
molecules and separated from class I heavy chains and 
β2m by passage through Centriprep filtration units with 
a 10 kD, and the complex peptide pool was fractionated 
on a 15 cm x 200 μm RP-C18 (Reprosil-Pur C18-AQ 3 
μm) column, packed in house. The gradient was run 
from 0% to 50% solvent B (10/90/0.1 v/v/v water/aceto-
nitrile/formic acid) in 45 min. 
Peptide fractions from the first dimension separation 
ing to the Declaration of Helsinki. This was approved 
by the review board ('Medisch Ethische Toetsing-
scommissie, METc') of the VU University Medical 
Center, Amsterdam, The Netherlands. Classification 
of acute promyelocytic leukemia (APL) was based on 
standard genetic and molecular detection of t(15;17), 
as part of routine diagnostic procedures at our depart-
ment. HLA-DR-negative AML patients contained high 
numbers of myeloid cells (>80% of the total WBC 
count), which were defined as CD45dim/SSClow-int 
by flow cytometry. Mononuclear cells were isolated 
using Ficoll-PaquePLUS (Amersham Biosciences, 
Freiburg, Germany) and directly used for protein anal-
ysis or cryopreserved in liquid nitrogen.  
Cell lines and culturing
Human leukemic cell lines KG-1, THP-1 and Kasumi-1 
were purchased from the American Type Culture Col-
lection (ATTC). KG-1 cells were maintained in IMDM 
(Gibco, Paisley, UK) supplemented with 20% FBS 
(Greiner, Alphen a/d Rijn, The Netherlands), 25 mM 
Hepes (Sigma-Aldrich, St Louis, MO, USA), 1% L-glu-
tamine and 50 μM 2-ME (both Gibco). THP-1 and Ka-
sumi-1 were cultured in RPMI 1640 medium (Gibco) 
containing 10% and 15% FBS, respectively. For pep-
tide elutions, Epstein-Barr virus (EBV)-transformed 
B-lymphoblastoid cell lines (B-LCLs) were generated 
from peripheral blood mononuclear cells (PBMC) from 
healthy blood donors or patients. This was performed 
in approval with the Leiden University Medical Center 
review board. EBV-transformed B-LCL JY, PHEB and 
5544 were cultured in IMDM containing 8% FBS, 100 
IU/ml penicillin and 2 mM L-glutamine. For the compe-
tition-based peptide binding assays, B-LCLs express-
ing HLA-I alleles of interest were a generous gift from 
Dr. J. Kessler (Leiden University Medical Center; ref. 
21). T2 cells were obtained from Dr. P. Cresswell (Yale 
University School of Medicine, New Haven, CT, USA).
Antibodies and immunofluorescence stainings
We used the following mouse anti-human monoclonal 
antibodies (MoAbs): PE-labeled anti-CLIP (clone cer-
CLIP.1; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and anti-HLA-ABC (clone W6/32; Dako, 
Glostrup, Denmark); FITC-labeled CD74, anti-HLA-
DR (clone L243) and anti-HLA-DRPQ; PerCP-labeled 
CD45 (all BD Biosciences, San Jose, CA, USA). Anti-Ii 
MoAb (clone PIN1.1) was kindly provided by Dr. P. 
Cresswell. For stainings of murine cells, PE-labeled 
CD8 (clone 53-6.7; Biolegend, San Diego, CA, USA) 
and APC-labeled anti-IFN-γ (clone XMG1.2; BD Bio-
sciences) antibodies were used.
For immunofluorescence, cells were incubated with 
10% human γ-globulin (60 mg/ml; Sanquin, Amster-
dam, The Netherlands) before the MoAb of interest 






to HLA-I, competition-based cellular peptide binding 
assays were performed as described earlier [21]. In 
short, B-LCLs were treated with a mild acid (1:1 mixture 
of 0.263M C6H8O7*H2O and 0.126M Na2HPO4*2H2O) 
for 1 min to remove the naturally HLA-I bound peptides. 
Cells were buffered with cold IMDM containing 2% FCS 
immediately thereafter and resuspended at a concen-
tration of 4 x 105 cells/ml in 2% FCS and 1.5 mg/ml hu-
man β2m (Sigma-Aldrich). Then, 4 x 104 cells/well were 
incubated with 150 nM of fluorescently labeled refer-
ence peptide and a serial dilution of one of the eluted or 
predicted peptides. The following HLA-I allele-restrict-
ed reference peptides were used: FLPSDCFPSV (for 
HLA-A0201), KVFPCALINK (for HLA-A0301), APAPAP-
CWPL (for HLA-B0702) and GEFGGCGSV (for HLA-
were reduced to near dryness and resuspended in 
95/3/0.1 v/v/v water/acetonitrile/formic acid. These re-
suspended fractions were analyzed by on-line nano-
HPLC mass spectrometry using a system earlier de-
scribed [25]. Fractions were injected onto a precolumn 
(100 μm×15 mm; Reprosil-Pur C18-AQ 3 μm, 5 μm, 
Phenomenex) and eluted via an analytical nano-HPLC 
column (15 cm×50 μm; Reprosil-Pur C18-AQ 3 μm). The 
gradient was run from 0% to 50% solvent B (10/90/0.1 
v/v/v water/acetonitrile/formic acid) in 90 min. The nano-
HPLC column was drawn to a tip of approximately 5 μm 
and acted as the electrospray needle of the MS source.
For mass spectrometry, we used a LTQ-FT Ultra mass 
spectrometer (Thermo, Bremen, Germany) that was 
operated in data-dependent mode, automatically 
switching between MS and MS/MS acquisition. Full 
scan mass spectra were acquired in the Fourier-
transform ion cyclotron resonance (FT-ICR) with a 
resolution (m/Δm at full width half maximum) of 25,000 
at a target value of 5,000,000. The two most intense 
ions were then isolated for accurate mass measure-
ments by a selected ion monitoring scan in FT-ICR 
with a resolution of 50,000 at a target accumulation 
value of 50,000. The selected ions were then frag-
mented in the linear ion trap using collision-induced 
dissociation at a target value of 10,000. In a post analy-
sis process, raw data were converted to peak lists us-
ing Bioworks Browser software, Version 3.1. For pep-
tide identification, MS/MS data were submitted to the 
human IPI database using Mascot Version 2.2.04 
(Matrix Science) with the following settings: 2 ppm and 
0.8-Da deviation for precursor and fragment masses, 
respectively; no enzyme was specified. Mascot output 
files were loaded into Scaffold (http:// www.proteome-
software.com) and exported to Excel.
HLA class I binding prediction and synthesis 
of peptides
The capability of peptides to bind to which HLA-I mol-
ecules was predicted via the netMHC server (http://
www.cbs.dtu.dk/services/NetMHC; refs 26,27), which 
makes use of approximation algorithms via artificial 
neural networks (ANNs) and is trained on 9- to 11-mer 
peptides to predict binding to HLA-I antigen binding 
pockets. Predicted peptides were synthesized by stan-
dard Fmoc chemistry and using a Syro II peptide syn-
thesizer (MultiSyntech, Witten, Germany), as described 
previously [28]. The integrity of each peptide was rou-
tinely validated by HPLC and mass spectrometry.
Competition-based cellular peptide binding 
assay
To test binding affinity of eluted and predicted peptides 
Figure 1 











Figure 1. Surface display of the CLIP epitope on HLA-II-
negative leukemic cells and influence of the invariant 
chain on HLA-I expression. (A) Surface expression of CLIP, 
HLA-DR, total HLA-II (‘HLA-DRPQ’) and invariant chain 
(‘CD74’) of myeloid cells from an acute promyelocytic leuke-
mia (APL) patient, as determined by flow cytometry. Myeloid 
cells were defined as CD45dim/SSClow/int and expression 
thresholds were set according to unstained myeloid cells. (B) 
Quantitative analysis on frequencies of myeloid cells from 
APL patients that express CLIP (n=9), HLA-DR (n=9), total 
HLA-II (n=6) and CD74 (n=6). Frequencies indicate percent-
age tumor cells that reach threshold expression based on 
unstained leukemic cells. (C) The effect of invariant chain Ii 
down-modulation in KG-1 (CLIP-) and THP-1 (CLIP+) leukemic 
cells on HLA-I expression at the cell surface. Intracellular 
staining (ICS) of Ii (PIN1.1) and surface staining of HLA-I 
(W6/32) were compared between Ii siRNA-transduced and 
non-transduced cells.
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invariant chain peptides were pooled to a total of 50 μg 
each. As positive control, mice were injected with 50 
μg of MLIVYVRFWWL. At day 13, blood samples were 
taken and tested for CD8+ T cell reactivity by overnight 
incubation with the corresponding peptide and intra-
cellular staining for IFN-γ.
Results
CLIP presented on HLA-DR-negative leukemic 
cells from patients is not explained by plasma 
membrane expression of HLA-II or CD74
We found that patients with acute promyelocytic leuke-
mia (APL; ref. 31), a genetically determined subtype of 
HLA-DR-negative acute myeloid leukemia (AML), 
contained a high frequency of leukemic cells with sur-
face display of the CLIP epitope. Since CLIP expres-
sion was not observed on normal promyelocytes from 
healthy individuals, this remarkable observation may 
suggest that CLIP presentation at the plasma mem-
brane of these leukemic cells is leukemia-specific and 
occurs in the context of other types of HLA-II proteins 
or as unprocessed Ii. To examine the underlying 
mechanism of CLIP presentation, we analyzed protein 
expression of total HLA-II and CD74 (i.e. unprocessed 
Ii) at the plasma membrane. Flow cytometric analysis 
however showed a lack of both proteins on HLA-DR-
CLIP+ leukemic cells (Figure 1A and B), which shows 
that the expression of CLIP can neither be attributed to 
its presentation by HLA-DP or HLA-DQ molecules, nor 
to the expression of unprocessed Ii.
Invariant chain silencing in myeloid leuke-
mia cell lines differentially influences HLA-I 
surface expression
In the mutant TAP- and HLA-II-deficient T2 cell line, 
the precursor of CLIP, Ii, was shown to interact with H-
2Db alleles [32]. In addition, Ii can transport HLA-I 
molecules to endosomal compartments where exoge-
nous peptides are present [33]. We next investigated 
B4002), each containing a fluorescent label bound to 
the cysteine residue [21]. After overnight incubation at 
4ºC, cells were washed twice in PBS supplemented 
with 1% BSA and fixed in 0.5% paraformaldehyde. 
Cells were analyzed with CellQuestPro or FlowJo soft-
ware (Tree Star, Ashland, OR, USA). IC50 values were 
defined with GraphPad Prism 4.02 (GraphPad Soft-
ware Inc., La Jolla, USA) using the following formula: 
Y=Bmax*X/(IC50+X), in which Bmax is the maximal 
binding capacity of the positive control peptide, X the 
concentration of peptide tested and IC50 the concen-
tration of peptide needed to reach half-maximal bind-
ing.
Mouse immunizations
HLA-A2 transgenic mice (B6 background HLA-A2/H2-
D; ref. 29) were immunized subcutaneously with 50 μg 
of invariant chain peptides and 150 mg HBV T helper 
peptide (TPPAYRPPNAPIL) in PBS. The injection side 
was covered with 60 mg of Aldara cream containing 
5% imiquimod (3M Pharma Nederland BV). Immuniza-
tion was repeated on day 7 combined with two intra-
peritoneal injections of 600.000 IU human recombi-
nant IL-2 (Novartis) on day 7 and 8 [30]. The predicted 
Table I. HLA-I binding affinity of eluted peptides 
derived from the invariant chain. 








1 SRGALYTGFSIL  10.89 Int  1.39 High
2 LLAGQATT  >100 -  40.85 Low
3 RMATPLLMQALPM  13.66 Int  0.36 High
4 LPMGALPQGPM  >100 -  0.41 High
5 ETIDWKVFESW  >100 -  >100 -
* See Figure 2 for amino acid position in the invariant chain protein
† IC50 is the concentration used to obtain half maximal competition and 
represents the mean value of two independent experiments.
‡ Binding affinity is classified according to the following IC50 cut-off values: 
high affinity, ≤5 μM; intermediate (int) affinity, 5-15 μM; low affinity, 
15-100 μM; no binding, >100 μM [21]. 
Figure 2. Invariant chain-derived peptides identified in isolated HLA-I molecules of B-LCLs. Peptide elutions of purified 
HLA-I molecules from EBV-transformed B-LCLs resulted in the identification of five peptides originating from the invariant chain. 
HLA-I purification and subsequent mass spectrometry analysis are described in Materials and Methods. Of note, peptide 3 and 
4 are located in the CLIP region, known for universal binding to HLA-II molecules. 






brane. The peptide repertoires of HLA-I molecules on 
EBV-transformed B cells, including CLIP-positive JY 
cells (Figure S3) were evaluated through biochemical 
purification. Out of the total characterized peptide 
repertoire, five peptides were derived from the Ii pro-
tein (Figure 2 and Table I), the sequences of which 
were validated by mass spectrometry according to 
their synthetic counterparts. Remarkably, two pep-
tides were located within or near the CLIP region, 
known for its association with HLA-II peptide-binding 
grooves. Isolation of the 5 identified peptides was re-
stricted to HLA-A0201 and HLA-B0702 alleles pre-
sented on EBV-transformed B cells. To examine the 
HLA-I allele specificity and binding affinity of these 
peptides, competition-based peptide binding assays 
were performed (Table I). Four out of five peptides had 
binding capacity to the B0702 allele and three of these 
were even categorized as high affinity binders. Nota-
bly, peptide 1 and peptide 3, the peptide located within 
the CLIP region, also bound to the A0201 allele, which 
might suggest a promiscuous binding capacity of 
these peptides to HLA-I. Altogether, these data dem-
onstrate that surface HLA-I molecules are able to 
present a variety of peptides generated from Ii.
Invariant chain-derived peptides located at 
the CLIP region show promiscuous binding 
to various HLA-I alleles
As CLIP is known to bind promiscuously to the binding 
groove of a broad range of HLA-II molecules [35], we 
further explored the HLA-I binding specificity of the 
eluted peptide located at the CLIP region of Ii (peptide 
whether there was a relation between Ii and HLA-I cell 
surface expression in CLIP-presenting and non-pre-
senting leukemic cells. Retroviral introduction of Ii-
specific siRNAs strongly downmodulates CLIP ex-
pression on several myeloid leukemia cell lines, as we 
recently reported [7]. When these cell lines were as-
sessed for HLA-I protein expression by flow cytometry, 
KG-1 cells, which present low surface levels of CLIP 
[34], revealed hardly any effect of Ii silencing (Figure 
1C). In THP-1 cells, which highly express CLIP [34], 
however, silencing of Ii induced a strong reduction in 
HLA-I surface expression (Figure 1C). In addition, we 
found indications that Ii was indeed able to associate 
with HLA-I-related products in leukemic cells, since Ii 
isoforms were present in HLA-I and Ii immunoprecipi-
tates (Figure S1A), respectively. This was mostly seen 
in Ii-overexpressing Kasumi-1 cells (Figure S1A and 
S2), which also showed an increase in free β2m ex-
pression after Ii silencing (Figure S1B). The involve-
ment of Ii in HLA-I plasma membrane expression in 
CLIP-presenting leukemic cells suggests a relation 
between surface expression of CLIP and HLA-I mole-
cules. Also TAP expression was limited in CLIP+ THP-1 
cells, in contrast to CLIP- KG-1 cells (Figure S2), indi-
cating that the involvement may rely on the ability to 
process endogenous antigens for loading in the ER. 
Peptides derived from the invariant chain 
are presented at the cell surface by HLA-I 
molecules
We next assessed whether HLA-I molecules can in-
deed present Ii-derived peptides at the plasma mem-
Figure 3. Promiscuous binding of CLIP-peptide to distinct HLA-I alleles, representing four supertypes. The CLIP 
peptide RMATPLLMQALPM (peptide 3) was tested for binding affinity in a competition-based cellular peptide binding assay. 
The four tested HLA-I alleles (HLA-A0201, -A0301, -B0702 and -B4002) harbor a completely distinct binding pocket and bind 
different peptide ligands. CLIP peptide shows intermediate to high binding affinity to all of these. Separate positive control 
peptides efficiently bind to their respective HLA allele: GILGFVFTL (A0201 peptide), QVPLRPMTYK (A0301 peptide), SPSVD-
KARAEL (B0702 peptide) and GEFGGFGSV (B4002 peptide) with IC50 values of 3.7, 0.2, 0.7 and 0.2, respectively [21]. The 
peptide concentration started at 100 μg/ml for HLA-A0201, -A0301 and -B4002 and 25 μg/ml for HLA-B0702, followed by a se-
rial dilution of a factor two. Exact IC50 values of the CLIP peptides are depicted in Table II
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leles with reasonably high affinity (Table II), indicating 
that peptides located in the CLIP region of Ii have uni-
versal binding abilities to polymorphic HLA-I mole-
cules. Finally, we tested whether the identified Ii-de-
rived peptides were immunogenic in the context of 
HLA-I, as reported for self peptides termed T-cell epit-
opes associated with impaired peptide processing 
(TEIPPs; refs 37–39), but immunizations of HLA-A2 
transgenic mice with these peptides showed no CD8+ 
CTL responses (Figure S4). From these data, we con-
clude that the CLIP region of Ii harbors a unique pep-
tide sequence that can accommodate binding to 
structurally completely different grooves of both HLA-I 
and -II. 
Discussion
Processing and presentation of antigens via HLA mol-
ecules by APCs is the key mechanism for generating a 
specific immune response against pathogens and 
TAAs. In normal APCs, Ii and CLIP have essential roles 
in the HLA-II antigen presentation pathway. We and 
others previously described that in tumor cells that are 
able to function as APC, expression of Ii and CLIP 
could serve as immune escape mechanism by interfer-
ence with HLA-II-mediated TAA presentation [5,8,40]. 
Here, we reveal that Ii can also be associated with 
HLA-I antigen presentation in malignant cells. This 
study points at an alternative HLA-I antigen presenta-
tion pathway that may affect current concepts of anti-
gen cross-presentation and tumor immune escape. 
One of the early events during HLA-I processing is the 
binding of heavy chains to β2m in the ER. This results 
in HLA-I stabilization, appropriate folding and incorpo-
ration into the class I peptide-loading complex, con-
sisting of TAP and other ER-resident chaperones im-
portant for efficient HLA-I peptide loading. Our obser-
no. 3; Figure 2 and Table I). This naturally presented 
peptide (RMATPLLMQALPM) demonstrated a high 
affinity for both HLA-A0201 and -B0702 (Table I). To 
determine if peptide RMATPLLMQALPM could bind 
promiscuously to HLA-I molecules, we addressed its 
binding capacity to HLA-I molecules bearing structur-
ally different binding grooves. HLA-I molecules are 
classified according to overlapping binding repertoires 
and consensus structures in the main peptide binding 
pockets, so-called supertypes [36]. HLA-A0201 and 
-B0702 are well known representatives of the A2 and 
B7 supertype, respectively. The same accounts for 
HLA-A0301 and -B4002, which represent the common 
supertypes A3 and B40 [36]. Interestingly, peptide 
RMATPLLMQALPM bound with a relatively high affin-
ity to all four HLA-I alleles (Figure 3), which have com-
pletely different peptide-binding grooves, suggesting 
that the CLIP sequence involved in promiscuous HLA-
II binding also underlies a promiscuous binding to 
HLA-I molecules. 
The unexpected promiscuous binding of peptide 
RMATPLLMQALPM to distinct HLA-I molecules 
prompted us to systematically assess length variants 
of peptides located in the CLIP region of Ii for such 
binding feature. The CLIP amino acid sequence of Ii 
was subjected to standard HLA-I binding prediction 
algorithms for 9- to 11-mer peptides [26,27], which re-
sulted in highly predictive values of three length vari-
ants (9-, 10- and 11-mer) of the naturally presented 
13-mer RMATPLLMQALPM (Table II). The three pep-
tides were predicted to selectively bind to HLA-A2 
subtypes and, in case of the 11-mer, also to -B7 sub-
types. Subsequently, we tested these predicted pep-
tides for actual binding to our selected alleles repre-
senting four different supertypes, HLA-A0201, -B0702, 
-A0301 and -B4002. In contrast to their predictions, all 
the length variants bound to each of the four HLA-I al-
Table II. HLA-I binding affinity of peptide length variants located in the CLIP region of the invariant chain.
HLA-I allele   HLA-A201 HLA-B0702 HLA-A0301 HLA-B4002
Peptide sequence Position† Predicted allele‡ IC50§ Affinity¶ IC50 Affinity IC50 Affinity IC50 Affinity
RMATPLLMQALPM* 92-104 NA 13.81 Int 0.36 High 3.35 High 3.43 High
KMRMATPLL 90-98 A0201 10.90 Int 0.47 High 6.43 Int 0.44 High
RMATPLLMQA 92-101 A0201 8.08 Int 7.75 Int 2.45 High 2.05 High
RMATPLLMQAL 92-102 A0201+ B0702 4.49 High 1.85 High 4.28 High 0.48 High
* Peptide found with HLA-I elutions
† Amino acid (AA) position in the invariant chain protein
‡ Predicted HLA-I allele to which the peptide binds. Peptide binding prediction was done with netMHC (http://www.cbs.dtu.dk/services/NetMHC). Binding 
predictions can be made for peptide lengths between 8 and 11 for all alleles with a novel approximation algorithm using artificial neural networks trained 
on 9-mer peptides [26,27]. Only peptides are shown with a predicted binding affinity of 500 nM or stronger. 
§ IC50 is the concentration used to obtain half maximal competition and represents the mean value of two independent experiments.
¶ Binding affinity is classified according to the following IC50 cut-off values: high affinity, ≤5 μM; intermediate (int) affinity, 5-15 μM; low affinity, 15-100 μM; 
no binding, >100 μM [21].






on tumor immune escape. In Ii overexpressing leuke-
mias, such as AML (e.g. Kasumi-1 cells; Figure S2) 
and chronic lymphocytic leukemia (CLL; ref. 45), but 
also colorectal carcinoma [46], Ii instead of TAA-de-
rived peptides may be bound to HLA-I molecules after 
synthesis in the ER, thereby preventing TAA presenta-
tion at the plasma membrane and recognition by TAA-
specific CTLs. In TAP-deficient tumors, self peptides 
termed TEIPPs have been identified that are specifi-
cally detected by CTLs [37,39]. In addition, we ob-
served a possible relation of TAP and CLIP expression 
in leukemia, with CLIP- leukemic cells positive and 
CLIP+ leukemic cells negative for TAP (including APL 
cells in Figure 1A; Figure S2 and ref. 6). Therefore, the 
formation of HLA-I/Ii complexes may lead to process-
ing of Ii into CLIP and surface presentation of this self-
peptide as a TEIPP. In immunized HLA-A2 transgenic 
mice however, we could not detect CTL responses 
against CLIP-related Ii peptides (Figure S4). Another 
possibility is that HLA-I/Ii complexes in leukemic cells 
are transported from the ER into the endo-lysosomal 
pathway to be loaded with TAA-derived peptides ob-
tained from authophagy and lysosomal processing. In 
normal APCs, Ii is classically known for its role in traf-
ficking HLA-II molecules to the MIICs. It was recently 
demonstrated that in DCs Ii is also able to direct CD70 
molecules to these compartments [20], indicating that 
the interaction of Ii with HLA-I molecules could ac-
count for such a transporting function as well and rep-
resent a novel cross-presentation pathway. Sugita and 
colleagues already demonstrated a role for Ii in the 
transport of HLA-I molecules to endosomes [33], 
which might explain the accumulation of newly synthe-
sized HLA-I molecules in endosomal storage compart-
ments [13]. Indeed very recently, in murine DCs, Ii was 
shown to be critical in MHC class I trafficking from the 
ER to late endosomes for antigen loading, serving as a 
mediator of cross-presentation [47]. Although further 
HLA-I/Ii processing for peptide loading in such endo-
somal compartments remains undefined, we detected 
CLIP-related Ii peptides in HLA-I-specific eluates of 
B-LCLs (Table I and Figure 2), indicating that Ii can be 
processed to CLIP in HLA-I. These peptides were not 
derived from HLA-II molecules, as validations for con-
tamination with HLA-II during each step of peptide 
elution showed HLA-I heavy chains and β2m, but no 
HLA-II monomers. It is thus appealing to further exam-
ine HLA-I-mediated exchange of CLIP for antigenic 
peptides in the endo-lysosomal pathway as well as 
presentation of CLIP at the plasma membrane for the 
effect on CTL activation. 
In this report, we present important data showing the 
promiscuous involvement of Ii and CLIP in the HLA-I 
antigen presentation pathway of leukemic APCs. To 
define the similarity with HLA-II processing, further 
vation that Ii is involved in HLA-I processing in leukemic 
cells (Figure 1C and Figure S1) indicates that it may 
take part of this process as well. This agrees with ear-
lier studies using HLA-I-transfected T2 cells [32,41,42] 
and suggests that like newly synthesized HLA-II αβ 
complexes, also HLA-I/β2m heterodimers can interact 
with Ii in the ER lumen until peptides are loaded. As Ii 
inhibits premature peptide binding to HLA-II complex-
es in the ER [10], the question rises how the associa-
tion of HLA-I with Ii is related to the function of the 
class I peptide-loading complex in this compartment. 
Ii-silenced THP-1 cells lacking the TAP molecule (Fig-
ure S2) revealed a strong reduction in HLA-I surface 
expression level, in contrast to TAP-expressing KG-1 
cells (Figure 1C). Additionally, in transfected TAP-defi-
cient T2 cells, HLA-I/Ii complexes relied on the ab-
sence of TAP-dependent HLA-I peptides for their sta-
bility [32,41] and were also part of the class I peptide-
loading complex [43]. For this, we propose that two 
different types of competition mechanisms can be ac-
tive in APCs: one involving the binding of Ii to either 
HLA-I or HLA-II and one involving the binding of either 
Ii or peptide loading complex peptides to HLA. In this 
model, the balance between TAP and Ii expression 
might be of major importance. The likelihood of Ii to 
interact with HLA-I molecules increases in the ab-
sence of TAP, as has been described for T2 cells [43], 
but likely also in the situation of Ii abundance, as we 
demonstrate for Ii-high Kasumi-1 cells (Figure S1 and 
S2). Our finding that peptides derived from Ii were 
predicted and able to bind to HLA-A0201 and -B0702 
(Table I and Figure 2) further suggests that the pep-
tide-binding groove is the HLA-I site with which Ii as-
sociates. Indeed, mutations in the binding groove of 
HLA-B7 molecules affected their interaction with Ii and 
expression at the plasma membrane in transfected T2 
cells [42]. It remains to be determined which specific 
HLA-I alleles are prone to bind to Ii, but the promiscu-
ous binding of CLIP-related Ii peptides to the four test-
ed HLA-I superfamilies (Table II and Figure 3) indicates 
great similarity to the promiscuous binding capacity of 
the CLIP region in the context of HLA-II [44]. However, 
this contradicts with the large differences in key an-
chor motifs between each HLA-I superfamily. The 
shallow binding grooves of HLA-II binds peptides 
based on favorable interactions rather than need of 
specific amino acids at each position. Even one amino 
acid with high affinity to the HLA-II binding groove is 
sufficient for peptide binding, which could also be the 
case for HLA-I, as the methionine at position 99 of the 
CLIP region served as crucial anchor residue for H2-
Kb molecules [43].
The observed involvement of Ii and CLIP in HLA-I pro-
cessing in leukemic cells, as the result of a potentially 
imbalanced TAP/Ii ratio, can have different outcomes 
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immunotherapeutic strategies that modulate their ex-
pression, thereby controlling antigen presentation with 
the purpose to target immune surveillance against 
leukemias and possibly prevent autoimmunity.
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Supplementary methods
Western blotting
10-20 x 106 snap-frozen cells were dissolved in ice-
cold lysis buffer, consisting of PBS with 1% Ipegal and 
15% protease inhibitor cocktail [Complete, 1 tablet/7.5 
ml H2O; Boehringer Mannheim, Mannheim, Germa-
ny]). Cell remnants and nuclei were removed by cen-
trifugation (5 min, 10,000 g) and protein content was 
assessed by the Bio-Rad protein assay (Biorad Labo-
ratories, Hercules, CA, USA). Western blotting was 
performed by electrophoresis of samples on 12.5% 
polyacrylamide gels with SDS and their subsequent 
transfer onto methanol-activated PVDF membranes. 
Different protein amounts from whole cell lysates were 
used for loading on gel: 20 μg for Ii and 70 μgfor TAP1. 
Membranes were pre-incubated for 1 h at 4°C in block-
ing buffer (5% blotting grade nonfat milk [Biorad]) in 
TBS-T; 10 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% 
Tween-20) and incubated overnight with MoAbs After 
washing with TBS-T (4x), membranes were incubated 
for 1 h with HRP-conjugated goat anti-mouse antibody 
(Dako). Protein complexes were visualized using Am-
ersham ECL Western Blotting Detection Reagents 
(GE Healthcare, Buckinghamshire, UK).
Immunogenetics 54: 74-81.
42.  Vigna JL, Smith KD, Lutz CT (1996) Invariant chain association 
with MHC class I: preference for HLA class I/beta 2-microglobulin 
heterodimers, specificity, and influence of the MHC peptide-
binding groove. J Immunol 157: 4503-4510.
43.  Powis SJ (2006) CLIP-region mediated interaction of Invariant 
chain with MHC class I molecules. FEBS Lett 580: 3112-3116.
44.  Weenink SM, Milburn PJ, Gautam AM (1997) A continuous central 
motif of invariant chain peptides, CLIP, is essential for binding to 
various I-A MHC class II molecules. Int Immunol 9: 317-325.
45.  Veenstra H, Jacobs P, Dowdle EB (1996) Abnormal association 
between invariant chain and HLA class II alpha and beta chains in 
chronic lymphocytic leukemia. Cell Immunol 171: 68-73.
46.  Moller P, Koretz K, Schlag P, Momburg F (1991) Frequency of 
abnormal expression of HLA-A,B,C and HLA-DR molecules, 
invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its 
impact on tumor recurrence. Int J Cancer Suppl 6: 155-162.
47.  Basha G, Omilusik K, Chavez-Steenbock A, Reinicke AT, Lack N, 
Choi KB, Jefferies WA (2012) A CD74-dependent MHC class I 
endolysosomal cross-presentation pathway. Nat Immunol 13: 237-
245
Supplementary Figure S1. (A) Immunoblotting of Ii in both 
HLA-I (W6/32) and Ii (PIN1.1) immunoprecipitates of KG- 1, THP-
1 and Kasumi-1 cells. IgG immunoprecipiates were used as 
negative controls. (B) The Presence of free-form β2m (12 kD) in 
total lysates of leukemic cells derived from the Ii- overexpressing 
Kasumi-1 cell line. Immunoblots for Ii and β2m were performed 
under SDS conditions and antibodies used for staining were 
against Ii (PIN1.1) or β2m (rabbit polyclonal antibody, kindly pro-
vided by Dr. J.J. Neefjes, NKI, Amsterdam, The Netherlands).






Supplementary Figure S2. Immunoblot analysis of invariant 
chain (Ii) and TAP expression in total cell lysates of the KG-1 
(CLIP-), THP-1 (CLIP+) and Kasumi-1 (CLIP+) leukemic cell 
line. Blots were stained with primary anti-Ii (clone PIN1.1) and 
anti-TAP1 (clone 148.3, a kind gift from Dr. E.J. Wiertz and Dr. 
M.E. Ressing, University Medical Center Utrecht, The Neth-
erlands) MoAb, demonstrating specific bands of 33 kD and 74 
kD, respectively.
Supplementary Figure S3. CLIP expression on the surface 
of T2 and EBV-transformed JY cells, as determined by flow 
cytometry using a PE-labeled cerCLIP.1 MoAb.
Supplementary Figure S4. HLA-A2 transgenic mice (n=3 
per group) were immunized with Ii-derived peptides identified 
in peptide elution studies (see Table I for numbering), or with a 
pool of Ii-derived peptides identified on basis of an in silico 
prediction algorithm (see Table II). After 13 days, peptide-re-
active CD8+ T cells from blood were stained with PE-labeled 
CD8 and APC-labeled anti-IFN-γ antibodies and analyzed by 
flow cytometry. IFN-γ-positive CD8+ T cell frequencies are 
expressed as the percentage within the total pool of CD8+ T 
cells.
Discussion Part I: 


















In this thesis I focus on the presence of the human 
TEIPP repertoire and its possible implications for im-
mune therapy. I conclude that TEIPP exist within the 
human population and that cognate CD8 T cells are 
able to eradicate a broad diversity of processing-im-
paired cancer cells. 
Previous studies showed the presence of TEIPP in a 
mouse model and they identified the Trh4 epitope as 
the first TEIPP (1, 2). This epitope is derived from the 
ER-membrane spanning Trh4 protein and belongs to 
the family of fatty-acid regulators (2). It is likely that the 
Endoplasmic Reticulum (ER) of humans harbors simi-
lar MHC-I peptides that are processed like the Trh4-
epitope independently of TAP. In humans a set of 
TAP-independent peptides was presented in HLA-I 
molecules of TAP-deficient cells (3). This peptide rep-
ertoire was clearly different from its TAP+ counterpart, 
indicating that upon TAP-impairment neo-antigens in-
cluding TEIPP emerge at the cell-surface (3). 
To see whether the human population also harbors T 
cells with specificity for TAP-impaired targets we used 
an autologous system. Hereby we inhibited the TAP-
function in professional antigen presenting cells and 
use these cells as target cells to stimulate T-cells. As 
described in chapter 2 of this thesis, we observed 
strong TEIPP-reactivity at the polyclonal T-cell level of 
ten healthy donors. Remarkably, TEIPP-specificity 
was already observed four weeks after the initial stim-
ulation and we were able to characterize three T-cell 
clones with different HLA-I restriction. Unfortunately, 
the exact peptides recognized by these T cells remain 
unknown. However, this chapter illustrate that like 
mice the human T-cell repertoire contains T cells spe-
cific for TAP-impaired targets and they can be rapidly 
induced. We conclude that T cells directed against 
TEIPP are present in humans.
The presence of TEIPP in humans is further illustrated by 
the identification of the CALCA-epitope. This epitope is 
derived from the carboxy-terminus region of the prepro-
calcitonin signal peptide (4, 5). The CTL was isolated 
from a lung carcinoma patient and recognized the autolo-
gous lung carcinoma cell-line (IGR-Heu), while the au-
tologous B-LCL was not recognized. A cDNA library de-
rived from the IGR-Heu tumor cell-line revealed the 
HLA-A2 presented minimal epitope VLLQAGSLHA (the 
CALCA-epitope). Recently it is shown that the expres-
sion of TAP is low in the IGR-Heu lung carcinoma cell-line 
and once the levels of TAP are increased by IFNg the 
recognition of the CALCA specific CTL is decreased (5). 
We, therefore, conclude that the CALCA-epitope repre-
sents the first molecularly characterized human TEIPP.
To identify other TEIPP, we used a reverse immunology 
approach in chapter 3. Hereto a candidate list of self-
peptides, containing potential TEIPP, was created us-
ing in silico prediction programs based upon the bio-
logical knowledge of the two known TEIPP antigens 
Trh4 and CALCA. Reactivity against five of these pep-
tides was detected in HLA-A2 transgenic mice. Mini-
cultures of human CD8 T-cell libraries from healthy do-
nors confirmed the immunogenicity of these peptides. 
Three of these peptides triggered immune responses 
in naïve T-cell libraries from three healthy donors. We 
conclude that this confirms the existence of human 
TEIPP-specific T cells. To show that these peptides are 
indeed bona fide TEIPP-antigens, we need to isolate 
specific T-cell clones and characterize their capacity to 
recognize and kill TAP-impaired tumors. 
Characteristics of TEIPP
TEIPP is processed via TAP-independent 
antigen presentation pathways
TEIPPs are presented on cells that have an impaired 
MHC-I antigen-processing pathway. T-cells to TEIPP 
exhibit higher reactivity to processing-defective target 
cells than to the processing-proficient counterparts. 
This is illustrated by both known TEIPPs: Trh4-specific 
CTL in mice fails to recognize the TAP-positive coun-
terpart of RMA-S cells (RMA) (2) and restoration of 
TAP levels in the IGR-Heu lung carcinoma decreased 
the recognition by the CALCA specific CTL (5).
A major target for disruption of the antigen-processing 
pathway in cancer is the transporter molecule TAP. 
The majority of peptides presented at the cell-surface 
are transported into the ER through this TAP molecule, 
and therefore upon inhibition these peptides cannot be 
presented anymore. It is frequently observed that the 
expression of TAP is down regulated in tumors, and 
resulting in low MHC-I surface expression as a result 
(6, 7). However, TEIPP profit from the absence of TAP-
dependent peptides as they are processed in a TAP-
independent fashion. Their chances to be presented in 
MHC-I molecules are increased due to the absence of 
TAP-dependent peptides.
The CALCA-epitope is processed through the signal 
sequence pathway, which involves the enzymes Sig-
nal Peptidase (SPase) and Signal Peptide Peptidase 
(SPPase) (4).  The signal sequence of the preprocalci-
tonin is directed towards the ER membrane where 
cleavage of SPase, and SPPase occurs.  After cleav-
age the CALCA-epitope remains inside the ER and in 
the absence of TAP it is loaded in HLA-A*0201 mole-
cules (4, 5). Inhibition of the enzymes SPPase and 
SPase confirmed that processing of the CALCA-epit-
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ope was dependent on the activity of these enzymes 
(4). Moreover, this process is independent of the pro-
teasome, as inhibition with epoxomicin had no effect 
on the recognition (4). 
The Trh4-epitope in mice is derived from the ultimate 
C-terminus of the membrane spanning protein Trh4. 
Possible candidates involved in the antigen process-
ing route of this epitope are furin, and enzymes be-
longing to the family of carboxypeptidases or endopro-
teases (8-15). Furin cleavage sites can be predicted by 
ProP 1.0 server (http://www.cbs/dtu.dk/services/ProP/ 
(16)) and analysis of  amino-acid sequence of the 
Trh4-protein reveals that there is no furin cleavage site 
near the Trh-4 epitope (data not shown). This is con-
firmed by an experiment in which the furin enzyme is 
blocked by 50μM of decanoyl-RVKR-chloro-methyl-
ketone (10), in which no decrease in recognition by the 
Trh4-specific CTL (data not shown). It is, therefore, 
unlikely that furin is involved in the processing of the 
Trh4 epitope. Enzymes from the family of carboxypep-
tidases or endoproteases are more likely candidates 
to be involved in the TAP-independent processing of 
the Trh4-epitope (11, 12). Further research needs to 
reveal the exact proteolytic enzyme responsible for 
the liberation of this C-terminal epitope. 
It is interesting to see that the Trh4-epitope in mouse is 
derived from the C-terminus of the protein whereas the 
CALCA-epitope is derived from the N-terminus, indi-
cating that numerous TAP-independent pathways can 
lead to presentation of TEIPP. 
TEIPP benefits from the absence of TAP- 
dependent peptides
Even though both preprocalcitonin 
and Trh4 are expressed in a variety 
of tissues, their corresponding epit-
opes are not presented on the cell-
surface if these cells have no disrup-
tion in their TAP-dependent antigen 
presentation pathway (4, 5, 17). This 
is most likely due to two factors: 1: the presence of 
large quantities of TAP-dependent peptides, 2: the 
expression levels of the protein. 
Transfecting the IGR-Heu cell-line with TAP, or induc-
ing TAP expression via IFNg results in decreased rec-
ognition by the CALCA-specific CTL, showing that 
upon restoration of TAP levels, the availability of TAP-
dependent peptides decreases the chances of the 
CALCA-epitope to be presented in HLA-A2 molecules 
(5). Cell-lines that were recognized by the CALCA-
specific CTL, highly overexpressed preprocalcitonin in 
comparison to PBMCs (5). Also the CALCA-specific 
T-cell recognized the Medullary Thyroid Carcinoma 
(MTC) cell-line TT, once TAP was down regulated. 
This means that the CALCA-epitope is also an inter-
esting target for MTCs.
At this moment, it is unclear if these high expression 
levels are needed for surface display of CALCA pep-
tides. T-cell recognition is observed in TAP-impaired 
cells in which they introduce low concentrations of the 
CALCA-epitope.  However, higher gene copies were 
needed if the TAP transporter was active (5). For the 
application of the CALCA-epitope in immunotherapy, it 
has to be investigated how much expression of prepro-
calcitonin is needed for presentation of the CALCA-
epitope at the cell-surface of TAP-deficient cells. 
Testing whether the CALCA-specific CTL recognizes 
the TAP-deficient T2 cell-line is an attractive experi-
ment as the T2 cells do express CALCA but in much 
lower levels than the lung-carcinoma cell-lines or the 
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Figure 1: Availability of TEIPP. TEIPPs 
are not presented at the cell-surface in 
the presence of TAP-function. The major-
ity of peptides are transported into the ER 
via TAP, and we hypothesize that in the 
presence of TAP-dependent peptides 
TEIPP peptides are not loaded in MHC-I 
molecules due to their low frequency (left 
part of figure). Once TAP is impaired, the 
majority of peptides do not enter the ER 
anymore. In this case, TEIPPs have a 
much higher chance to be loaded in 







In mice, the limited availability of TEIPP, in TAP profi-
cient cells is illustrated by overexpression of the Trh4-
epitope in TAP+ RMA cells. Overexpression results in 
recognition by the Trh4-specific CTL (17), showing that 
the availability of the epitope is limited in TAP-proficient 
cells. It can be concluded that under normal circum-
stances TEIPPs are not presented at the cell-surface 
due to low quantities of the epitope in comparison to 
the TAP-dependent peptides (figure 1). 
Presentation of TEIPP in HLA-E
Apart from presentation of TEIPP in classical MHC-Ia 
molecules there are indications that TEIPP can also be 
presented in non-classical MHC-Ib molecules, like 
HLA-E (18). This MHC-Ib molecule mainly present one 
set of peptides, derived from the leader sequence of 
classical MHC-Ia molecules (19-21). These leader se-
quences are conserved throughout mammalian spe-
cies pointing at a conserved function of this HLA-E/
peptide complex (20). HLA-E displaying the leader 
sequence can be recognized by Natural Killer cells 
through the CD94/NKG2 complex, serving either as an 
inhibitory or activating signal.
Studies in mice reveal that the peptide repertoire of 
Qa-1b (the mouse homolog of HLA-E) is altered upon 
the inhibition of the TAP-molecule (18). The TAP-de-
pendent classical leader sequences are hereby re-
placed by a broad repertoire of peptides. T-cells rec-
ognizing peptides presented in Qa-1b were identified, 
but the epitopes remain unknown (18).
We show that like Qa-1b the peptide repertoire of HLA-
E is altered upon the inhibition of TAP (chapter 4). Like 
Qa-1b it is observed that upon inhibition of the TAP-
molecule the peptide repertoire presented in HLA-E is 
altered compared to the TAP+ counterpart. Only eight 
peptides were found in both TAP+ and TAP- cells, indi-
cating the impact in peptide presentation upon disrup-
tion of the antigen-processing pathway. T cells re-
sponses against HLA-E presented peptides derived 
from Mycobacterium-, and Epstein Bar Virus (EBV), 
have been identified, indicating that the T cell receptor 
fits with this HLA molecule (22-24). 
The conserved nature of HLA-E makes it an interest-
ing target for immunotherapy. In humans only two 
HLA-E variant are known, which differ by only one 
amino acid. To explore the possible application of im-
munotherapy, we examined in chapter 5 the HLA-E 
expression levels in large panels of ovarium- and cer-
vical carcinomas. It appeared that high levels HLA-E 
positively correlates with the levels of components of 
the antigen presentation pathway. One could, there-
fore, argue that HLA-E up-regulation in tumors results 
in presentation of more leader peptides instead of tu-
mor specific peptides to which T cells can react. More-
over we show in chapter 5 that the T-cell infiltrate in 
tumors express the inhibiting CD94/NKG2A receptor 
suggesting that up-regulation of HLA-E has a more 
regulatory than pro-inflammatory effect in tumors. This 
is further illustrated in cells infected with Mycobacteri-
um tuberculosis, were both HLA-E restricted CD8+ T-
cells effector cells and regulatory CD8+ T-cells were 
found (24).
Another interesting feature of HLA-E is its binding-
motif. In chapter 4 we defined a peptide-binding motif 
based on 407 9mer peptides eluted from TAP-impaired 
K562.HLA-E cells. This motif was remarkably similar 
to the HLA-A0201 binding-motif and numerous HLA-
A0201 described peptides were presented in HLA-E 
upon TAP-impairment. Furthermore the peptides have 
affinity for both HLA-E and HLA-A0201 as shown in 
chapter 4. The HLA-A0201 molecule is present in 
25% of the Caucasian population. Peptide vaccination 
induced T cells could be generated on either the HLA-
A0201 molecule or the HLA-E molecule. The effects of 
this possibility should be explored in great detail to see 
whether this effect is beneficial or not. Hereby, it is im-
portant to investigate under which conditions HLA-E 
restricted T-cells shows either an effector or regulatory 
function.
Exploitation of the human TEIPP 
CALCA in immunotherapy
The CALCA-epitope is so far the only identified human 
TEIPP epitope and the application of CALCA-specific 
immunotherapy remains to be investigated. Expres-
sion of preprocalciton is only detected in 27 out of the 
209 tested lung carcinoma samples (4). This indicates 
that the application of a CALCA based immunothera-
peutic approach is limited for treatment of lung-carci-
noma patients. In medullary thyroid carcinoma, how-
ever, preprocalcitonin is frequently over expressed 
and serves as one of the biomarkers to detect MTC 
(25). Moreover, the CALCA-specific CTL also recog-
nizes the MTC cell-line TT once TAP is down-regulated 
(5). Therefore a CALCA based immunotherapy ap-
proach might be applicable for MTC patients.
To successfully apply the CALCA-based immunother-
apy I highly recommend that the expression levels of 
preprocalcitonin will be determined in combination 
with the TAP-expression levels and correlated to the 
recognition by the CALCA CTL. It might also be inter-
esting to study the expression levels of SPase, and 
SPPase in order to find out whether this forms a factor 
could influencing the availability of the CALCA-epitope 
at the cell-surface. 
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Apart from the absence of TAP, there might be more 
antigen processing mechanisms which could influ-
ence the peptide repertoire presented at the cell-sur-
face. For example it is shown that the furin-mediated 
pathway can contributes to roughly one third of the 
peptides presented at the cell-surface of cells (10). In 
the absence of TAP, contribution of this furin-mediated 
pathway is increased (10). 
Binding of CLIP in HLA-I mole-
cules
In our search for human TEIPP we came across leuke-
mic cells showing surface expression of CLIP, a region 
derived from the invariant chain (Ii). It is known that 
CLIP is expressed at the cell-surface in HLA-II mole-
cules. However these leukemic patients were negative 
for HLA-II, meaning that CLIP was presented in an-
other molecule.
Inhibition of the Ii in leukemic cells resulted in reduced 
levels of HLA-I surface expression, indicating that the 
Ii is somehow involved in the antigen processing of 
HLA-I molecules. This involvement was illustrated by 
immune-precipitation were we observed a unique fea-
ture of a complex of Ii and HLA-I molecules. Previous 
studies showed that HLA-I/Ii complex formation is 
more frequently observed in cells with a down-regulat-
ed TAP expression (26, 27). In chapter 6 of this thesis 
we noticed a CLIP region derived 13mer peptide, elut-
ed from HLA-I molecules, which showed promiscuous 
binding to a variety of HLA-A and HLA-B alleles. This 
13mer could play a role in the complex formation of the 
Ii and HLA-I molecules. To examine this further, one 
could remove this 13mer within the Ii and then test 
whether the complex formation between Ii and HLA-I 
molecules is absent. 
The presentation of CLIP at the cell-surface could also 
indicate that this CLIP peptide might represent a 
TEIPP antigen in humans, since it is normally not pre-
sented in HLA-I. To confirm this, T cells have to be 
isolated recognizing the CLIP peptide in HLA-I. How-
ever, injection in HLA-A2 transgenic mice showed no 
T-cell responses against the CLIP peptide and further 
studies need to confirm whether T-cell responses 
against the CLIP peptide can be observed.
Regardless whether the CLIP-peptide represents a 
human TEIPP, the complex formation of the Ii and 
HLA-I in leukemic patients is an interestingly finding. 
Previous reports observed Ii and HLA-I complexes in 
the T2 cell-line and EBV-JY. In line with our study, a 
role for the CLIP peptide in the complex forming of the 
Ii and HLA-I is seen (28). Moreover the Ii/HLA-I com-
plex is directed towards the endosomal compartment 
(26). This indicates that Ii/HLA-I complex formation 
could play a role in cross-presentation by delivering 
“empty” HLA-I molecules to endolysosomal compart-
ments where it then can be loaded with exogenously 
derived peptides. 
So far, two cross-presentation routes have been pro-
posed and we hypothesize that the Ii/HLA-I complex 
plays a role in the vacuolar route in which the exoge-
nous derived peptides remain in the endocytic/endo-
somal compartment. I envisage that due to Ii/HLA-I 
complex formation the HLA-I is transported to the en-
dosomal compartment where it engages with exoge-
nously derived peptides, and subsequently transport-
ed to the cell surface. 
Vaccination studies in mice in which antigens are di-
rectly coupled to Ii in adenoviral vectors also points to 
the existence of such a pathway (29, 30). Furthermore 
this vaccination resulted in increased CD8+ T-cell re-
sponses and better memory formation compared to 
vaccination expressing only the CD8+ epitope in ade-
noviral vector (29, 30). The addition of the invariant 
chain in peptide-vaccination might therefore enhance 
CD8+ T-cell responses and it is interesting to study the 
antigen processing upon vaccination with a CD8+ T-
cell epitope in combination with the Ii.
We believe that vaccination with TEIPP-antigens com-
bined with adjuvants is an attractive strategy to coun-
teract MHC-I deficiencies in tumors. However there 
are other therapies that focus on restoration of the 
MHC-I antigen-processing pathway. These therapies 
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Defects in MHC-I antigen presentation represent a 
common feature of cancer and allow evasion from T 
cell recognition. Recent findings from immunotherapy 
in melanoma suggested that irreversible MHC-I de-
fects enable escape from immune pressure. Although 
loss of antigen presentation is known for many years, 
strategies to counteract these defects are scarce and 
largely unexamined. Now that the first forms of T-cell 
based immunotherapy show clinical efficacy and 
reach FDA approval, this issue deserves urgent 
awareness. Here we describe possible roads leading 
to corrections of MHC-I defects in tumors and describe 
a salvage pathway for CTL by targeting novel tumor 
antigens that we recently uncovered.
Introduction
CD8+ T cell immunity depends on MHC-I mediated 
antigen presentation. The polymorphic MHC-I surface 
molecules heavily impact on T cell repertoires and 
mediate surveillance of all nucleated cells of the body 
sensing malfunctioning. The classical processing 
pathway engages multiple components of the Antigen 
Processing Machinery (APM), including proteasomes 
and the peptide pump TAP (see Box I for a summary). 
Impediments in this pathway are frequently found in 
chronic viral infections and are a common feature of 
cancer. Consequently it mediates evasion from 
surveillance by cytotoxic T cells. The first reports on 
loss of MHC-I expression on tumors encountered 
some doubts, due to confusion on reagents and 
mouse strains. However, by now these defects have 
overwhelmingly been reported in most tumor types 
and, more importantly, the underlying molecular 
mechanisms have largely been unraveled. 
Interestingly, the frequent finding of loss of 
heterogeneity (LOH) at the MHC-I and b2m loci at 
chromosome 6 and 15, respectively, resembles 
inactivation mechanisms of tumor suppressor genes 
[1], suggesting that MHC-I mediates resistance to 
tumor progression.
The apparent selection and outgrowth of tumor 
variants with low MHC-I expression might represent a 
sign of immunoediting by which an active immune 
system shapes tumor phenotypes [2;3]. Several 
mouse models have shown that processing defects 
indeed represent a real escape mechanism [4-6]. On 
the contrary, loss of MHC-I expression might merely 
correlate with genetic instability of cancer cells. 
Nonetheless, two recent case reports showed that the 
difference between regressing and progressing 
melanoma metastases during immunotherapy was 
related to the failure to restore MHC-I expression in the 
progressing lesions [7;8]. This implies the urgent need 
for strategies that can counteract antigen presentation 
defects, especially now the first forms of T-cell based 
immunotherapy show clinical efficacy and reach FDA 
approval [9-12]. Defects in MHC-I can not be neglected 
anymore, despite the seeming lack of possibilities that 
deal with this problem. 
Mechanisms of antigen 
processing defects in cancer: 
epigenetics into the picture.
We will not elaborate here on all described MHC-I de-
fects in tumors, since excellent reviews on this sub-
jects are already available [1;6;13;14]. We just like to 
stress that impediments in MHC-I antigen presenta-
tion are present in most cancer types, ranging from 
approximately 30–80%; are already present in early 
malignant lesions, but are regularly associated with 
tumor progression; and can be divided in reversible 
and irreversible defects [1] Irreversible (or ‘hard’) de-
fects usually result from structural defects of MHC-I, 
b2m and APM genes, for example. LOH or point muta-
tions. Lack of one MHC-I allele or haplotype will only 
mildly affect total MHC-I surface levels, but still might 
result in functional escape from a focused CTL re-
sponse. Lack of the peptide transporter TAP, as fre-
quently found in cancers [12], results in a more gener-
alized MHC-I decrease. Although genetic alterations 
are frequently found in some cancer types [1;15], the 
dominant underlying molecular mechanism seems to 
reside at the transcriptional level [1]. Repression of 
gene transcription (or ‘soft’ defects) can be operated 
by activated oncogenes, like Her2/Neu, HPV E7 and 
p53 [16-18], and is often exerted via histone modifica-
tions. Indeed, lack of MHC-I and APM gene expres-
sion in tumor cells can be restored by DNA de-methyl-
ating agents (e.g. 5-azacytidine and decitabine) and 
inhibitors of histone de-acethylases (HDAC) (e.g. 
trichostatin A (TSA)) [1;13;19;20]. These agents modu-
late the histone code, induce relaxation, and enhance 
accessibility of the chromatin. Alternatively, immunos-
timulatory cytokines, like interferons, can restore 
MHC-I expression in tumors. Most involved genes en-
code interferon-stimulated responsive elements 
(ISRE) in their promoter regions [14]. The fact that 
MHC-I antigen presentation in tumors is frequently 
controlled at the transcriptional level, and not by struc-
tural alterations of the genes, suggests that they are 
often reversible and can be corrected. However, the 
situation is somewhat more complex, since resistance 
to epigenetic modification or interferon signal trans-
duction pathways have been reported [1;13;14]. This 
indicates that not all transcriptional defects can be re-
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stored, and turn out to belong to the so-called ‘hard’, 
irreversible aberrations [1]. Moreover, upregulation of 
interfering miRNAs has been described as a novel 
mechanism for silencing MHC-I molecules in tumors 
[21], suggesting that regulation at even additional lev-
els needs to be taken into account. 
Strategies to correct antigen pre-
sentation defects.
Although the problem of MHC-I defects in tumors has 
extensively been portrayed, solutions remain chal-
lenging. We will mention three approaches that have 
been described in literature and will close with a novel 
strategy that we recently unraveled.
Gene therapy
A straight forward approach is the replacement of the 
defective genes. This solves structural alterations in 
MHC-I and APM genes, but also transcriptional re-
pression, since strong heterologous promoters in the 
vectors take over the endogenous gene regulation. 
Introduction of viral vectors encoding the peptide 
transporter TAP or b2m were shown to reconstitute 
surface expression of MHC-I molecules in APM defi-
cient tumor cells [22-25]. Recognition by antigen-spe-
cific CTL in vitro was also restored, indicating that 
these single defects were the key factors. Interestingly, 
application of recombinant viruses in established tu-
mors in vivo resulted in expression at the tumor site, 
restoration of surface MHC-I in the tumor area and, 
furthermore, augmented immune cell infiltration. 
Moreover, gene therapy resulted in delayed tumor 
outgrowth, compared with empty viruses [22-24]. The 
major limitation of this approach, however, is the local 
delivery of the gene, especially when the tumor is situ-
ated in internal organs.
Epigenetic modulation
Decreased expression levels of antigen presentation 
genes due to low recruitment of RNA polymerase II 
complex and hyper-methylation has been described 
for MHC-I, APM components, but also for the proin-
flammatory signal transducers STAT-1 and IRF-1, il-
lustrating the wide de-regulation of antigen processing 
genes in cancer [13;26;27]. It was found that treatment 
with TSA and Valproic acid could change the histone 
code and restore the promoter activity of TAP-1 to 
similar levels as observed in TAP-expressing cells 
[19;27]. Administration of TSA in an in vivo mouse 
model demonstrated improved survival due to in-
creased immunogenicity of the tumor. Importantly, the 
effects were absent in T-cell deficient nude mice, dem-
onstrating that the TSA-induced tumor control was 
immune mediated [27]. HDAC inhibitors and de-meth-
ylating agents are clinically applied for a variety of 
cancers, but thus far no studies were reported on their 
impact on MHC-I reconstitution. HDAC inhibitors are in 
general well tolerated, but accumulation of acetylated 
histones in normal tissues may induce toxicity and 
lead to unwanted gene expression profiles. For in-
stance, long term application of TSA in animal models 
has shown an enhanced frequency of regulatory T 
cells, which dampen immune responses [28;29]. In our 
opinion, the clinical application of epigenetic modifiers 
with the aim to increase immune recognition of tumors 
first requires better pre-clinical analysis. 
Interferons
Interferons are at the heart of immune-mediated con-
trol of tumors as demonstrated by the sensitivity to tu-
mor formation of mice deficient for one of the associ-
ated genes (cytokines, receptors or signal transduc-
ers) [3]. Both types of interferon (type I: IFN-α and 
IFN-b; and type II: IFN-g) are known to potently stimu-
late MHC-I mediated antigen presentation via tran-
scriptional activation. Indeed, interferon treatment 
regularly restores MHC-I defects in human cancer cell 
lines and improves CTL-mediated lysis [14]. In high risk 
cutaneous melanoma, IFN-α treatment does lead to 
improved survival [30] and has been shown to shift the 
balance in tumors from STAT-3 towards a favorable 
STAT-1 signaling, resulting in increased expression of 
TAP in the tumor cells [31]. Interestingly, a case study 
reported that metastatic melanoma lesions with irre-
versible MHC-I defects progressed during IFN-α treat-
ment, whereas all reversible lesions regressed [8]. 
Together, these findings suggest that interferons are 
potential modifiers to restore ‘soft’ defects in antigen 
presentation, in particular because IFN-α is already a 
FDA approved therapeutic agent for several types of 
cancer [1;14]. By contrast, administration of IFN-γ is 
not very successful for treatment of cancers due to its 
severe adverse effects. Local delivery of IFN-γ, how-
ever, can indeed be very effective, as recently shown 
in a mouse model [32]. Unfortunately, cancers can 
develop permanent resistance to interferons, via 
downmodulation of the receptor, activation of the cyto-
kine suppressor SOCS or decreased STAT1 expres-
sion [20;33;34].
We conclude that gene delivery, epigenetic regulation 
and interferons might be exploited to counteract MHC-
I defects in tumors, but that all three have significant 
limitations, in particular for the irreversible alterations 







A novel CTL-based strategy for 
 tumors with processing-defects.
Some years ago we discovered a unique population of 
CTL that was capable of recognizing MHC-Ilow tumors 
[35]. Surprisingly, these CTLs displayed preferential 
killing for tumors with defects in the antigen process-
ing pathway and targeted a novel category of tumor 
antigens [35;36]. This novel peptide-repertoire emerg-
es in MHC class I at the cell-surface upon impediments 
in the classical processing route, for example protea-
some, TAP or tapasin, implying that processing de-
fects block the conventional tumor antigens, but stimu-
late alternative processing routes (see Box I). We 
designated this novel category of tumor antigens as 
TEIPP (T-cell Epitopes associated with Impaired Pep-
tide Processing) as they are selectively presented by 
processing deficient cells (see Table I). TEIPP pep-
tides are derived from normal housekeeping proteins 
and represent widely shared tumor antigens [35]. Tu-
mor cells with complete absence of MHC-I at the cell 
surface, due to for instance b2m loss, are not recog-
nized by TEIPP-CTL and we demonstrated that the 
cognate T cell receptors engage peptide-epitopes in 
the residual MHC-I molecules of tumor immune es-
cape variants. In mouse models, we showed the ex-
ploitability of TEIPP antigens in several ways: vaccina-
tion with the molecular identified TEIPP peptides, cel-
lular vaccination with dendritic cells and adoptive 
transfer of in vitro expanded CTL [35;37]. In all three 
cases, TEIPP targeted immunotherapy mediated 
clearance of tumors with irreversible MHC-I defects, in 
particular TAP-deficiencies. Although the reactivity of 
TEIPP CTL resembles that of natural killer cells, TEIPP 
Box I: The manifold roads to load MHC-I molecules
The presentation of peptide antigens to CD8+ T-cells is largely mediated via the classical MHC-I processing 
pathway in which the proteasome and the peptide loading complex (PLC) in the ER are involved. Components 
of the PLC include: peptide transporter TAP, tapasin, calreticulin, and the thiol oxidoreductase ERp57. This 
pathway is further facilitated by the proteases TPPII, TOP, and ERAP-1 for fine tuning of the peptide 
repertoire [43-45]. In addition to this main TAP-dependent pathway, other pathways are clearly independent 
from TAP. One of these TAP-independent routes is the processing of peptides located in N’-terminal signal 
sequences, which are released in the ER by Signal Peptidase (SPase), and Signal Peptide Peptidases 
(SPPase) [46]. Only a few substrates for SPPase have been indentified, and the exact specificity of SPPase 
remains largely unknown [46]. The Golgi-route represents yet another pathway. The protease furin is located 
in the trans-Golgi network where it mediates maturation of many proproteins by cleaving at precise stretches 
of three of four basic residues. If MHC-I epitopes are located downstream of the furin cleavage sites they 
can be loaded in MHC-I molecules through a TAP-independent secretory pathway [47]. A couple of furin-
processed peptides-epitopes have been described so far [47;48], but the exact loading compartments are 
elusive. MHC-I molecules normally travel to the cell-surface in their peptide-filled conformation, therefore 
peptides generated in the Golgi network have to be either transported back to the ER, or bind to empty 
MHC-I molecules en route to the cell-surface [47]. Sufficient evidence points at yet more processing 
pathways.
TAP-independent peptide-epitopes play an important role in viral infections and it is striking that TAP-defi-
cient individuals do not succumb of viral infections, but are prone for bacterial problems [49;50]. Some of the 
involved TAP-independent antigens have been characterized in EBV [51], melanoma [52], and a calcitonin 
signal peptide in lung carcinoma [41]. 
Table I: Categories of human tumor antigens recognized by CTL
Category Description Examples
Viral antigens Virus-induced tumors (e.g. EBV, HPV) EBNA-1, E6, E7
Point mutations Unique for each tumor MUM-1, CDK-4, p53, Caspase-8
Differentiation antigens Expressed in tissue lineage Tyrosinase, GP100, Mart-1
Cancer testis antigens Largely expressed during development and cancers MAGE, NYO-ESO-1
Cryptic epitopes Associated with aberrant transcription and translation RU2, GnT-V, HPX42B
TEIPP Associated with antigen processing defects CALCA
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antigens behave like conventional tumor antigens for 
CTL. In addition to irreversible defects in APM compo-
nents, a subpopulation of TEIPP CTL was capable to 
eradicate cells with total loss of MHC-I. This subset 
appeared to target peptide-epitopes when presented 
by the non-classical MHC-I Qa-1, the homolog of HLA-
E [36;38]. This non-classical MHC-I is very conserved 
in the human population, suggesting that the same 
TEIPP peptides are presented in all tumor escape vari-
ants [39]. Moreover, HLA-E expression in tumors is 
frequently preserved or even overexpressed (our own 
observations). Next to tumors with irreversible defects 
in MHC-I, we envisage a role for TEIPP CTL in the 
context of reversible MHC-I defects, since tumors with 
partial deficiencies also present TEIPP at their cell 
surface [35;36;38], albeit to lower degree. TEIPP CTL 
might provide the first local immune activation and cy-
tokine release upon recognition of these reversible 
defects, leading to correction of transcriptional silenc-
ing. Recently we demonstrated TEIPP-reactive CTL in 
the human population and found that this CTL specific-
ity was readily detectable, pointing at a relative high 
precursor frequency [40]. We have indications that the 
previously reported signal peptide from the CALCA 
gene might represent a human TEIPP [41]. Molecular 
identification of additional human TEIPP antigens will 
enable the development of TEIPP targeted immuno-
therapy in the future. 
Several basic questions on the TEIPP concept remain, 
especially concerning the TAP-independent 
processing pathway that leads to presentation of these 
novel antigens (see Box I) and the reason why they are 
not presented by normal, processing-proficient cells. 
We are also examining the most optimal protocol to 
activate TEIPP CTL in vivo, as this might be different 
from conventional CTL. TEIPP CTL seems to be poorly 
cross-primed from cellular vaccines and need a 
combined T cell co-stimulation with TAP-inhibition on 
the same cell [24;42]. Preliminary data also indicate 
that peptide formulations, including the powerful long 
synthetic peptides [10], do elicit TEIPP CTL in vivo. 
Conclusion
The commonly observed MHC-I defects in tumors 
constitute a potential problem for the upcoming forms 
of T-cell based immunotherapy. Convincing objective 
tumor regressions have been reported for prostate 
cancer, melanoma and HPV-induced neoplasia for a 
fraction of the patients, however the impact of MHC-I 
defects on the non-responding tumors is largely 
unknown and corrections of antigen presentation in 
these tumor types might result in much higher success 
rates. Two recent case reports nicely illustrated that 
the progressing metastases in a melanoma patient 
were the ones that failed to restore MHC-I expression 
during immunotherapy, whereas all regressing 
metastatic lesions expressed residual MHC-I [7;8]. In 
this review we speculate that reversible (so-called 
‘soft’) defects might be corrected via epigenetic 
modulation or interferon treatment, however this 
remains to be confirmed in clinical tests. Histone 
methylase- or de-acetylase inhibitors or interferons 
are safe and well tolerated as monotherapy and might 
simply be tested in combination with different forms of 
immunotherapy. Resistance to these modulators via 
unresponsiveness or because of ‘hard’ genetic MHC-I 
defects, necessitates other options. In theory, one 
could correct the defects by gene therapy, however, 
we propose to pursue a strategy in which the novel 
TEIPP antigens are exploited. Although this discovery 
is still in an early phase, the presentation of these 
antigens on tumors with reversible and irreversible 
MHC-I defects makes them attractive immune targets. 
We are currently unraveling the human TEIPP antigens 
and investigate the efficacy of different 
immunotherapeutic protocols. In the future, T cell 
based immunotherapy might be complemented with 
TEIPP-directed immune responses in order to prevent 
immune escape via MHC-I defects.
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doen: 1. De kankercel zorgt ervoor dat er minder of 
geen HLA-I moleculen meer gemaakt worden; 2. De 
kankercel blokkeert de route die tumorantigenen 
moeten afleggen om in het HLA-I molecuul gepresen-
teerd te worden. 
Voordat eiwitten in een HLA-I molecuul gepresenteerd 
kunnen worden gaat het door de antigeen presenter-
ende route (figuur 1). Om beladen te worden in een 
HLA-I molecuul wordt een eiwit eerst door het protea-
soom in kleine stukjes eiwitten gehakt. Daarna vervol-
gen de kleine stukjes eiwitten binnen de cel hun route 
richting het endoplasmatisch reticulum (ER). Om het 
ER binnen te komen worden ze in het algemeen get-
ransporteerd door het TAP molecuul, wat een kanaal 
in het ER-membraan is dat veel kleine stukjes eiwit 
gemakkelijk naar binnen pompt. Als de stukjes eiwit 
eenmaal in het ER zijn kunnen ze geladen worden in 
een HLA-I molecuul waarna het gehele complex  naar 
de buitenkant van de cel wordt getransporteerd om 
eventueel herkend te worden door T cellen. 
Kankercellen blokkeren soms het TAP molecuul waar-
door de tumorantigenen niet meer het ER kunnen bin-
nenkomen. Deze tumorantigenen worden dan niet 
meer door HLA-I aan T cellen gepresenteerd waar-
door het moeilijker wordt om de cel als eventuele 
kankercel te herkennen. Gelukkig zijn er ook stukjes 
eiwit die het ER weten binnen te komen zonder gebruik 
te maken van het TAP molecuul. Deze TAP-onafhan-
kelijk eiwitten zijn echter sterk in de minderheid en 
hebben normaliter geen kans om in voldoende mate 
gepresenteerd te worden door een HLA-I molecuul 
(figuur 1). De kankercel die TAP blokkeert geeft deze 
peptiden de kans om in het HLA-I molecuul te komen. 
Nederlandse Samenvatting
In het jaar 2010 overleden ongeveer 44 duizend 
mensen in Nederland aan de gevolgen van kanker. Dit 
is een stij ging van 2% ten opzichte van 2009. Toch is er 
hoop. Door vele onderzoeken is de diagnostiek en 
behandeling van kanker al sterk verbeterd. Naast de 
traditionele bestralings- en chemotherapie wordt er 
steeds vaker gebruik gemaakt van immuuntherapie. 
Deze therapie is erop gericht om het immuunsysteem 
van het lichaam beter te activeren en het te helpen om 
de kankercellen op te ruimen.
De immuuntherapieën die nu in ontwikkeling zijn, en 
waarvan sommige al zijn goedgekeurd als behandel-
ingsmethode, zijn erop gericht om het immuun sys-
teem tumorantigenen te laten herkennen. Dit wordt 
ook wel therapeutische vaccinatie genoemd. Deze tu-
morantigenen zijn stukjes eiwit die specifiek door 
kankercellen worden gepresenteerd in HLA-I of HLA-II 
moleculen. HLA moleculen kunnen herkend worden 
door T cellen. Een T cel komt in actie wanneer deze 
een HLA molecuul met daarin een tumorantigeen 
herkent. De immuunreactie die hierdoor op gang is 
erop gericht om de kankercel te vernietigingen. Bij 
patiënten met kanker is de immuunreactie niet krachtig 
genoeg waardoor de kanker kan uitgroeien. Met de 
komst van immuuntherapieën is dat hopelijk voorbij.
Tumorantigenen kunnen in verschillende klassen 
onderverdeeld worden. Zo heb je virus afkomstige 
tumor antigenen die worden gepresenteerd door 
kankercellen die zijn ontstaan als gevolg van een vi-
rale infectie. Een goed voorbeeld hiervan is baarmoe-
derhalskanker wat ontstaat als gevolg van een infectie 
met het humaan papiloma virus (HPV). Een andere 
groep tumorantigenen kenmerkt zich door mutaties. 
Door die mutaties komt een eiwit er iets anders uit te 
zien waardoor het als lichaamsvreemd herkend kan 
worden door de T cel. Daarnaast zijn er eiwitten die 
specifiek tot expressie worden gebracht in een aantal 
organen en hierdoor ook in eventuele kankercellen die 
ontstaan uit deze organen. De expressie en herken-
ning van deze zogenoemde differentiatie antigenen 
zijn met name onderzocht bij melanoompatiënten. 
Andere groepen van tumorantigenen zijn de zogeno-
emde kanker/testis-antigenen en een  kleine groep 
genaamd cryptische antigenen.
Recentelijk is er een nieuwe groep tumorantigenen 
ontdekt. Deze antigenen die wij TEIPP noemen wor-
den alleen op kankercellen gepresenteerd die het im-
muunsysteem proberen te ontwijken door de presen-
tatie van tumorantigenen in HLA-I moleculen tegen te 












Figure 1: Nederlandse samenvatting
Figuur 1: De klasse I antigeen presenterende route. Ei-
witten in de cel worden in kleine stukjes peptiden gebroken 
door het proteasoom alvorens zij het ER binnengaan via het 
TAP-molecuul. In het ER worden de stukjes peptiden beladen 
op klasse I moleculen. Het klasse I molecuul met peptiden 
wordt vervolgens naar het cel-oppervlak getransporteerd 
waar CD8 T-cellen het kunnen herkennen. Een aantal pep-
tiden kan ook het ER binnenkomen zonder gebruik te maken 
van het TAP-molecuul.
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In hoofdstuk 5 van dit proefschrift is er gekeken naar 
de HLA-E expressie op ovarium en baarmoederhals 
tumoren. In 80% van alle tumoren werd een hogere 
HLA-E expressie aangetroffen dan op de gezonde cel-
len. Deze HLA-E expressie was gecorreleerd aan de 
expressie van andere HLA-I moleculen, maar ook aan 
moleculen die betrokken zijn bij de antigeen presenta-
tie route. Vervolgens werd er ook onderzocht of een 
hoge HLA-E expressie zorgde voor een betere over-
leving. Bij mensen met een ovarium tumor was dit he-
laas niet het geval. De T cellen die aanwezig waren 
binnen deze tumoren werden niet goed geactiveerd 
omdat er op de oppervlakte van de T cel een molecuul 
aanwezig was dat voor een remmend signaal zorgde 
als HLA-E herkent werd. Dit CD94/NKG2A molecuul 
zorgde er dus voor dat de T cellen niet actief werden, 
wat met name in ovarium kanker voor een probleem 
zorgde omdat in deze tumoren al weinig T cellen te 
vinden waren.
Ook is er onderzocht wat voor soort eiwitten een HLA-
E molecuul presenteert. Een gezonde cel laat maar 
een paar eiwitten in het HLA-E molecuul aan T cellen 
zien. Deze eiwitten zijn afkomstig van stukjes HLA-A, 
-B en –C moleculen. Het lijkt er dus op dat HLA-E mol-
eculen aan T cellen kunnen laten zien dat alles in orde 
is. Als de antigeen presenterende route echter ver-
stoord wordt door het blokkeren van TAP laat het HLA-
E molecuul hele andere stukjes eiwit zien. In hoofd-
stuk 4 van dit proefschrift laten we zien dat deze 
stukjes eiwit lijken op de stukjes die een HLA-A2 
molecuul presenteert aan een T cel. Het zou interes-
sant zijn om een vaccin te ontwikkelen die verschil-
lende T cellen via beide moleculen kan stimuleren 
omdat dan blokkade van TAP niet automatisch leidt tot 
ontsnapping van de kankercel aan het immuunsys-
teem.
Nog een belangrijke stap die zou kunnen helpen bij het 
ontwikkelen van immuuntherapieën is de optimaliser-
ing van antigenpresentatie in HLA-I en HLA-II molecu-
len. Behalve de hierboven beschreven route zijn er 
namelijk nog vele andere routes die kunnen leiden tot 
het presenteren van eiwitten in HLA-I en HLA-II mole-
culen. Een molecuul dat voor deze andere routes een 
grote rol kan spelen is de invariante keten. In hoofd-
stuk 6 van dit proefschrift is onderzocht hoe de invari-
ante keten een rol speelt in het presenteren van eiwit-
ten in HLA-I moleculen. Tot nu toe wist men dat de in-
variante keten helpt om HLA-II moleculen te beladen 
met eiwitten. In dit proefschrift wordt aangetoond dat 
de invariante keten ook bij de belading van HLA-I mol-
eculen kan helpen. Met name kan dit een rol kunnen 
spelen bij leukemiepatiënten omdat hier de binding 
Doordat de T cellen deze TAP-onafhankelijke eiwit-
ten normaal niet zien worden beschouwen ze deze 
peptiden als vreemd en komt een immuunreactie op 
gang. 
De blokkering van het TAP molecuul komt in kanker 
best vaak voor. Hoe vaak verschilt per soort kanker, 
maar gemiddeld genomen komt het in 50% van alle 
kankergevallen voor. Als de kankercellen ook nog 
uitzaaien gebeurt het zelfs nog vaker dat het TAP 
molecuul geblokkeerd wordt. De toevoeging van 
TEIPP-antigenen aan therapeutische vaccins wat 
gebruikt wordt bij de immuuntherapie van kanker 
kan dus van groot belang zijn. 
In hoofdstuk 2 van dit proefschrift wordt be-
schreven dat mensen T cellen hebben die specifiek 
reageren op cellen waarvan het TAP-molecuul ge-
blokkeerd is. Dit betekent dus dat de ontdekking van 
humane TEIPP-antigenen mogelijk is. In 2011 werd 
ook het eerste humane TEIPP-antigeen beschreven. 
Dit antigeen is gevonden in een longtumor, maar 
kan misschien ook gebruikt worden voor medullair 
schildkliercarcinoma. Op dit moment wordt onder-
zocht in hoeverre dit antigeen toegepast kan worden 
voor de immuuntherapie van kanker, en welke 
patiënten voor deze therapie geschikt zijn. Om nog 
meer TEIPP-antigenen te identificeren hebben we in 
dit proefschrift in hoofdstuk 3 een methode be-
schreven waarbij met behulp van bio-informatica 
mogelijke TEIPP-antigenen ontdekt kunnen wor-
den.
Een uitdaging voor de ontwikkeling van de immuun-
therapie van kanker is de grote hoeveelheid ver-
schillende HLA moleculen. Zo zijn er 6 groepen 
HLA-I moleculen: HLA-A, -B, -C, -E, -F, -G. Deze 6 
groepen vertegenwoordigen vervolgens ook weer 
allemaal varianten. Zo zijn er 124 varianten HLA-A 
moleculen, 258 HLA-B moleculen en 74 HLA-C 
moleculen. Elk persoon heeft maar twee varianten 
van elke HLA-A, -B, -C, -E, -F en –G, in zijn immuun-
systeem wat dus voor een grote diversiteit in de 
bevolking zorgt. Door deze grote verscheidenheid is 
het dus lastig om een therapie te ontwikkelen die 
voor iedereen geschikt is. 
Recent is echter ontdekt dat elk persoon bijna 
dezelfde HLA-E moleculen heeft. Tot nu toe zijn er 
maar twee varianten van HLA-E ontdekt. Dit betek-
ent dat elk persoon bijna hetzelfde stukje eiwit in 
HLA-E toont aan het immuunsysteem. Het is dus 
interessant om te ontdekken welke eiwitten door 
HLA-E gepresenteerd worden en of er T cellen zijn 
die deze eiwitten herkennen. 
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van de invariante keten met het HLA-I molecuul wordt 
waargenomen. De toevoeging van de invariante keten 
aan immuuntherapie zou dus voor een betere T cel 
reactie kunnen zorgen, maar dit moet nog verder 
onderzocht worden.
De hoofdstukken beschreven in dit proefschrift tonen 
aan dat de immuuntherapie nog volop in ontwikkeling 
is en dat er nog veel winst behaald kan worden door 
het bestuderen van de antigeen presenterende routes 
en de eventuele uitschakeling hiervan in tumoren.
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